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1. LIST OF ABBREVIATIONS 
  
 5-hydroxytryptamine                                 5-HT 
 Acetylcholine                        ACh 
 Adrenocorticotropic hormone                   ACTH  
 Calcitonin gene related peptide                     CGRP 
 Central Nervous System                                        CNS 
 Central Pattern Generator                                                                                   CPG 
 Commissural interneurons                                                         CNs 
 Corticotropin-releasing factor                         CRF 
 Corticotropin-releasing hormone                      CRH  
 Diacylglycerol                      DAG 
 Dopaminergic neurons                        DA 
 Electroencephalogram                       EEG 
 Flexion reflex afferent                         FRA 
 Food and Drug Administration                      FDA 
 Glucocorticoid Receptor                        GR 
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 Glucocorticoid response elements                    GREs 
 Glucocorticoids                          GC 
 Heat shock protein                        HSP 
 Hypothalamic–pituitary–adrenal axis                        HPA axis 
 Inositol-trisphosphate                                     IP3 
 Intracerebroventricular                        i.c.v 
 Intravenous                            i.v 
 Mesencephalic locomotor region                                MLR 
 Methylprednisolone                             MP 
 Muscarinic acetylcholine receptor                mAChR 
 Nicotinic acetylcholine Receptor                           nAChR 
 Nitric oxide                          NO 
 Nitrous oxide                         N2O   
 N-Methyl-D-aspartic acid                  NMDA 
 Pathological medium                         PM 
 Pedunculopontine nucleus                       PPN 
 Progenitor domain                            p 
 Pro-opiomelanocortin                                 POMC 
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 Reciprocal Ia inhibitory neurons                  rIa-INs 
 Rhythm generating neurons                           R 
 Short stature homeobox protein 2                           SHOX2 
 Spinal cord injury                                                                                               SCI 
 γ-aminobutyric acid                                 GABA 
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2 ABSTRACT 
 
Background: Mammalian locomotor behaviour called fictive locomotion can be elicited 
in an isolated spinal cord in the absence of higher brain center or sensory input. This 
relatively simple behaviour is produced by the motoneuronal rhythmic activity which is 
under the control of spinal neuronal networks called central pattern generators (CPGs). 
Disturbance of this rhythmic motor output can occur following spinal cord injury (SCI). 
This elementary isolated spinal cord model gives us an opportunity to study the basic 
physiology of locomotion during control conditions, the pathological processes following 
lesion (which can be induced chemically), and eventually the application of therapeutic 
approaches curbing injury.   
Objectives: Multiple aspects of spinal functions can be demonstrated by stimulating 
or/and blocking specific inputs and measuring the outputs using electrophysiological, 
immunohistochemical and calcium imaging tools. Using isolated neonatal rat spinal cords 
and organotypic spinal slices as SCI models, the basic mechanisms (such as dysmetabolic 
state or excitotoxicity) which can develop during the early phase of the lesion were 
addressed and studied. The injury was evoked chemically by applying either pathological 
medium (to mimic dysmetabolic/hypoxic conditions) or kainate (to produce excitotoxicity 
that completely abolishes fictive locomotion and network synaptic transmission) for 1 h. 
Fictive locomotion was examined stimulating the lumbar dorsal root and recording from 
the ipsilateral and ipsi-segmental ventral roots. Other network parameters were also 
studied such as synaptic transmission and rhythmicity. Various therapeutic drugs such as 
methylprednisolone sodium succinate (MPSS), propofol, nicotine and celastrol were used 
during or after the injury (to produce neuroprotection) and network properties were 
characterized during the treatment and after 24 h as well. Subsequently, the structural 
properties were monitored using different biomarkers (isolated spinal cord sectioned 
slices) and calcium imaging (here organotypic spinal slices were used).  
Results and conclusions: We found that dose-dependent application of MPSS produced 
modest recovery of white matter damage evoked by pathological medium resulting in the 
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emergence of sluggish chemically induced fictive locomotor patterns. However, it could 
not prevent damage (to gray matter) evoked by the excitotoxic agent kainate. Therefore, 
to provide better neuroprotection to gray matter, we tested the widely used intravenous 
anaesthetic propofol. This drug has shown comparatively good protection to spinal 
neurons and motoneurons in the gray matter. As it is an anesthetic it acted by depressing 
the functional network characteristics by lowering the N-methyl-D-aspartate (NMDA) 
and potentiating the γ aminobutyric acid (GABAA) mediated receptor responses.  
The next issue we addressed was to study the neuroprotective roles of nicotinic 
acetylcholine receptors (nAChRs) by using the receptor agonist nicotine. Recent studies 
have shown that nicotine could provide good neuroprotection to the rat brainstem. To 
further investigate its effect on the spinal cord, we applied nicotine at the same 
concentration used in previous studies in the brainstem: such a concentration was toxic to 
spinal ventral motoneurons. Therefore the correct dose of nicotine was optimized and was 
found to be ten times lower. Thus, satisfactory protective effects to spinal neurons and 
motoneurons and the fictive locomotor patterns were observed. These neuroprotective 
effects were replicated with calcium imaging by using organotypic spinal slice cultures. 
The mechanism of protection predominantly involved α4β2 and less α7 nAChRs.   
In addition, the subsequent goal of our study was to explore whether the 
motoneuron survival after excitotoxicity relies on cell expression of heat shock protein 70 
(HSP70) or some other mechanisms. To test this hypothesis we used a bioactive drug, 
celastrol which induces the expression of HSP70. Prior application of the drug followed 
by kainate preserved network polysynaptic transmission and fictive locomotion, however, 
it could not reverse the depression of monosynaptic reflex responses. In vivo studies are 
necessary in the future to further investigate the long-term neuroprotective role of these 
drugs.  
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3 INTRODUCTION 
 
3.1 Central pattern generators for mammalian locomotion 
 
“Thus, from the war of nature, from famine and death, the most exalted object which we 
are capable of conceiving, namely, the production of the higher animals, directly follows. 
There is grandeur in this view of life, with its several powers, having been originally 
breathed into a few forms or into one; and that, whilst this planet has gone cycling on 
according to the fixed law of gravity, 
from so simple a beginning endless forms most beautiful and most wonderful have 
been, and are being, evolved.” 
 
 Charles Darwin 
 
When speculating about the beginning of life on earth, one can get fascinated by 
tremendous animal behaviour. All kind of movements in animals, vertebrate or 
invertebrate are controlled by specific neural circuits that generate precise phasing and 
timing of muscle activation and thus locomotor behaviour (Grillner, 2003; Selverston, 
2005). These networks are called Central Pattern Generators (CPGs). All animals have a 
stock of CPGs distributed in different parts of the Central Nervous System (CNS) and 
thus allow animals to perform distinct behaviour and movement (Grillner, 2006). 
Considering locomotor activity, which is an innate rhythmic motor act, different from 
simple reflex, provide animals and humans to move. There are diverse locomotor forms 
such as walking, swimming, running, hopping and feeding (Delcomyn, 1980; Roberts & 
Roberts, 1983). Locomotion does not require sensory input and is generated by CPG 
 
 
Page 9 
 
(Grillner, 2006), although sensory input is important for the refinement of CPG to 
respond to external events (Grillner 1985). CPGs do not produce fixed action patterns; 
otherwise, animals have behaved like stereotype robots. Rather they provide a malleable 
template which can be easily modified according to changes in the environment (Grillner, 
2006).  
Locomotion was first precisely characterized when Étienne-Jules Marey and Eadweard 
James Muybridge (in the 1880s), known for their pioneering work on animal locomotion, 
developed the photographic techniques which allowed users to capture motion in stop-
motion photographs as shown in Fig. 1.  
 
 
Fig. 1 An example of multiple locomotion pictures showing the consecutive 
motions of different locomotor acts by animals (http://www.imaging 
resource.com/news/2012/11/27/eadweard-muybridge-the-photographic-pioneer-who-
froze-time-and-nature) 
 
A major improvement in understanding the neural substrate for producing 
mammalian locomotion came into limelight in the 20th century when a Scottish 
neurophysiologist Thomas Graham Brown showed that the basic stepping pattern can be 
induced in the transected spinal cord of cats, rabbits and guinea pigs without sensory 
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inputs (Graham Brown, 1911, 1914). Thus, Graham Brown has concluded that spinal cord 
neuronal networks are able to produce flexor-extensor movements in the absence of 
sensory stimuli. To better understand the mechanism of action of CPG in the generation 
of movement in spinal cord, it is necessary to know the anatomy of the spinal cord. 
 
3.1.1 Anatomy of spinal cord 
The spinal cord is a part of CNS, extends caudally from the brainstem. It is enclosed in a 
protective bony structure, vertebral column. It is encircled by three meninges, i.e., dura 
mater (outer layer), arachnoid and pia mater as shown in Fig. 2. Unlike the brain, the 
cross-section of the peripheral region of the spinal cord is composed of white matter, 
comprising bundles of myelinated axons of neurons. Internal to the peripheral region of 
the cord is the butterfly-shaped gray matter region, which resembles the letter H, 
consisting of cell bodies of neurons, unmyelinated axons and neuroglia. At the centre of 
the gray commissure, which forms the crossbar H, is the central canal containing 
cerebrospinal fluid (CSF) circulating to and from the ventricles in the brain (Kandel et al., 
2000). 
 
.  
 
 
 
 
 
 
 
Fig. 2 A cross-section of spinal cord representing distinct layers and the butterfly 
pattern of white and gray matter of spinal cord (Jacquelyn L. Banasik, Structure 
and Function of the Nervous System, Chapter 43) 
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The spinal cord is about 17–18 inches (43–48 cm) long in humans and according 
to rostrocaudal location the 31 segments (varies from specie to specie) are divided into 
five parts, i.e., 8 cervical, 12 thoracic, 5 lumbar, 5 sacral and 1 coccygeal segments 
(Netter, 2006) (Fig. 2). In rats, 34 segments are grouped into; 8 cervical, 13 thoracic, 6 
lumbar, 4 sacral and 3 coccygeal (Molander et al., 1984; Molander et al., 1989). Besides 
the medial sagittal plane, anterior and posterior median fissures divide the spinal cord into 
two portions which are further associated with transverse anterior and posterior 
commissure as shown in Fig. 3. The anterior and posterior lateral fissures depict the locus 
where the sensory and motor nerve rootlets emerge from the spinal cord to spinal nerves.  
 
Fig. 3 Diagram of longitudinal section of spinal cord showing division of segments 
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At each side, the spinal cord is further divided into the dorsal, central and ventral 
horn (Fig. 2). From the dorsal horn, the dorsal roots emerge, integrate into bundles and 
enter into dorsal root ganglia (DRG), which contain cell bodies of sensory neurons, are 
afferent (Ham & Cormack, 1987). Away from the ganglia, the dorsal and ventral roots 
unite to form spinal nerves. These spinal nerves emerging from vertebrae form plexus 
which have both sensory and motor functions like muscle contraction, sensations (of cold, 
heat, pain) etc.  
 
 Cytoarchitecture of spinal cord 
The first cytoarchitecture of the spinal cord was identified by Bror Rexed in the 1950s 
(Rexed, 1952; 1954) who labelled the portions of gray columns as 10 rexed laminae in 
cats. Each lamina carries several distinct characteristics in terms of physiological, 
histochemical and cytoarchitectonics (Heise and Kayalioglu, 2009). Molander and his 
colleagues examined the organization of these rexed laminae in neonatal and adult rat 
spinal cord at lower thoracic and lumbosacral segments and found similar architecture as 
in cats (Molander et al., 1984, 1989). Other scientists also confirmed the presence of these 
lamination patterns in the rats (Watson et al., 2009), mice (Sidman et al., 1971; Watson et 
al., 2009) and humans (Schoenen and Faull, 2004) at different time periods.  Furthermore, 
there is not much difference in neonatal and adult rat spinal laminae except that there are 
less distinct borderlines between laminar regions.  
 
 Laminae I cover the tip of the dorsal horn (See Fig. 4). 
 
 Laminae II correspond to substantia gelatinosa where the first order neurons of 
spinothalamic tract synapse exist. There are two main subtypes of cells present 
in laminae II: Islets cells and stalked cells. Islets cells are considered as 
inhibitory cells of these laminae as they consist of GABA, which is an 
inhibitory neurotransmitter. 
 
 Laminae III can be easily recognized because of less density of neurons. It is 
mainly composed of GABA and glycine neurotransmitters (Todd & Sullivan,  
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1990). 
  
 Laminae IV neurons send projections to midbrain and brainstem and re-send 
the processes back to itself. 
  
 Laminae V and VI complement to reticular formation in brainstem. 
 
 
 Laminae VII consist of the intermediolateral nucleus (T1-L1) and dorsal 
nucleus of Clarke (T1-L2). Intermediolateral nucleus performs an important 
role in autonomic and sensory motor functions. On the other side, axons from 
dorsal nucleus of Clarke make ascending fibres of the dorsal spinocerebellar 
tract. 
 
 Laminae VIII–IX make the ventral horn of spinal cord mainly consists of 
motoneurons.  
 
 Laminae X form substantia grisea centralis, surround the central canal and 
consist of preganglionic neurons and neuroglia (Dafny, 1999). 
 
 
 
 
 
 
 
 
 
Fig. 4 Transverse section of lumbar 5 segment of spinal cord comprising different 
laminar regions (Ostroumov, 2006) 
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3.1.2 Selection and initiation of locomotion 
 
The first question to answer in locomotion is how are these central motor programs 
selected and generated after selection?   
 
Particular CPGs for a specific action (at a given moment) are selected by neuronal 
mechanisms in the brain. Experiments on different animal models, like vertebrates have 
shown that basal ganglia are the dominating selection system, select locomotor behaviour 
(Grillner et al., 2005a; Hikosaka et al., 2006).   
Striatum (input layer of basal ganglia) receives excitatory sensory input from the 
cortex in mammals (known as pallium in lower vertebrates) or directly from thalamus 
(Fig. 5). It comprises the inhibitory neurotransmitter, γ-aminobutyric acid (GABA), 
activated at high threshold. Striatal neurons project onto pallidum (output layer of basal 
ganglia) and substantia nigra. The pallidum is also composed of inhibitory GABAergic 
neurons with even higher threshold which maintain CPGs at tonic inhibition at rest. For a 
locomotor behaviour to be elicited, striatum needs to be activated which further inhibits 
pallidum resulting in activation of particular CPGs providing an input to induce dis-
inhibition, important for locomotion. The dopaminergic neurons play a crucial role in 
facilitating the response of striatal neurons to activation. Deficiencies or hyperactivation 
of dopaminergic system eventually leads to Parkinson-like hypokinetic or hyperkinesias 
symptoms, respectively in all vertebrates—from lamprey to man (see Grillner et al., 
2005c). 
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Fig. 5 Scheme of selection of specific behaviour by basal ganglia (Grillner, 2006) 
 
Two regions which may be associated with initiating locomotor behaviours in 
different behavioural context are medial and lateral hypothalamus. Medial hypothalamus 
involves in escape or defensive locomotor behaviour, whereas lateral hypothalamus is 
involved in behavioural context when animal searches for food. 
 
 Neurons of mesencephalic locomotor region (MLR) project to the medial reticular 
formation in the lower brain stem which further projects its neurons onto locomotor CPG 
in the spinal cord to execute locomotion as shown in Fig. 6.   
 
Fig. 6 Scheme of 
organization of 
neural structures 
controlling 
locomotion (Kiehn, 
2016) 
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The next query is the initiation of locomotion once selected by basal ganglia... 
The output layer of basal ganglia, pallidum, projects its neurons onto MLR in 
mesencephalon (midbrain) (Fig. 6). After the selection of locomotion, the high resting 
activity of globus pallidus neurons declines, which relieve the tonic GABAergic 
inhibition of these neurons in MLR. After the release of inhibition, MLR becomes active 
and initiate locomotion.  
 
Neurons in MLR are excitatory. The pedunculopontine nucleus (PPN) is located 
in the ventrolateral portion of caudal MLR and is composed of neurons comprising 
glutamate and acetylcholine (ACh) (Clements & Grant, 1990; Lavoie & Parent, 1994; 
Takakusaki et al., 1996; Mena-Segovia et al., 2008; Takakusaki et al., 2016). Previous 
studies have suggested that cholinergic neurons are important in maintaining the rhythm 
of locomotion and postural muscle tone (Bohnen & Albin, 2011; Takakusaki et al., 2011). 
These glutamatergic and cholinergic input signals arising from MLR may control the 
excitability of reticulospinal neurons that project to spinal CPGs to initiate stepping (Le 
Ray et al., 2011; Skinner et al., 1990). 
 
There are two main systems involved in the execution of locomotion: 
Glutamatergic and serotonergic locomotor pathways as previously been studied in 
mammals (Guertin, 2009; Ghosh & Damien, 2014). Therefore, it seems that there are 
parallel pathways, at least in mammals, activating the spinal locomotor networks.    
 
The next point to discuss is the localization of CPG in the spinal cord of mammals… 
CPG locomotor networks are localized in the ventromedial part of spinal cord (Fig. 7) 
which is distributed along the lumbar segment of mice (Nishimaru et al., 2000) and 
humans (Dimitrijevic et al., 1998). Locomotor activity is specifically found in the gray 
matter intermediate zone, ventral horn and central canal areas (e.g., Kjaerulff et al., 1994; 
Cina and Hochman, 2000). Locomotor CPG neurons have been identified as the 
populations of HB9 (Wilson et al., 2005), EphA4 (Kullander et al., 2003), V0 (Lanuza et 
al., 2004), V1 (Gosgnach et al., 2006), V2 a/b (Lundfald et al., 2007), V3 (Zhang et al., 
2008), excitatory Ib (Guertin et al., 1995; Angel et al., 2005), lamina VII-IN (Jankowska 
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et al., 1967a,b), ChAT-positive/c-fos-labeled ascending (Huang et al., 2000), rhythmic 
interneurons which are activated by group II afferent (Edgley and Jankowska, 1987) and 
descending commissural interneurons (dCIN) (Butt et al., 2002) (See Fig. 7). 
 
 
Fig. 7 Localization of spinal networks (Guertin, 2009) 
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3.1.3 Generation of rhythm and pattern of locomotor behaviour 
 
Rhythm generation in mammals is more complex than lower vertebrates (Grillner, 1985; 
Guertin, 2009). There are two main aspects with control the coordination of limbs.  
 The left-right pattern generating circuits – maintain the coordination during 
movement on both sides of the body along with, rhythm-generating circuits – 
which drive the activity and modulate the speed in non-limbed locomotion. 
 Flexor–extensor pattern-generating circuits – which maintain intra-limb 
coordination in limbed locomotion. Limbed locomotion also requires left-right 
pattern generating circuits (in addition to flexor-extensor circuits) for locomotor 
movement to occur.  
 
 Left–right coordination circuits 
Commissural neurons (CNs) play an important role in providing left-right coordination 
during locomotion at different frequencies (speeds). CNs that are associated with motor 
control in mammals are localized in at the ventral part of spinal cord and composed of 
inhibitory (GABA and glycine) and excitatory (glutamate) neurotransmitters (Bannatyne 
et al., 2003; Weber et al., 2007; Restrepo et al., 2009). 
V0 CNs evolved from p0 progenitor domain in the ventral horn of cord. Five progenitor 
domains are present in ventral (p0-p3, pMN) and six in the dorsal horn (pd1-pd6) (Jessell, 
2000; Alaynick et al., 2011) (Fig. 8). After maturation, these progenitor cells differentiate 
into neurons and motoneurons. The V0 neurons split into inhibitory dorsal V0D and 
excitatory ventral V0V neurons and produce left-right alternations. V0D neurons maintain 
hindlimb alternation at a lower speed of locomotion and V0V control hindlimb alternation 
at high frequencies (Kiehn, 2016). According to previous in vitro genetic studies on mice, 
ablation of V0 resulted in lack of hindlimb alternations in mice (Fig. 9 A) (Talpalar et al., 
2013). When studied in vivo in mice model, mice explicit four basic gaits (two alternating 
gaits, walk and trot; one synchronous gait, bound and an intermediate gait, gallop) in the 
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presence of V0 neurons (V0D and V0V) (Fig. 9 B). These four gaits occurred at different 
locomotion speeds. Walk is expressed at a minimum (1-4 Hz) and bound at the maximum 
(10-14 Hz) speed (Fig. 9 B). When both V0 CNs were deleted mice expressed only bound 
gait in which pairs of hindlimbs and pairs of forelimbs are moved in synchrony. When 
V0D were deleted mice died before birth. However, when V0V were deleted mice were 
able to walk, gallop, bound but unable to trot.  
 
Fig. 8 Development of CNs from progenitor domain in the mouse spinal cord 
(Kiehn, 2016) 
 
Fig. 9 Genetic ablation studies of V0 CNs in vitro (a) and in vivo (b) in mouse spinal 
cord (Kiehn, 2016) 
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Further, these V0D and V0V neurons are recruited in ascending order as the locomotor 
speed increases (Fig. 10). Therefore, at low speed like walking rhythm-generating 
neurons (R) activate V0D CNs on the same side of the spinal cord, which in turn inhibit 
motoneurons on the other side of the cord. At high speed of locomotion, V0V neurons are 
activated which leads to trot movement by inhibition of locomotor network circuits 
including motoneurons on the other side of the cord. At higher frequencies of locomotion, 
which lead to a bound movement, arises by the preservation of left-right synchrony by 
non-V0 neurons which might be V3 (Quinlan & Kiehn, 2007; Crone et al., 2008; 2009; 
Talpalar et al., 2013; Bellardita & Kiehn, 2015).  
 
 
 
Fig. 10 Schematic diagram of hypothesized V0 CNs locomotor pathways activated 
with different speed of locomotion (Kiehn, 2016) 
 
 Flexor-extensor coordination  
Motoneurons control flexor-extensor muscles during mammalian locomotion and these 
muscles are activated in alternation. This flexor-extensor coordination is produced by 
reciprocal Ia inhibitory neurons (rIa-INs), which reciprocally inhibit antagonist 
motoneurons and each other. These rIa-INs are one synapse away from flexor-extensor 
motoneurons (Fig. 11) and are activated by Ia afferents from muscle spindle. rIa-INs are 
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rhythmically active while locomotion (Hultborn, 1976). As they are reciprocally 
connected to extensor-flexor motoneurons, they have been proposed as originators of 
rhythmic inhibition of motoneurons during locomotor activity. Experiments on mice by 
genetically ablating glutamate networks showed that minimum inhibitory network is 
enough for flexor-extensor alternation (Fig. 11 a) (Talpalar et al., 2011). When V1 and 
V2b (inhibitory neurons) were removed, flexor-extensor alternations were absent, instead 
synchronous activity was observed (Fig. 11 b) (Zhang et al., 2014).  
 
 
Fig. 11 Proposed scheme of flexor-extensor antagonism in mammals (Kiehn, 2016) 
 
Fig. 11 c shows various levels of the intact circuit with all neuronal elements. Excitatory 
rhythm generating circuits (R) providing inputs to excitatory neurons and rIa-INs (which 
also belong to V1 and V2b neurons) which are further reciprocally providing rhythmic 
excitation and inhibition to flexor-extensor muscles respectively.  Therefore, these V1 
and V2b inhibitory neurons evoke reciprocal inhibition between flexor and extensor 
rhythm generators (Endo & Kiehn, 2008; Talpalar et al., 2011; Zhang et al., 2014).  
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 Rhythm generating circuits 
Akoi and his co-workers have explained slow rhythm generating circuits in lamprey 
spinal cord (Akoi et al., 2001) (Fig. 12). They proposed that, apart from network 
providing the swimming rhythm in the lamprey cord, there is also a network generating 
slow reciprocal alternation into dorsal and ventral parts of the myotome. During steering 
movement, the dorsal and ventral myotomes are selectively triggered and the neural 
networks generating the slow rhythm may depict activity in the spinal machinery used for 
steering (Fig. 12). 
 
 
Fig. 12 Scheme of slow rhythm generating networks in the lamprey spinal cord. A) 
Four slow oscillators for dorsal and ventral myotomes are present on both sides, which 
are connected in three ways: diagonal inhibitory, ipsilateral excitatory and contralateral 
excitatory coupling. B) Dorsal-ventral reciprocal patterns are produced by lowering the 
strength (dashed line) of ipsilateral excitatory connections with respect to the other 
couplings. C) Diagonal reciprocal patterns are evoked by decreasing all excitatory 
couplings relative to diagonal inhibitory couplings. D) The synchronous patterns are 
induced by reducing the diagonal inhibitory connections. E) Left-right reciprocal patterns 
are evoked by decreasing the contralateral excitatory coupling. 
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Rhythm generating circuits (in the mammalian spinal cord) contain neurons which 
express short stature homeobox protein 2 (SHOX2) (Fig. 13). These circuits also drive 
left-right coordinating circuits like non-V (which might be V3) neurons, V2a and V2a 
SHOX2+ (Crone et al., 2008; 2009). It is evident from optogenetic studies that blocking 
SHOX2+ synaptic output disturbs the rhythm without completely abolishing it which 
shows that some unknown excitatory interneuron is still generating the rhythm 
(Dougherty et al., 2013). 
 
Fig. 13 Organizational and molecular delineation of rhythm-generating circuits 
(extracted from Kiehn, 2016) 
 
3.1.4 Dis-inhibited activity in an isolated spinal cord 
Locomotors like rhythmic activity, which is termed as fictive locomotion can be evoked 
in an isolated neonatal rat spinal cord in a ventrally located pre-motoneuronal network 
(Kjaerulff & Kiehn, 1996) by application of N-methyl-D-aspartate (NMDA) (Kudo & 
Yamada 1987) and serotonin (5-HT) (Cazalets et al., 1992) or high K
+ 
solutions (Bracci et 
al., 1998) or dopamine (Kiehn & Kjaerulff, 1996). The relation of disinhibited rhythm to 
the locomotor activity is of particular interest and has been investigated previously (Beato 
& Nistri, 1999). The isolation (split-bath) experiments revealed strong synergy between 
disinhibited rhythm and locomotor pattern. This synergy is expressed in the presence of 
typical alternation between locomotor-like patterns produced during each interburst 
interval even in the absence of 5HT or/and NMDA, despite the presence of strychnine 
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and bicuculline in the caudal area (5HT or/and NMDA applied to the rostral region). 
Moreover, it is also evident that organotypic rat spinal cultures show synchronous 
bursting by blocking GABAA and glycine receptors (Streit, 1993). These studies have 
suggested that spinal rhythmic generators could work even in the absence of synaptic 
inhibition although inhibition is important for temporal phasing of motor patterns (Bracci 
et al., 1996b). Further, GABAB receptors were not necessary for rhythm generation. 
Therefore, Bracci (Bracci et al., 1996b) hypothesized mechanisms that might be involved 
in primary discharge could be the activation of AMPA receptors at excitatory synapses 
and for late oscillations, ascribed to dendritic calcium spikes (Traub et al., 1993). 
 
3.1.5 Reflex pathways in the spinal cord 
 
The gray matter neurons form spinal reflex pathways (also called reflex arc) which are 
simpler than locomotor circuits. These spinal arcs are associated with classical reflexes. 
In vertebrates, most sensory neurons do not pass directly into the brain; instead make 
direct synapses in the spinal cord, which allow faster reflex actions via activation of 
spinal motor neurons. Activation of a simple reflex in response to a corresponding 
specific stimulus typically leads to rapid, repeated, stereotyped and involuntary motor 
reaction.  They could be simple mono-, di- or polysynaptic reflexes with their 
corresponding neurons (i.e., interneurons and motoneurons). Simple reflexes may have an 
autonomic (eyes, blood vessels, etc.) or somatic (skeletal muscle responses) origin. 
Somatic spinal reflexes have been studied in detail in cats and  Ia, Ib, II, FRA (flexion 
reflex afferent) reflexes were described, however, their function in control of locomotion 
remain incompletely understood. 
 
 Monosynaptic reflexes 
Monosynaptic reflexes are evoked by primary afferents (Ia) in response to muscle stretch 
(from muscle spindles) like tendon jerk (knee or ankle) or tap or myotatic reflex. Ia 
afferent (sensory) signal enters the spinal cord from dorsal horn and forms a single 
synaptic connection with homonymous α-motoneuron in the ventral horn of gray matter 
of cord (Fig. 14). In response to muscle elongation, this excitatory reflex will cause 
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muscles to contract. Apart from homonymous α-motoneurons, Ia afferents also make 
monosynaptic connections with synergistic α-motoneurons. It has previously been 
experimentally demonstrated that monosynaptic activity level depends on task and 
circumstances like the amplitude of H reflex is more in standing position and decreases 
while walking. Also, H reflex has more amplitude in extension phase than flexion (swing) 
phase (Stein and Capaday, 1988). Moreover, the precise analysis of Ia monosynaptic 
reflex could provide important information about the neuropathological conditions 
(Matthews, 1972; 1991; Henneman, 1974).  
 
 Ib reflex (inverse myotatic reflex or autogenic inhibitory reflex) is connected to 
peripheral afferent inputs via Ib afferent fibres (Golgi tendon organs). It has found to be 
silent during locomotion and replaced by other Ib afferent reflex pathway, which induces 
more excitation to homonymous and synergistic α-motoneurons (at lower extremities; 
Gossard et al., 1994; Guertin et al., 1995). Moreover, clasp knife reflex may be caused by 
communication between Ia monosynaptic excitatory and Ib autogenic inhibitory actions 
on α-motoneurons in spastic patients (with descending tracts injury). 
 
 
 
Fig. 14 Monosynaptic reflex pathways mediate stretch reflexes 
(http://www.krigolsonteaching.com/uploads/4/3/8/4/43848243/chapter_35-
_spinal_reflexes.pdf) 
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 Polysynaptic reflexes 
Flexion (withdrawal) reflex pathways are activated in response to high threshold, A and C 
fibres. It consists of two interneurons (3 or more synapses) in many segments of cord and 
α-motoneurons of many flexor muscles. In response to an intense (painful) stimulus, it 
causes the withdrawal of limb (Fig. 15). Precisely it consists of two excitatory 
interneurons (3 synapses) for ipsilateral flexor and two interneurons for ipsilateral 
extensor (1 excitatory and 1 inhibitory) motoneurons inhibition. Contralateral pathways 
are activated with a more intense stimulus which results in cross-extension reflex, further 
producing an extension of the contralateral limb. Cross-extension pathways are involved 
in enhancing the postural support while withdrawing a limb from the harsh stimulus. Its 
corresponding interneurons are proposed to be a part of locomotor CPGs (Jankowska et 
al., 1967 a, b). 
 
 
Fig. 15 Polysynaptic reflexes mediate flexion and crossed-extension reflexes 
(http://www.krigolsonteaching.com/uploads/4/3/8/4/43848243/chapter_35-
_spinal_reflexes.pdf) 
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3.2 Spinal cord injury 
 
Spinal cord injury (SCI) is considered to be an incurable condition despite extensive 
advancement in medical and surgical treatment strategies. Traumatic SCI is divided into 2 
groups: 1) penetrative in which damage to the spinal cord by any sharp object, 2) non – 
penetrative in which compression is caused by accident. Acute SCI occurs due to a 
traumatic injury to the spine that fractures or dislocates vertebrae which leads to bruising, 
partially or completely tearing of ligaments in the spinal cord tissue. SCI is a common 
cause of permanent disability and death in children and adults. Recent clinical data 
indicate that in addition to traumatic SCI, there is growing etiopathogenetic importance of 
non-traumatic injuries (McKinley et al., 1999; van den Berg et al., 2010) which may 
occur because of degeneration of spinal column, inflammation, infection, tumour/cancer 
etc. Non-traumatic SCI is more often seen in elderly (Sekhon & Fehlings, 2001). SCI is 
also classified into complete or incomplete, no matter of its origin. With the complete 
injury, the spinal cord is unable to deliver signals below or above the level of injury, 
which ultimately leads to paralysis. With the incomplete injury, some sensation is still 
present below the level of injury (Ryan et al., 2014).  
 
 According to American spinal injury association (ASIA) impairment scale, it is 
classified into five grades: 
 
 Grade A = Complete injury, where no function, whether sensory or motor, is 
preserved in S4-S5 (sacral) segments. 
 
 Grade B = Sensory incomplete, where sensory (not motor) functions are preserved 
below injury including sacral segments.   
 Grade C = Motor incomplete, in which motor functions are preserved below the 
injury and most key muscles below the level of cord injury have a muscle grade 
less than 3. 
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 Grade D = Motor incomplete, where motor functions are preserved below the 
injury and at least half of the key muscles below the neurological level have a 
muscle grade of 3 or more. 
 
 Grade E = Normal, where no motor or sensory deficits, but deficits existed in the 
past. 
 
3.2.1 Epidemiology 
The quantification of incidence and prevalence of SCI is necessary to gain better potential 
impact of healthcare management strategies and health policies to prevent and minimize 
the consequences of injury. In the past, many studies have reviewed the worldwide 
incidence and prevalence of SCI. In 2004, Ackery reviewed and reported the annual 
incidences of injury from 11.5- 57.8 cases/million (Ackery et al., 2004). Later in 2006, 
Wyndaele & Wyndaele reported SCI incidences range from 10.4 – 83 cases/million 
population (Wyndaele & Wyndaele, 2006). Then in 2010, Cripps and his colleagues 
reported prevalence varied from 236 to 1009 cases/million, and the annual incidences in 
North America, Australia, and Western Europe were reported as 39, 16, and 15 
cases/million population, respectively (Cripps et al., 2010). Recently, Chiu and his 
fellows reported the injury incidence ranges from 13.1 to 52.2 cases/million population 
yearly among 13 different countries (Chiu et al., 2010). More recently, van den Berg 
found incidence rates varied from 12.1 to 57.8 cases/million population in different 
countries (van den Berg et al., 2010). These figures indicate that it is difficult to compare 
data from distinct countries as different methods are used to report SCI incidences. 
Table1 shows the incidence of SCI in different countries within Europe (Fulran et al., 
2013). 
 
All studies have shown SCI cases are more prevalent among males than females. 
However, in Manitoba, the male to female ratio was significantly reduced from 12:1 to 
4:4:1 from the 1980s to 2000s due to more cases of motor vehicle injuries among females 
(McCammon & Ethans, 2011). Fig. 16 shows motor vehicle accidents being the leading 
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cause of injury worldwide followed by falls, sports and so on. The injury ratio in Alaska 
was 5:1 (Warren, 1995). The average age of injury varies from 15 -30 years (Price et al., 
1994; Warren et al., 1995; Dryde et al., 2003). According to the National SCI database, 
length of stay in hospitals in the acute care unit has declined from 24 days to 11 days 
since the year 1970 to 2010, respectively. Substantial downward trends are also noted for 
days in the rehabilitation unit (from 98 to 36 days). Neurologic level and extent of lesion: 
the most frequent neurologic category is incomplete tetraplegia followed by incomplete 
paraplegia, complete paraplegia, and complete tetraplegia. Less than 1% of persons 
experienced complete neurologic recovery by the time they were discharged from 
hospital (National SCI Statistical Center, 2014). 
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Table 1 SCI cases in Europe (extracted from Fulran et al., 2013) 
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Fig. 16 Causes of SCI cases in different countries around the globe (Singh et al., 
2014) 
 
 
Lifetime costs: The average annual health care and living expenses and the estimated 
cost over a lifetime vary according to the severity of the injury as shown in Table 2.  
 
 
 
Table 2 Average yearly expenses and lifetime cost of SCI (Economic Impact of SCI 
published in the journal Topics in Spinal Cord Injury Rehabilitation, Volume 16, 
Number 4, in 2011) 
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3.2.2 Pathophysiology 
 
Pathophysiology of SCI is divided into two phases: primary and secondary phase of 
injury.  
 
Primary injury refers to direct mechanical injury to the cord. Primary injury is further 
classified into four types: 1) concussion (transitory spinal cord dysfunction in the absence 
of structural damage), 2) contusion (where the damage is because of vertebral disc 
displacement), 3) compression (similar to contusion although the continuity of columns 
are immediately restored without any intervention (Bailey, 1971; Jaillenger, 1976) and 4) 
laceration (where the injury is due to vertebral fracture). It can last up to 2 h. The initial 
insult tends to damage central gray matter with relative sparing of white matter, especially 
at the periphery (Wolman, 1965). Haemorrhage within the spinal cord develops early 
followed by disruption of blood flow after the initial mechanical injury, resulting in local 
infarction because of hypoxia and ischemia. This particularly damages the gray matter 
due to high metabolic requirements. Neurons near the injury site are disrupted and myelin 
thickness diminished (Young, 1993). Nerve transmission is also disrupted due to oedema 
(Anderson & Hall, 1989; Geiser et al., 1991; Lapcak et al., 2001).  
In most clinical situations, secondary injury following the primary insult is a 
therapeutic target for preventing extension of injury (Rowland et al., 2008). Secondary 
injury begins in minutes after the primary insult and lasts from days to even months. It is 
further divided into three phases: 1) Acute 
(2h – 2 weeks), 2) Sub-acute 
(intermediate; 1-2 months post-injury) and 
3) chronic phase (> 6 months) (Fig. 17). 
 
 
 
Fig. 17 Phases of secondary insult after 
SCI (Young et al., 2017) 
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Secondary injury causes the activation of local factors such as vascular effects 
(leading to hemorrhage, increased permeability, ischemia and formation of free radicals; 
Xiong et al., 2007; Donnelly & Polovich, 2008), glutamate release (causes excitotoxicity 
because of overactivation of glutamate receptors, which further changes the membrane 
potential and activation) (Li & Styts, 2000) and inflammation (leads to activation of 
microglia and neutrophils which further changes the gene expression) (Fig. 18). All these 
factors ultimately converge to apoptosis and finally cell death (Li et al., 1999; Park et al., 
2004).  
 
 
Fig. 18 Pathophysiology of secondary SCI (Young et al., 2017) 
 
 
 
 
“The time window between primary and secondary injury gives us an opportunity to 
develop neuroprotective strategies combat spinal injury”. 
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In recent years our lab has developed an in vitro model of rat SCI. The usefulness of 
using this in vitro preparation is its survival for up to 24 h in physiological conditions. It 
provides us with an opportunity to study the secondary phase of injury for 24 h. In 24 h, 
we are able to study the mechanisms of neuroprotection produced by treating the 
preparation with different drugs after lesion. The lesion is induced by application of either 
glutamate agonist, kainate for 1 h, which induces excitotoxicity at the gray matter of 
spinal cord or pathological medium (PM) which produces hypoxia-like conditions, 
leading to white matter damage. Also, Kuzhandaivel in 2011 has reported, despite kainate 
washout, the secondary lesion progresses within first few hours (Kuzhandaivel et al., 
2011) which enable us to test locomotor spinal networks and imply pharmacological 
treatment for the injury.  
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3.3 Glucocorticoid system 
 
Corticoids (or corticosteroids) are steroid hormones produced by the adrenal cortex of 
vertebrates, as well as the synthetic analogues of these hormones. They are classified into 
two groups: mineralocorticoids and glucocorticoids. 
 
Mineralocorticoids: such as aldosterone (produced in the adrenal cortex), helps in the 
regulation of electrolyte and water balance in kidneys by regulating ion transport in renal 
tubules (Lui et al., 2013).  
 
Glucocorticoids (GCs): also known as glucocortico-steroids are hormones synthesized 
and released by the adrenal cortex in a circadian manner and in response to stress. The 
secretion of these hormones is maintained by the hypothalamic-pituitary-adrenal (HPA) 
axis (Fig. 19). Hypothalamus secretes corticotropin-releasing hormone (CRH), in 
response to internal and external stimuli which acts on the anterior pituitary to stimulate 
the synthesis and secretion of adrenocorticotropic hormone (ACTH). ACTH further acts 
on the adrenal cortex to secrete glucocorticoids. It is present in all vertebrate animal 
cells. The name glucocorticoid (glucose + cortex + steroid) is composed of its role in the 
regulation of glucose metabolism. Glucocorticoids play important role in regulation of 
homeostasis, metabolism, immune functions, skeletal growth, cardiovascular function, 
reproduction and cognition, etc (Barnes, 1998; Sapolsky et al., 2000). GCs are also 
important part of feedback mechanism in immune system where they release in response 
to stress and help in reduction of inflammation. Hence they are also used as a medicine to 
treat diseases where the immune system is over-activated like in autoimmune diseases, 
asthma and various allergies etc.  
 
They show anti-inflammatory effects by inhibiting inflammatory mediators (by 
transrepression) and inducing anti-inflammatory mediators (called as transactivation) 
(Häggström & Richfield, 2014). Their vaso-constrictive effects are mediated by blocking 
the action of inflammatory mediators (histidine) (Häggström & Richfield, 2014). GCs 
also help in immunosuppression effects by suppressing delayed hypersensitivity reactions 
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(by acting directly on T-lymphocytes). Further their anti-proliferative effects are induced 
by inhibition of DNA synthesis and epidermal cells turnover (Häggström & Richfield, 
2014). 
 
 
Fig. 19 Effects of glucocorticoids on Hypothalamus-Pituitary-Adrenal (HPA) axis. 
The scheme represents sites of synthesis and the targets of action of glucocorticoid. 
Question marks indicate uncertainty as to the mechanism of action. Corticotropin-
releasing hormone (CRH) (also known as a corticotropin-releasing factor, CRF), 
adrenocorticotropic hormone (ACTH) and pro-opiomelanocortin (POMC) 
(extracted from Newton, 2000) 
 
Once in the bloodstream, GCs diffuse into tissues and cells and bind to 
glucocorticoid (GR) or mineralocorticoid nuclear receptors (MR). In normal conditions, 
GC binding favours MRs, even though GRs are still occupied by GCs at low levels 
(Spencer et al., 1990). When the level of GCs increases in response to stress, they bind to 
GRs at higher levels. Unbound GRs are present in the cytoplasm in complex with heat 
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shock proteins, HSP90 and HSP70, and FK506-binding proteins, FKBP51. When GCs 
bind to GRs, these receptors undergo a conformational change and nuclear translocation 
to induce gene transcription (Sanchez, 1990; Oakley & Cidlowski, 2011; Maiarù et al., 
2016). GRs mediate gene transcription by binding to glucocorticoid response elements 
(GREs) (Datson et al., 2008; Revollo & Cidlowski, 2009). Many transcriptional GR 
targets block the release of cytokines (like TNFα and IL-1β) making GR activation a 
powerful tool to suppress inflammation (Joyce et al., 1997; Revollo & Cidlowski, 2009). 
Therefore, GCs are prescribed to treat acute and chronic inflammatory diseases, 
autoimmune diseases and after an organ transplant (Oakley & Cidlowski, 2011).  
 
In the CNS, GRs are expressed in neurons throughout the brain and spinal cord.  
 Hippocampal CA1 neurons have maximum expression of GRs (McEwen et al., 1968; 
Herman et al., 1989). Moreover, all glia express GRs. Schwann cells (the myelinating 
cells of the peripheral nervous system, PNS), brain and spinal cord microglia (originate 
from bone marrow-derived monocytes and are the resident macrophages of CNS), 
oligodendrocytes (myelinating cells of CNS) and astrocytes (major support cells to CNS 
neurons) all bind synthetic GR agonists and are positive to GR immunoreactivity 
(Warembourg et al., 1981; Vielkind et al., 1990; Sierra et al., 2008; Shaqura et al., 2016). 
MRs co-localize with calcitonin gene-related peptidergic (CGRP) nociceptive neurons in 
the spinal cord and dorsal root ganglia (Shaqura et al., 2016) and not present in spinal 
astrocytes, microglia and oligodendrocytes. In contrast, oligodendrocytes, spinal cord 
astrocytes, and microglia are mostly absent of MR immunoreactivity (Matsusue et al., 
2014; Shaqura et al., 2016). It may be possible that cells lacking MRs have more GRs 
(Shaqura et al., 2016; Shaqura et al., 2016). It has been reported that spinal microglia are 
activated in response to stress/GCs (Alexander et al., 2009), providing evidence for direct 
stress/GC-induced plasticity in microglia. 
 
Unfortunately, its therapeutic benefits are limited by side effects like re-
appearance of inflammation or pain, abdominal obesity, glaucoma, growth retardation in 
children, and hypertension (Oakley & Cidlowski, 2011; 2013). Apart from this, GCs 
uptake may lead to neuropsychiatric disorders like depression mood imbalance and 
anxiety (Dubovsky et al., 2012). However, agonists of GCs are still prescribed in 
hospitals because of their beneficial effects.  
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Prednisone is one of the commonly prescribed steroid drug for chronic conditions 
(the structure is shown in Fig. 20). It is more popular also because of its low cost. It is a 
prodrug which is biotransformed to an active metabolite, prednisolone after incorporation. 
Thus it is available only for oral use that allows for first-pass metabolism during 
absorption. 
 
Betamethasone is available in markets in many forms: betamethasone 
dipropionate (branded as Diprosone, Diprolene, Celestamine, Procort (in Pakistan), and 
others), betamethasone sodium phosphate (branded as Bentelan in Italy) and 
betamethasone valerate (branded as Audavate, Betnovate, Celestone, Fucibet, and others). 
In the United States and Canada, betamethasone is mixed with clotrimazole and sold as 
Lotrisone and Lotriderm etc. Its molecular structure is depicted in Fig. 20. Betamethasone 
was approved for medical purpose in the United States in 1961 (The American Society of 
Health-System Pharmacists, 2015). Betamethasone may suppress astrocytes activation 
and elevate TNF-α and IL-1β levels in neuropathic pain of rat. Local injection of 
betamethasone leads to a small increase in spinal GR expression and thus relieve from 
pain as compared to intrathecal injection (Wang et al., 2013).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 Molecular structures of some glucocorticoids (Becker DE, 2013) 
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Methylprednisolone (MP, Medrol) is a widely used medication for the treatment 
of patients with chronic SCI (Hurlbert et al., 2013; Fallah et al., 2016; Fehlings et al., 
2017). It is available to administer orally or via injection. Methylprednisolone has also 
been reported to promote recovery of neurological function after spinal cord injury in rats 
(Lu et al., 2016). The neuroprotective effect of MP on SCI may be because of the 
activation of the Wnt/β-catenin signalling pathway and this inhibition of apoptosis, 
providing a novel molecular mechanism underlying the role of MP for the treatment of 
SCI (Lu et al., 2016) (Fig. 21).  
 
 
 
Fig. 21 Neuroprotective effect of MP after SCI in vitro (Lu et al., 2016) 
 
 
 
 
 
 
 
 
 
Page 40 
 
 
It also exhibits antioxidant properties and inhibits lipid peroxidation (Hall & 
Springer, 2004) (Fig. 22).  
 
 
 
Fig. 22 Hypothesized role of inhibition of lipid peroxidation by MP and production 
of neuroprotective effect after acute SCI (Springer & Hall, 2004) 
 
 
However, due to its side effects which makes it as a controversial drug of choice. We 
tested this drug on our in vitro rat SCI model (Sámano et al., 2016) to investigate its pros 
and cons on the lesioned spinal cord in vitro.  
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3.4 General anesthetics 
 
An ancient Greek surgeon Dioscorides who originally used the term “anaesthesia” and it 
was resurrected by Dr Oliver Wendell Holmes in 1846 which means lack of sensation 
produced by inhalation of ether (Nuland, 1988; Kissin, 1997). The objectives of general 
anaesthesia include amnesia, unconsciousness (also termed hypnosis), and 
immobilization. According to its definition, it reversibly produces all of these three 
therapeutic effects (Grasshoff et al., 2005; Mashour et al., 2005).  
 
General anaesthetic drugs include inhaled gases as well as intravenous agents. 
Other classes of drugs used to achieve specific clinical goals during surgery 
(Woodbridge, 1957) could be the use of selective blockers of neuromuscular transmission 
to restrict movement of patients while surgery.  
 
 These anaesthetics have been broadly divided into three groups based on relative 
potencies for distinct clinical endpoints and their impact on electroencephalogram (EEG) 
(Forman & Chin, 2008).  
 
Group 1: consists of etomidate, propofol, and barbiturates, intravenous drugs, which can 
potentially produce unconsciousness than immobilization. For example in case of 
propofol unconsciousness (hypnosis) is attained at 3 µg/ml of plasma concentration 
whereas immobility (during skin incision) is achieved with four times higher 
concentration of the drug (Smith et al., 1994). They shift EEG (recorded from cortex) to 
lower frequencies which enable to reproduce correlation with anaesthetic depth 
(Kuizenga et al., 2001). 
 
Group 2: composed of gaseous (volatile) anaesthetics such as nitrous oxide (N2O), xenon 
and cyclopropane, along with ketamine, an intravenous agent. They are capable to induce 
analgesia however hypnotic and immobilizing ability is weak. N2O and ketamine may 
increase the EEG frequencies however, the anaesthetic depth monitored via EEG is not 
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stable (Rampil et al., 1998; Anderson & Jakobsson, 2004). There are some contradictory 
data for xenon based on EEG monitoring (Goto et al., 2000; Laitio et al., 2008).  
 
Group 3: consists of the volatile halogenated anaesthetics: halothane, isoflurane, 
sevoflurane, desflurane and methoxyflurane. They produce amnesia, hypnosis and 
immobility in a predictable manner (Campagna et al., 2003; Mashour et al., 2005). They 
reduce the frequency of EEG and anaesthetic depth monitors show reliable correlations 
with the level of consciousness. 
 
 It has extensively been studied that anaesthetics produce neuroprotective effects 
on spinal neurons and motoneurons (Salzman et al., 1993; Sooner et al., 2003; Baranović 
et al., 2014; Ishikawa et al., 2014; Bao et al., 2017). Therefore our lab has recently tested 
the volatile anesthetic, methoxyflurane (Shabbir et al., 2015), which is less frequently 
used these days because of its toxic effects (Paul et al., 1976; Wharton et al., 1980), 
showed strong neuroprotective effects on spinal motoneurons and fictive locomotion has 
recovered back by this drug. Back in 2005, the Food and Drug Administration (FDA) 
disapproved its usage in the market because of safety concerns (Mazze, 2006). However, 
it is still used in Australia for emergency purposes as an analgesic for the initial 
management of pain due to acute trauma. 
 
 On the other hand, an intravenous anaesthetic, propofol (Fig. 23) which is a 
widely used drug these days in hospitals by surgeons to induce anaesthesia before 
surgery. More usage is because of its fast recovery of consciousness, however, fast 
recovery means eye-opening (Grundmann et al., 2001) and not complete recovery of 
cognitive functions (Mirski et al., 1995).  Propofol also exerts other advantages such as 
minimal side effects, controllable anaesthetic state and quick onset (Glen, 1980; Glen & 
Hunter, 1984). Further it also exerts non-anaesthetic effects (stimulates constitutive nitric 
oxide (NO) production and inhibits inducible NO production, produce anxiolytic effects, 
has antioxidant, immunomodulatory, analgesic, antiemetic and neuroprotective effects) 
reported in animals (Rossi et al., 1996; Pain et al., 1999; Yamasaki et al., 1999; Ishii et 
al., 2002; Wang et al., 2002;  Kurt et al., 2003; Nishiyama et al., 2004; Kushida et al., 
2007; Sanchez-Conde et al., 2008) as well as in humans (Zacny et al., 1996; Aoki et al., 
1998; Grouzmann et al., 2000; Veselis et al., 2004; Gonzalez-Correa et al., 2008; Veselis 
et al., 2008).  
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Fig. 23 Structure of propofol (also known as 2, 6-di-isopropylphenol or Diprivan or 
Disoprofol or Disoprivan) 
(http://www.drugfuture.com/pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_
m70460.html) 
 
 
 
Mechanism of action of neuroprotective effect of propofol 
 
Propofol shows neuroprotective effect via potentiation of GABAA (β2 and β3 subunits) 
mediated receptor responses (Fig. 24) (Belelli et al., 1997; Forman & Chin, 2008; 
Bajrektarevic & Nistri, 2016) and depressed the glutamate (mainly NMDA) mediated one 
(Vasileiou et al., 2009).  
 
GABA receptors are a class of receptors which respond by binding of the 
inhibitory neurotransmitter, GABA. GABA receptors are classified into two groups: 
GABAA and GABAB. GABAA receptors are ligand-gated ion channels also called as 
ionotropic receptors [which also include nicotinic acetylcholine receptors (nAChR), the 
5-hydroxytryptamine (5-HT) type-3 receptors, and the glycine receptors], whereas 
GABAB receptors are G protein-coupled receptors (also known as metabotropic 
receptors). 
 
GABAA receptors are made up of five subunits that belong to different subclasses 
(α, β, γ, δ, ε, π, θ, ρ) (Fig. 24). The subunits exhibit a 60–70% homology within each 
class, however, the homology between the classes is 30–40% (Sieghart, 1995; Barnard et 
al., 1998). So far, a total of six α-, three β-, three γ-, one δ-, one ε-, one π-, one θ-, and 
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three ρ-subunits of GABAA receptors and alternatively spliced isoforms of these subunits 
have been cloned and sequenced from the mammalian CNS (Sieghart, 1995; Barnard et 
al., 1998). In the human brain, this subunit seems to be final as no new GABAA receptors 
were detected by applying search algorithms from human to nematodes (Simon et al., 
2004). 
 
 
Fig. 24 Structure of GABAA receptor-chloride (Cl
-
)
 
channel complex with binding 
sites for different drugs in CNS. GABA binds to two sites located between α and β 
subunits, trigger the opening of the Cl
- 
 channel, which produces membrane to 
hyperpolarize resulting in a reduction of neuronal firing rate 
(http://tmedweb.tulane.edu/pharmwiki/doku.php/overview_of_cns_neurotransmitt 
rs) 
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3.5 Nicotinic Acetylcholine Receptors 
 
The importance of nicotinic acetylcholine receptors (nAChRs) to regulate biological 
functions lies in their ability to bind endogenous agonist, acetylcholine (ACh), which 
makes the receptor in motion and gates the channel allowing the flow of ions and thus 
produces a cellular response. In 1936, Henry Dale and Otto Loewi shared the Nobel prize 
in Physiology and Medicine for their pioneering research on chemical neurotransmission; 
in particular, the discovery of first identified neurotransmitter, ACh. The history of this 
neurotransmitter was based on critical experiments performed by H. Dale (Dale, 1914) 
who determined the role of ACh in vasodepression and O. Loewi (Loewi, 1921), who 
described the chemical neurotransmission in frog nerve-heart preparation. This story was 
concluded after 15 years when ACh was actually found in mammalian organs (Dale & 
Dudley, 1929). Since that time, the history of ACh in neuroscience has been of extreme 
advancement to our knowledge in various functions in the nervous system and in 
neuropathologies.  
The name ACh is derived from its chemical structure as it is an ester of acetic acid 
and choline with chemical formula, CH3COOCH2N
+
(CH3)3. In cholinergic neurons, it is 
synthesized from choline and acetyl-CoA by the enzyme choline acetyltransferase, located in 
the cytosol. Choline is supplied from extracellular space by the high-affinity active transport 
system, whereas acetyl-CoA is synthesized in mitochondria. After synthesis, ACh is stored 
into synaptic vesicles along with ATP. Upon nerve stimulation, it is released into the synaptic 
cleft, by exocytosis through the synaptic vesicles, where it may activate cholinergic receptors 
or be rapidly degraded by acetylcholinesterases to choline and acetate.  
 
3.5.1 Receptor types and distribution 
 
The key molecules to which ACh bind are cholinergic muscarinic (mAChRs) and 
neuronal nicotinic acetylcholine receptors (nAChRs). Muscarinic receptors were named 
 
 
Page 46 
 
as such because they are sensitive to muscarine and nicotinic receptors for their 
sensitivity to nicotine.  Both are expressed by either neuronal or non-neuronal cells 
throughout the body. These two receptors are structurally and functionally different. 
mAChRs occur primarily in CNS and belong to a family of G-protein coupled 
receptors. They use an intracellular secondary messenger system which increases 
intracellular calcium resulting in the transmission of signals inside the cells. Upon ACh 
binding to mAChRs causes conformational changes at the receptors leading to activation 
of intracellular G-protein and conversion of GTP to GDP (in order to become activated 
and dissociate from the receptor). The active G-Protein acts as an enzyme to further 
catalyze downstream signalling cascades. These receptors play an important role in 
modulating various physiological functions like the release of neurotransmitter, 
contraction of smooth muscles and heart rate etc. They are classified into five types of 
metabotropic receptors: M1 to M5 (Bonner et al., 1987; Peralta et al., 1987; Bonner et al., 
1988;  Bonner, 1989;  Caulfield et al., 1998). M1-M5 are localized in CNS, M1-M4 are 
also found in many tissues like M1 receptors are localized in salivary glands, M2 in 
cardiac tissues where they play a crucial role in closing calcium channels and therefore 
reduce the force and rate of contraction and M3 receptors are found in smooth muscles 
and secretion glands. M1, M3 and M5 are involved in activation of phospholipase C and 
thus produce two secondary messengers, Inositol trisphosphate (IP3) and diacylglycerol 
(DAG) eventually causing an increase of intracellular calcium (Wess, 1996; et al., 1998). 
M2 and M4 inhibit adenylate cyclase and thus causing the low production of cAMP 
which is a second messenger (Scarr, 2012).   
 
nAChRs are a member of the superfamily of cysteine-loop of pentameric ligand-
gated ion channels, widely expressed in both central and peripheral nervous system (Sine 
& Engel, 2006; Albuquerque et al., 2009). They are expressed in both neuronal and in 
non-neuronal systems (Dani & Bertrand, 2007; Wessler & Kirkpatrick, 2008). So far, 
seventeen vertebrate subunits (α1-10, β1-4, γ, δ, and ε) have been identified in the 
nervous system and muscles nevertheless, only the subunits expressed in the mammalian 
CNS are reviewed here.  
12 genes have been identified, encode for neuronal nAChR subunits, α2–α10 
(contain 2 adjacent cys-residues crucial for binding ACh) and β2–β4 (lack cys-residues) 
(Le Novere & Changeux, 1995; Lindstrom, 2000). Further, these receptors are mainly 
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divided into 2 categories, low affinity receptors (mainly α7 nAChRs) that bind the agonist 
with low affinity (with µM concentration) and high affinity (majorly α4β2 nAChRs) that 
bind receptors with high (with nM concentration) affinity in the chick (Whiting & 
Lindstrom, 1986a) and rat brain (Whiting & Lindstrom, 1986b; Whiting  & Lindstrom, 
1987).  In CNS, cholinergic transmission acts via nAChRs and modulates various 
activities such as cell excitability, neurotransmitter release etc and also control 
physiological functions like cognition, pain, anxiety, fatigue, reward, learning, memory 
(Changeux & Edelstein, 2001; Hogg et al., 2003; Christie et al., 2008). The brain 
cholinergic system is formed of a number of subsystems consisting of eight major and 
highly overlapping groups of cells, where dendrites of one cell are making contacts with a 
number of other cells. Therefore it can be assumed that these network interconnections 
may lead to firing of a group of neurons altogether in coordination and consequently to 
the activation of different cholinergic subsystems (Mesulam & Geula, 1988; Mesulam et 
al., 1989; Woolf, 1991). 
 Magnocellular basal complex: The most important group of cholinergic neurons, 
providing input to cortical and hippocampal neurons.  
 
 Pedunculopontine-laterodorsal tegmental complex: The second significant 
cholinergic complex in brain.  The neurons are localized at the pedunculopontine 
tegmental nucleus and innervating the thalamus and midbrain dopaminergic (DA) 
neurons. 
 
 Striatum: Dense cholinergic fibres evolving from inner cholinergic neurons 
located in the caudate nucleus and they do not innervate beyond striatum. 
 
 Lower brain stem: Cholinergic neurons localized in brainstem reticular formation 
and spinal intermediate gray matter which innervate the superior colliculus, 
cerebellum and cortical nuclei. 
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 Habenula–interpeduncular system: Cholinergic neurons present in the medial 
habenula project to the interpeduncular nucleus. Thalamus is providing input 
signals to habenula and thus it is a significant point through which the brainstem 
reticular formation is being influenced by the limbic system. 
 
 Autonomic nervous system: The preganglionic neurons in sympathetic and 
parasympathetic systems are cholinergic. The parasympathetic preganglionic cells 
are present in encephalic trunk nuclei and in S2–S4 segments of the spinal cord 
and are innervating to target organs.  The sympathetic preganglionic neurons are 
located in the intermediolateral gray matter (T1–L3 segments) of the spinal cord 
and innervating to paravertebral sympathetic ganglia. 
 
3.5.2 Structure and topology of nAChR 
 
The pentameric neuronal nAChRs (Fig. 25 B) encode for peptides having hydrophilic 
extracellular -NH2 domain (M1-M3), a large intracellular loop and a fourth hydrophobic 
transmembrane domain (M4) (Sargent, 1993; Hogg et al., 2003) (Fig. 25 A). During 
evolution, these receptor subunits are highly conserved with < 80% amino acid identity of 
the same subunit among different vertebrate species (Le Novere & Changeux, 1995).  
These nAChRs are further divided into 2 classes: homomeric (consisting of single types 
of subunits; made of α7– α9 subunit homo-pentamers) or heteromeric (composed of 
several subunit types; made up of α7, α8 or α9, α10 subunit hetero-pentamers). Although, 
nAChRs, which contain the α2– α6 and β2– β 4 subunits form only heteromeric receptors 
that bind to the agonists with high affinity (Lindstrom, 2000) (Fig. 25 C). nAChR 
subunits are organized around the central canal, where the receptor has binding sites for a 
ligand, ACh. ACh has two components, principal and complementary. In heteromeric 
nAChRs, α2– α4 and α6 subunits carry principal component and β2 or β4 subunits carry 
the complementary component. In case of homomeric receptors, each subunit has both 
components to bind ACh (Changeux & Edelstein, 1998; Corringer et al., 2000; Fig. 25 
C). However, these components are absent in α5 and β3 subunits, therefore, called as 
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auxiliary subunits. nAChRs are permeable to Na
+
, K
+
, and in some cases, Ca
2+
 ions. The 
channel opens immediately (with a time constant of about 20 μs) upon binding of least 
two ACh molecules to the receptor. In the open state, the nAChR channel has a pore 
diameter of 9-10 Å with a conductance in the range from 5 to 35 pS.  
 
 
Fig. 25 The structure of neuronal nAChRs. (A) Scheme of transmembrane topology 
of nAChR subunits. (B) An assembled pentameric arrangement of nAChR receptor 
subunits. (C) Subunit arrangement in the homomeric α7 and heteromeric α4β2 
subtypes, and localization of the ACh binding site (Gotti & Clementi, 2004) 
 
 
3.5.3 Ligands –Agonists of nAChRs 
 
There are several molecules being reported to activate nAChRs exemplified in Fig. 26:   
 
 Nicotine acts as an agonist at most nicotinic nAChRs (IUPHAR Database, 2004; 
Malenka et al., 2009), except at two receptor subunits (α9 and α10) where it acts 
as a receptor antagonist.  Nicotine is an alkaloid found in the nightshade family of 
plants. In smokers, the peak concentration of nicotine in blood plasma is about 
0.31 μM (between 10 and 50 ng/ml), in the brain is about 1 μM, and after smoking 
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in lung fluids the concentration reaches to 60 μM (Clunes et al., 2008; Matta et al., 
2006). After inhaling the cigarette smoke, nicotine reaches the brain within 8-10 s 
through arterial circulation. Its half-life is about 2 h, and of cotinine (the major 
nicotine metabolite) is about of 16 h (Benowitz, 2009). Other nAChR analogues 
are also synthesized from nicotine (shown in Fig. 26, compound 1) by replacing 
pyridine or pyrrolidine rings or by conformational flexibility. 
 
 Compound 2 is highly selective for α4β2 receptor subtype (Romanelli & Gualtieri, 
2003; Bunnelle et al., 2004; Jensen et al. 2005).  
 
 Analogue in example 3 has nM affinity for β2-containing receptors (Wei et al., 
2005).  
 
 The compounds of general formula 4 and 5 (Pallavicini et al., 2004) possess 
affinity in µM range for the rat brain nAChRs labelled by [
3
H]-epibatidine. 
 
 Substitution of pyridine ring with a quinoline gives rise to compound 6 which 
behave as a nicotinic agonist in the hot-plate test on mice when injected 
intracerebroventricularly (i.c.v.) (Guandalini et al., 2006). 
 
 Compounds 7–10 designed with the motive of discovering new analgesic drugs. 
Compounds of general formula 7, but not 8 or 9, showed significant analgesic 
activity in the writing test in mice (Zhang et al., 2006), whereas compound 10 
showed analgesic activity in the formalin test on mice (Baraznenok et al.,  2005). 
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Fig. 26 Agonists of nAChRs (modified from Romanelli et al., 2007) 
 
 
3.5.4 Desensitization of nAChR 
 
Loss of physiological response after prolonged application of stimulus is termed 
desensitization. Desensitization of the nAChR is produced by prolonged exposure to 
agonists leading to inactivation of the channel. In spite of extensive studies on nAChRs, 
the detailed molecular mechanism of the nAChR desensitization is not known with 
certainty. Concerning desensitization, nAChRs in the mammalian nervous system can be 
divided into two main groups: α7-containing receptors which desensitize within 
milliseconds and non α7 nAChRs that desensitize slowly, in seconds (Quick & Lester, 
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2002; Giniatullin et al., 2005).  Desensitization depends on agonist concentration and 
time of exposure.  
 
nAChRs may exist in three distinct conformations: 1) the resting, 2) active and 3) 
desensitized states. Fig. 27 A, B demonstrates an idealized nicotinic cholinergic synapse 
where the presynaptic component composed of the neurotransmitter ACh (black dots) 
within synaptic vesicle and the postsynaptic membrane consists of the receptor. The 
receptor exists in an equilibrium mixture of two conformation states, resting (Re) and 
desensitized (D) state. The numbers below each conformation state imply amount or 
percent of each conformation state (Heidmann & Changeux, 1979; Boyd & Cohen, 1980). 
An action potential causes the release of ACh at the cleft produces conformational change 
resulting in an active state. As soon as ACh occupies all binding sites, the receptor 
affinity towards ACh increases which activates the D state.  
 
In classical desensitization, the agonist is applied from medium to a high (μM to 
mM) concentration which activates and then desensitizes the receptors which 
subsequently recovers after the removal of agonist. Classical desensitization develops in 
tens of millisecond range (Fig. 27 C). High-affinity desensitization occurs with low 
agonist concentration without apparent receptor activation. Both phenomena are nAChR 
subunit and agonist-dependent (Giniatullin et al., 2005). Desensitization can be regulated 
by exogenous and endogenous substances and by covalent modifications of the receptor 
structure. Modulators could be non-competitive blockers such as calcium (Giniatullin et 
al., 2005), thymic hormone peptides, substance P and receptor phosphorylation. 
Phosphorylation is correlated with the regulation and desensitization of the receptor 
through various protein kinases (Changeux & Edelstein, 1998). 
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Fig. 27 (A, B) Mechanism of desensitization (Ochoa et al., 1988). (C) Different 
timings of desensitization with respect to agonist concentration and time of agonist 
application (Giniatullin et al., 2005) 
 
 
 
3.5.5 Role in Neuroprotection 
 
 
Previous studies have indicated that nAChRs are important targets to attempt 
neuroprotective strategies against pathological insults such as excitotoxicity or 
oxygen/glucose deprivation. The present study was raised with the recent observation of 
nicotine, an agonist of nACRs protection against excitotoxicity applied to rat brainstem 
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motoneurons. Due to lack of information on similar effects on the rat spinal cord, we 
applied this procedure to our model to test the effects of nicotine on SCI model. There are 
many studies which show promising neuroprotection by nicotine application. Kihara and 
his colleagues have proposed that the neuroprotection may be achieved by activation of 
PI3-kinase-Akt system and upregulation of Bcl-2 in cultured cortical neurons (Kihara et 
al., 2001). Therefore, it could also be possible the involvement of PI3-kinase-Akt 
pathway in nAChR mediated neuroprotection in spinal motoneurons of rat (Nakamizo et 
al., 2005). It is also known that nAChR mediated neuroprotection against excitotoxicity is 
Ca
2+
 dependent (Donnelly-Roberts et al., 1996; Dajas-Bailador et al., 2000; Ferchmin et 
al., 2003) and does not involve inhibition of glutamate receptor function (Dajas-Bailador 
et al., 2000; Prendergast et al., 2001; Ferchmin et al., 2003).  
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3.6 Neuroprotection by a natural compound: Celastrol 
 
Identification of some bioactive compounds extracted from medicinal plants has drawn 
substantial interest in recent years for their strong and exclusive anti-oxidant, anti-
inflammatory, anticancer and neuroprotective properties. One classic example is 
Tripterygium wilfordii (TW) plant, widely used in Chinese medicine for the treatment of 
distinct chronic inflammatory and autoimmune diseases (Kannaiyan et al., 2011; Wong et 
al., 2012). TW or “lei gong teng” (called in Chinese) is also known as thunder god vine, 
is a vine used in traditional Chinese medicine.  The roots of this plant contain various 
therapeutic compounds such as steroids, terpenoids and alkaloids. There are more than 46 
diterpenoids (for example triptolide), 20 triterpenoids (like celastrol), 21 alkaloids (like 
euonine), and many other small molecules have been identified from TW. The most 
abundantly found bioactive compound extracted from its roots is celastrol, consisting of 
ample biological activities. Celastrol is a pentacyclic triterpenoid that belongs to the 
family of quinine methides (Fig. 28).  
 
Fig. 28 Structure of celastrol (http://www.chemspider.com/Chemical-
Structure.109405.html) 
Numerous studies have shown the pharmacological effects celastrol on several 
diseases (Allison et al., 2001; Salminen et al., 2010; Kannaiyan et al., 2011). Celastrol 
exhibited effects in suppression of microglial activation, production of pro-inflammatory 
cytokines and inducible nitric oxide (Allison et al., 2001). China Food and Drug 
Administration (CFDA) has approved the TW drug for the treatment of rheumatoid 
arthritis in China. More recent studies on animals model have shown that celastrol has the 
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ability to attenuate multiple sclerosis (MS) by regulating Th17 responses, balancing the 
pro- and anti-inflammatory cytokines and downregulating the expression of factor kappa-
B (NF-κB) (Abdin & Hasby, 2014; Wang et al., 2015). Celastrol has shown to potentially 
inhibit lipid peroxidation (Sassa et al., 1990; 1994) in rat liver mitochondrial membrane. 
Further, this drug has shown to exhibit neuroprotective effects in the rodent model of 
Huntington’s and Parkinson’s diseases by inducing heat shock protein 70 (HSP70) within 
dopaminergic neurons and reducing tumour necrosis factor-α and NF-κB and astrogliosis 
(Cleren et al., 2005). HSP70 is prominently induced during stress conditions and is also 
the best-conserved protein. It has demonstrated to be widely expressed in the CNS. It is 
expressed by neurons, glial cells (Brown et al., 1989; Nowak et al., 1990) and spinal 
motoneurons (Carmel et al., 2004; Cizkova et al., 2004) as well. Therefore we have 
investigated the neuroprotective effects of celastrol in our rat SCI model. We have pre-
treated our preparations with celastrol (0.75 µM) for 6 h by making a hypothesis that 
during this time course celastrol with activate HSP70 expression and decrease NF-κB. 
This hypothesis is based on previous studies and our lab reports where Shabbir has shown 
the expression of HSP70 in spinal motoneurons and its role in neuroprotection (Shabbir et 
al., 2015). After pre-treating the spinal cords we have applied excitotoxic agent, kainate 
(50 µM) for 1 h to induce excitotoxicity and record its effects the day after.  
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4 AIMS 
 
For any kind of rhythmic motor behaviour, like running or walking or swimming, CPGs 
have been presumed to be present (Grillner, 1986). Disturbance of finely tuned locomotor 
network within sensory input and pattern generation following central insult such as SCI, 
Parkinson disease, stroke, results in movement disorder. Therefore, it is important to 
understand the mammalian locomotor CPG in order to improve neuro-rehabilitation of 
patients with SCI (Rossignol et al., 1998; Edgerton et al., 2004). Without interpreting the 
spinal neuronal circuits which generate motor behaviours, it is hard to design suitable 
therapies to combat spinal lesion.  
 
Using this fundamental therapeutic approach as a first step, by using an in vitro rat SCI 
model, thesis project focuses at:  
 
 Gaining insight of early pathophysiological processes occurs after inducing spinal 
lesion by application of kainate (50 or 100 µM) (glutamate agonist, which is used 
to produce excitotoxicity by over-activation of glutamatergic system) or 
pathological medium (mimics dysmetabolic/hypoxic conditions after vascular 
dysfunction) for 1 h and studying the changes occurred in spinal reflexes, 
locomotor networks, neuronal and motoneuronal damage during injury by 
extracellular recordings, immuno-histochemistry and calcium imaging techniques.  
 
The next step was to: 
 
 Study the mechanisms of neuroprotection at the early phase of insult to prevent 
delayed pathological events by using pharmacological therapies.  
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 Methylprednisolone sodium succinate (6 &10 µM) – used to study how this drug 
could modulate fictive locomotor rhythms and attenuate neuronal, motoneuronal 
and astroglial damage. 
 Propofol (5 µM) – How this widely used intravenous anaesthetic could antagonize 
the effect of excitotoxicity by understanding its mechanism of action. 
 Nicotine (0.5, 1, 2 & 10 µM) – A potent parasympathomimetic stimulant used to 
investigate (using in vitro rat spinal cord and organotypic spinal cultures): 
o The correct neuroprotective dose. 
o Its effects on spinal locomotor CPGs before and after lesion. 
o How this drug could modulate the damage evoked by stimulation of 
excitotoxic pathways.  
o Which receptors at the spinal level are involved in the neuronal and 
motoneuronal recovery after SCI.  
 Celastrol (0.75 µM) – A bioactive extract used to examine the protective role of 
inducible HSP70 on spinal motoneurons against excitotoxic injury to rat spinal 
cord. 
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Abstract—Methylprednisolone sodium succinate (MPSS)
has been proposed as a ﬁrst-line treatment for acute spinal
cord injury (SCI). Its clinical use remains, however, contro-
versial because of the modest beneﬁts and numerous
side-eﬀects. We investigated if MPSS could protect spinal
neurons and glia using an in vitro model of the rat spinal
cord that enables recording reﬂexes, ﬁctive locomotion
and morphological analysis of damage. With this model, a
diﬀerential lesion aﬀecting mainly either neurons or glia
can be produced via kainate-evoked excitotoxicity or appli-
cation of a pathological medium (lacking O2 and glucose),
respectively. MPSS (6–10 lM) applied for 24 h after 1-h
pathological medium protected astrocytes and oligodendro-
cytes especially in the ventrolateral white matter. This eﬀect
was accompanied by the return of slow, alternating oscilla-
tions (elicited by NMDA and 5-hydroxytryptamine (5-HT))
reminiscent of a sluggish ﬁctive locomotor pattern. MPSS
was, however, unable to reverse even a moderate neuronal
loss and the concomitant suppression of ﬁctive locomotion
evoked by kainate (0.1 mM; 1 h). These results suggest that
MPSS could, at least in part, contrast damage to spinal glia
induced by a dysmetabolic state (associated to oxygen and
glucose deprivation) and facilitate reactivation of spinal net-
works. Conversely, when even a minority of neurons was
damaged by excitotoxicity, MPSS did not protect them nor
did it restore network function in the current experimental
model.  2015 IBRO. Published by Elsevier Ltd. All rights
reserved.
Key words: motoneuron, glial cells, glutamate, metabolic
perturbation, excitotoxicity, ﬁctive locomotion.
INTRODUCTION
The incidence of new cases of spinal cord injury (SCI) has
remained at a high, stable level throughout the last
decade (Jain et al., 2015) with poor long-term outcome
for neurological recovery (Chen et al., 2013; Furlan
et al., 2013). The acute phase of SCI (due to the primary
insult of mechanical, vascular or dysmetabolic nature)
rapidly evolves into secondary damage, characterized
by excitotoxicity caused by massive release of glutamate,
in turn triggering a complex pathophysiological cascade
generating toxic compounds (Dumont et al., 2001; Park
et al., 2004; Rowland et al., 2008; Forder and
Tymianski, 2009; Fatima et al., 2014). Thus, neuroprotec-
tion against secondary injury is a major therapeutic target
(York et al., 2013; Cox et al., 2014) to preserve the spinal
gray (Lipton, 2006; Sa´mano et al., 2012) and white matter
containing the long-ﬁber tracts (Kanellopoulos et al.,
2000; Lee et al., 2008; Margaryan et al., 2010; Sun
et al., 2010; Cox et al., 2014). Large-scale clinical trials
proposed the early i.v. administration of the glucocorticos-
teroid methylprednisolone sodium succinate (MPSS) in
high doses as the mainstay treatment especially directed
to white matter protection (Bracken et al., 1990, 1992;
Bracken, 2012). This approach stems from the potent
anti-inﬂammatory and antioxidant properties of MPSS to
reduce lipid peroxidation, and to alter gene transcription
(Oudega et al., 1992; Hall, 1993).
After the publication of the National Acute Spinal Cord
Injury Study trials (NASCIS I, II and III; Bracken et al.,
1990; Bracken, 1992), the MPSS treatment has become
controversial because the neurological improvements
were modest (Harrop, 2014; Fehlings et al., 2014) and
coupled to important side eﬀects (Bydon et al., 2013;
Harrop, 2014). Notwithstanding the debate about the clin-
ical use of MPSS, this drug is still used in several centers
as ﬁrst approach to SCI (Nicholas et al., 2009; Bracken,
2012; Druschel et al., 2013; Miekisiak et al., 2014;
Cheung et al., 2015). A large-scale clinical survey has
very recently re-examined the usefulness of MPSS
administration to SCI patients with debatable outcome in
terms of short- or long-term motor control (Evaniew
et al., 2015). Animal models of SCI have shown protection
especially for white matter oligodendrocytes
(Oudega et al., 1999; Lee et al., 2008; Xu et al., 2009;
Sun et al., 2010). These observations raise the issue
http://dx.doi.org/10.1016/j.neuroscience.2015.12.003
0306-4522/ 2015 IBRO. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: ANOVA, analysis of variance; ChAT, choline
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whether certain types of SCI might receive more beneﬁt
from MPSS than others.
In recent years we have developed an in vitromodel of
SCI in which transient application of the potent glutamate
agonist kainate or a ‘‘pathological medium” (PM;
mimicking the dysmetabolic conditions occurring after a
vascular dysfunction) evokes distinct alterations in
locomotor networks with primary damage to gray or
white matter, respectively (Taccola et al., 2008;
Nasrabady et al., 2012). Useful features of this model
are the limited tissue damage in analogy to the majority
of the new SCI cases that are incomplete (Jain et al.,
2015), and the study of how delayed drug administration
(mimicking the clinical setting) might work. The model
oﬀers the distinctive advantage of direct investigation of
locomotor spinal networks that express alternating motor
patterns recorded from lumbar ventral roots (Grillner,
2006; Kiehn, 2006). Thus, the aims of the present study
were to ﬁnd out if, in our in vitro model, any neuroprotec-
tion by MPSS could be observed and if it might be diﬀer-
entially eﬀective on white or gray matter (Taccola et al.,
2008; Margaryan et al., 2009; Kuzhandaivel et al.,
2010a,b).
EXPERIMENTAL PROCEDURES
Rat spinal cord preparation
The experiments were carried out on neonatal Wistar rats
(ages 1–2 days). All eﬀorts were directed toward
minimizing the number of animals used for the
experiments and their suﬀering. Under urethane
anesthesia (0.2 ml i.p. of a 10% w/v solution), the spinal
cords were carefully dissected out, superfused (7.5 ml/
min) with Kreb’s solution containing (in mM): 113 NaCl,
4.5 KCl, 1 MgCl27H2O, 2 CaCl2, 1 NaH2PO4, 25
NaHCO3 and glucose 11; gassed with O2 95%, CO2
5%, pH 7.4 at room temperature (22 C) (Taccola et al.,
2008; Margaryan et al., 2009). The experiments were
performed in accordance with the ethical guidelines for
the care and use of laboratory animals of National Insti-
tutes of Health (NIH). All treatment protocols were
approved by the Scuola Internazionale Superiore di Studi
Avanzati (SISSA) ethics committee and are in accor-
dance with the European Union guidelines on animal
experimentation.
Electrophysiological recordings
In order to study reﬂexes and ﬁctive locomotor rhythms,
the experiments were based on DC coupled recordings
with tight-ﬁtting suction electrodes from lumbar (L)
ventral roots (VRs) (Taccola et al., 2008). Signals were
routinely recorded from L2 and L5 VRs carrying mainly
ﬂexor and extensor motor signals to hind limb muscles,
respectively (Kiehn, 2006). Further analysis of recorded
signals was done using pClamp software (version 9.2;
Molecular Devices, Sunnyvale, CA, USA).
VR responses were evoked by stimulating a single
ipsilateral dorsal root (DR) via a bipolar suction
electrode once every 60 s. First, the minimum stimulus
intensity was estimated to produce a VR threshold
response homolaterally which is considered equivalent
to 1 threshold to induce monosynaptic reﬂexes
(Marchetti et al., 2001). Three times higher values of
threshold were used to elicit polysynaptic responses
(Baranauskas and Nistri, 1995). Generally a train of DR
stimuli (30 pulse trains at 2-Hz frequency, 0.1-ms pulse
duration) was given to electrically induce ﬁctive locomo-
tion. The responses were calculated by averaging the
peak amplitude and area of 3–5 events. Alternatively,
rhythmic cycles were recorded by application of
N-methyl-D-aspartate (NMDA; 3–6 lM) and 5 hydrox-
ytryptamine (5-HT; 10 lM) (Kiehn, 2006). The periodicity
and amplitude of cycles were measured from 20 continu-
ous oscillations as already described by Taccola et al.
(2008). Disinhibited bursting was induced by continuous
bath application of blockers of c-aminobutyric acid
(GABA)-A and glycine receptors, bicuculline (20 lM)
and strychnine (1 lM), respectively. Burst parameters
were analyzed in accordance with Bracci et al. (1996).
Protocols for spinal cord lesion and neuroprotection
Two experimental protocols were used: in the ﬁrst one,
spinal lesioning of the gray matter (with loss of ﬁctive
locomotion) was induced with 1-h application of the
excitotoxic agent kainate (KA, 0.1 mM) in standard
Krebs’ solution (Taccola et al., 2008; Margaryan et al.,
2009; Mazzone et al., 2010).With this approach white mat-
ter lesions are usually quite limited (Taccola et al., 2008).
The second protocol mimicked the condition of
anoxia/aglycemia that mainly damages the white matter
of the spinal cord and is thought to better simulate what
occurs after a non-traumatic lesion (Taccola et al.,
2008; Margaryan et al., 2009; Kuzhandaivel et al.,
2010a). Thus, spinal cord preparations were subjected
(for 1 h) to PM, namely a modiﬁed Kreb’s solution contain-
ing 10 mM H2O2, 500 lM sodium nitroprusside (SNP),
and lacking extracellular Mg2+, glucose and oxygen
(replaced by N2). NaHCO3 was replaced by 1 mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES)
to reach pH 6.75–6.80 (with 0.1 N NaOH), while the
osmolarity was lowered to 230–240 mOsm. This solution
is known to induce a pathological condition that includes
locomotor network depression and spinal damage
(Taccola et al., 2008; Margaryan et al., 2009).
With either protocol, we investigated any
neuroprotection by MPSS (Pﬁzer, Italy) after the
experimental (1 h) injury. MPSS was diluted with
distilled sterile water to get a stock solution of 100 mM,
from which test concentrations of 6 or 10 lM were
made. The MPSS solution was used within 24 h, since
the solution is unstable after 48 h as instructed by the
manufacturer. The selection of MPSS concentrations (6
or 10 lM) was based on published clinical guidelines
(Sauerland et al., 2000) and former reports with oligoden-
drocytes cell culture and an organotypic-based model of
spinal cord damage (Guzma´n-Lenis et al., 2009; Sun
et al., 2010). After the application of kainate or PM was
terminated with standard Krebs’s solution washout,
MPSS treatment (6 or 10 lM) started immediately and
lasted for up to 24 h. Longer observation periods were
prevented by the spontaneous deterioration of the spinal
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cord in vitro. Control groups treated with MPSS alone
were kept in standard Krebs’s solution for 24 h in vitro.
Sham spinal cord preparations run alongside the experi-
mental group were maintained in standard Kreb’s solution
for up to 24 h (Taccola et al., 2008).
Immunohistochemistry procedure
At the end of the experiment, spinal cord preparations
were ﬁxed with 4% paraformaldehyde and cryoprotected
in sucrose solution (30% w/v) for subsequent
immunohistochemistry (Taccola et al., 2008). Transverse
sections (30-lm-thick) of the spinal cord were cut with a
sliding microtome at 20 C and stored in phosphate-
buﬀered saline (PBS) until use. In accordance with our
former studies, we analyzed spinal regions of interest
(ROI) between L1 and L2 segments where the main com-
ponents of the locomotor central pattern generator (CPG)
are located (Kiehn, 2006). Single or double immunohisto-
chemical stainings were performed on the free-ﬂoating tis-
sue sections or on the sections immobilized on Superfrost
plus slides (Thermo Fisher Scientiﬁc GmbH, Germany)
and processed in a humid atmosphere. Sections were
preincubated for 1–2 h at room temperature in 5% normal
goat serum (NGS) or 5% normal donkey serum/5%
bovine serum albumin (BSA) and 0.3% Triton X-100, fol-
lowed by overnight incubation at 4 C in 1% NGS/1%
BSA/0.1% Triton X-100 solution containing the primary
antibodies listed in Table 1. Anti-NeuN (neuronal nucleus)
recognizes a neuronal-speciﬁc nuclear protein (NeuN) to
detect diﬀerentiated neurons (Taccola et al., 2008;
Margaryan et al., 2009; Cifra et al., 2012). Anti-SMI32 rec-
ognizes a non-phosphorylated neuroﬁlament in ventral
motoneurons, and anti-choline acetyltransferase (ChAT)
is the marker for choline acetyl transferase, the synthetic
enzyme of acetylcholine. Both antibodies are clearly iden-
tiﬁable in motoneurons (Cifra et al., 2012).
Anti-S100 recognizes the protein S100 that belongs to
the family of Ca2+-binding proteins found in the
cytoplasm and nuclei of astrocytes (Donato, 2003), while
anti-GFAP recognizes the glial ﬁbrillary acidic protein
(GFAP), an intermediate ﬁlament protein characteristic
for white matter astrocytes (Eng, 1985).The anti-O4
antibody is the earliest recognized marker speciﬁc for a
sulfated glycolipid antigen of oligodendroglia (Sommer
and Schachner, 1981). Oligodendrocyte and myelin
sheath marker (RIP) antibody selectively stains oligoden-
drocytes and their processes containing myelin basic pro-
tein (Friedman et al., 1989) (Table 1).
Tissue sections were rinsed thrice for 10 min each in
PBS–Triton X-100 (0.1 M PBS, 0.3% Triton X-100), and
then incubated for 2 h with the appropriate secondary
antibody, anti-mouse Alexa Fluor 488 or 594, or anti-
rabbit Alexa Fluor 488 or 594, or anti-goat Alexa 488, or
anti-donkey Alexa 488 antibodies. Finally, to identify
pyknotic nuclei, the sections were stained with 1 lg/ml
solution of 40,6-diamidino-2-phenylindole (DAPI) (Sigma,
Dorset, UK) for 10 min at room temperature and
processed with ﬂuorescence mounting medium (DAKO,
Milan, Italy) for analysis with an epiﬂuorescence
microscope (Zeiss Axioskope 2, Carl Zeiss,
Oberkochen, Germany). Selected spinal cord serial
sections with double or triple labeling staining were
further analyzed with confocal Leica (DMRI2, Wetzlar,
Germany) equipped with Ar/Arkrypton laser and
Metavue software (Molecular Devices, Sunnyvale, CA,
USA).
Cell analysis
Pyknotic nuclei, neurons and astrocytes were identiﬁed
and quantiﬁed with the cell counter software
‘‘eCELLence” (Glance Vision Tech, Trieste, Italy). For
each experimental condition, 5–6 spinal cords were
analyzed and for each spinal cord 10 transverse
sections from T12 to L2 segments were examined. We
quantiﬁed the percentage of pyknosis stained with
DAPI, the number of NeuN-expressing cells, SMI32-
labeled motoneurons, ChAT-positive motoneurons and
the S100 immunoreactive astrocytes in each section
according to four ROIs: (i) dorsal gray matter (Rexed
laminae I–IV), (ii) central gray matter (Rexed laminae
V–VII and X), (iii) ventral gray matter (Rexed laminae
VIII–IX) and (iv) ventrolateral white matter. For each
region, 5–7 ﬁelds of 350  350 lm (dorsal and central
regions in the gray matter), 520  520 lm (ventral horn),
Table 1. Antibodies used for immunoﬂuorescence labeling
Antibodies Type of antibody Coupled to Dilution Origin
Primary
NeuN Mouse monoclonal — 1:50; 1:100 Millipore; Chemicon. Milan, Italy
SMI32 Mouse monoclonal — 1:200 Covance. Emeryville, CA, USA
ChAT Goat polyclonal — 1:50 Millipore; Chemicon. Milan, Italy
S100 Rabbit polyclonal — 1:200 Dako. Glostrup. Denmark
GFAP Mouse monoclonal — 1:200 Sigma–Aldrich
RIP Mouse monoclonal — 1:100; 1:200 Millipore; Chemicon. Milan, Italy
R&D Systems. Minneapolis, MN, USA
O4 Mouse monoclonal — 1:200 Millipore; Chemicon. Milan, Italy
Secondary
a mouse IgG Goat Alexa Fluor 488 1:200; 1:250 Invitrogen. Milan, Italy
a mouse IgG Goat Alexa Fluor 594 1:200 Invitrogen. Milan, Italy
a rabbit IgG Goat Alexa Fluor 488 1:250; 1:500 Invitrogen. Milan, Italy
a goat IgG Donkey Alexa Fluor 488 1:200 Invitrogen. Milan, Italy
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or 100  500 lm (white matter) were analyzed. Complete
details of this analysis have been previously reported
(Taccola et al., 2008; Cifra et al., 2012).
Quantiﬁcation of immunoﬂuorescence intensity (gray
levels intensity expressed in arbitrary units, AU) was
performed by Metamorph image analysis system
(v.7.5.6; Universal Imaging Corporation, Molecular
Devices, Downington, PA, USA) or Metavue imaging
Software (Molecular Devices, Sunnyvale, CA, USA).
Using the densitometry function we calculated mean
speciﬁc immunoﬂuorescence labels to GFAP, RIP and
O4 that were more intense than the background level
(i.e. >mean ± 2 SD) for each ROI (640  480 lm2).
The values are mean ± SD (at least three diﬀerent
ﬁelds in each one of three diﬀerent sections from three
diﬀerent spinal cords).
Drugs
Kainate was purchased from Ascent Scientiﬁc (Bristol,
UK); SNP was obtained from Sigma–Aldrich; H2O2 from
Carlo Erba Reagents (Milan, Italy); and the drug MPSS
was purchased as SOLU-MEDROL (1000 mg/16 ml
from Pﬁzer, Italy).
Statistical analysis
Statistical analysis was performed with Sigma Stat
(Sigma Stat 3.1, Systat Software, Chicago, IL, USA).
Histology and electrophysiology data were expressed as
mean ± SEM. Parametric or non-parametric data
distribution was ﬁrst established with a normality test
and the signiﬁcance of diﬀerences between the means
was evaluated with either an independent Student’s
t-test or Mann–Whitney test, respectively. ANOVA was
used for analyzing multiple comparisons followed by a
post hoc Mann–Whitney test. The accepted level of
signiﬁcance was set as P< 0.05.
RESULTS
MPSS decreased the number of pyknotic nuclei in the
white matter after PM
Because previous reports indicate that PM induces early
white matter damage (Taccola et al., 2008; Margaryan
et al., 2009; Kuzhandaivel et al., 2010a), we ﬁrst con-
ﬁrmed that 24 h after 1 h application of PM, the regions
more prone to lesion were the dorsal and ventrolateral
white matter. Fig. 1A, B exempliﬁes and quantiﬁes the
damage evoked by PM, reaching the maximum occur-
rence of pyknotic nuclei in the ventrolateral white matter
ROI (61 ± 3%; n= 9) in comparison with sham prepara-
tions. MPSS (6 or 10 lM; 24 h) per se had no toxic eﬀects
on gray or white matter (Fig. 1A, B). When MPSS (6 or
10 lM) was applied for 24 h immediately after PM wash-
out, it could signiﬁcantly attenuate the number of pyknotic
nuclei in ventrolateral white matter regions (Fig. 1A, B) in
comparison with the eﬀect of PM alone (Fig. 1A, B). The
concentrations of 6 and 10 lM were equieﬀective (47
± 3% and 45 ± 3% pyknosis, respectively, vs. PM
preparations).
Fig. 1. Characterization of methylprednisolone sodium succinate (MPSS) eﬀect on hypoxic-dysmetabolic-perturbation (PM) damage after 24 h. (A)
Upper panel (left) shows a spinal cord half section with ROIs used for cell counting based on DAPI-staining. Bar = 100 lm. Right panels depict
representative images of the lateral white matter (WM) of sham, PM or PM- followed by MPSS (10 lM)-treated spinal cords stained with DAPI.
Bar = 50 lm. (B) Graph showing percent occurrence of pyknosis (as percentage of total count cell nuclei) in each ROI analyzed (dorsal, central,
ventral and ventro-lateral white matter) of the spinal cord for sham preparations in standard Kreb’s solution; MPSS (10 lM); PM and washout PM
followed by two diﬀerent concentrations of MPSS (6 or 10 lM). A statistically signiﬁcant increase in all four spinal cord regions is observed with the
pyknotic cell number in the samples treated with PM alone versus sham preparations (*P< 0.05, and **P< 0.01). MPSS signiﬁcantly reduces
(***P< 0.001) the number of pyknotic cells vs. PM alone in white matter regions. Data are averages taken from nine sections from three rats. The
Mann–Whitney test was used after performing One-Way Analysis of Variance test.
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MPSS protected white matter glial cells from PM
damage
As previously reported by Margaryan et al. (2009) and
Kuzhandaivel et al. (2010a,b)***, and in accordance with
data reported in Fig. 1, glial cells of the white matter are
the most vulnerable to PM. Thus, using markers for spinal
neurons (NeuN), astrocytes (GFAP or S100), and
oligodendrocytes (O4 and RIP), we investigated the cell
protection speciﬁcity by MPSS 24 h after the PM insult.
In line with our former reports (Margaryan et al., 2009;
Kuzhandaivel et al., 2010a; Bianchetti et al., 2013) that
demonstrate good neuronal preservation after PM appli-
cation, we observed that the number of NeuN-
immunopositive cells was unchanged throughout the gray
matter regions (data not shown). On the other hand, while
MPSS per se had no toxic action, PM application signiﬁ-
cantly decreased the immunoﬂuorescence intensity of
GFAP-positive ﬁbers of ventrolateral white matter regions
(40%) compared to sham preparations (Fig. 2A, B), in
coincidence with widespread pyknosis. However, when
MPSS was applied immediately after PM, the GFAP sig-
nal intensity signiﬁcantly increases by 27% and 29%,
respectively, vs. data after PM alone (Fig. 2B).
We also wished to explore whether the MPSS (6 or
10 lM) treatment after PM could protect oligonde
ndrocytes. Since O4 (like GFAP) staining is non-
nuclear, O4 immunoﬂuorescence intensity was
expressed as average AU in the white matter ROI.
Oligondendrocytes suﬀered PM-induced damage
because the signal intensity for O4 or RIP staining was
weak in the ventral white matter (VWM) ROI and
represented 42% and 49%, respectively, of the values
observed in sham preparations (Fig. 2C–F). When
MPSS (6 or 10 lM) was applied for 24 h immediately
after PM washout, the O4 immunoﬂuorescence intensity
increased signiﬁcantly vs. PM preparations, by 15% and
18%, respectively (Fig. 2D). Similar increases were
found with RIP staining (16% and 18%; Fig. 2F).
Fig. 2. MPSS administration followed by metabolic perturbation (PM) protects astrocytes and oligodendrocytes in the ventrolateral white matter
region. (A) Micrographs showing examples of GFAP positive ﬁbers detected after 24 h in sham, PM alone for 1 h, or PM followed by MPSS
treatment (PM/MPSS 10 lM) for 24 h. Note that PM triggers loss of GFAP signal, while PM/MPSS (10 lM) treatment induces some protection by
increasing the GFAP ﬁber signal. Bar = 100 lm. (B) Plots of immunostaining intensity (expressed in arbitrary units; AU) from GFAP positive ﬁbers
of sham, PM- or PM/MPSS (10 lM)-treated spinal cords. Comparisons of data from treated spinal cords with PM alone are signiﬁcantly diﬀerent
from sham samples with ***P< 0.001 and **P< 0.01 for those treated with PM followed by MPSS 10 lM vs. PM alone. (C, E) Panels show
examples of the O4 and RIP positive elements (oligodendrocytes) in the same region of GFAP analysis from sham, PM- or PM/MPSS- (10 lM)-
treated spinal cords. Note PM application induces large loss of O4 and RIP immunoreactivity, while PM/MPSS (10 lM) treatment increases
signiﬁcantly the ﬂuorescence signal of both markers. Scale bar = 100 lm. (D, F) Histograms quantifying immunoﬂuorescence intensity (AU) from
O4 or RIP signals of sham, PM- or PM/MPSS (10 lM)-treated spinal cords. The loss of O4 or RIP signal is signiﬁcantly diﬀerent from sham
preparations, ***P< 0.001 and *P< 0.05, respectively. The ﬂuorescence signal from both markers in preparations treated with MPSS (10 lM) after
PM vs. PM alone is signiﬁcantly diﬀerent, being ***P< 0.001 and *P< 0.05, respectively. For all experiments, data are from six spinal sections from
three rats. The Mann–Whitney test was used after performing One-Way Analysis of Variance test.
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To further quantify white matter astrocytes, we also
stained them with the antibody S100 that recognizes all
astrocytes (white matter GFAP-positive astrocytes, and
gray matter protoplasmic GFAP-negative astrocytes).
Twenty-four hours after PM, signiﬁcant loss of
ventrolateral white matter astrocytes was apparent
together with preservation of gray matter astrocytes
(Fig. 3A, B). This result is in accordance with the GFAP
signal (Fig. 2A, B). Fig. 3A, B demonstrates that MPSS
(6 or 10 lM) signiﬁcantly protected ventrolateral S100
positive glial cells (118 ± 8; 111 ± 4 cells, respectively)
compared to PM treatment (91 ± 7 cells). In summary,
these results show that the early toxic eﬀect produced
by PM on astrocytes and oligodendrocytes of white
matter could be attenuated by the immediate application
of MPSS for 24 h.
Poor neuroprotection by MPSS after kainate-
mediated excitotoxicity
We have previously shown that kainate (1 h) primarily
produces extensive spinal network damage with loss of
ﬁctive locomotion, and lesion of gray matter aﬀecting
neurons and motoneurons with very limited destruction
of white matter glia (Taccola et al., 2008; Margaryan
et al., 2009; Kuzhandaivel et al., 2010b; Sa´mano et al.,
2012). We ﬁrst explored if MPSS neuroprotection could
be achieved after a moderate excitotoxic insult, namely
1 h application of 0.1 mM kainate. An example of the
extent of pyknosis (n= 6) 24 h after washout of kainate
is provided in Fig. 4A. When MPSS (6 or 10 lM) was
applied for 24 h immediately after kainate, no change in
gray matter pyknosis in dorsal, central and ventral ROIs
Fig. 3. Quantiﬁcation of eﬀect of MPSS after metabolic perturbation (MP). (A) Inset shows a spinal cord half section of the white matter areas
analyzed (lateral and ventral white matter; LWM, VWM). Bar = 100 lm. The panels show examples of S100-immunoreactivity in the L2 LWM
(upper) and VWM (lower) ROIs in sham (left), PM (middle) or PM followed by MPSS (10 lM) after 24 h (right). The asterisks show lack of S100
staining in ventrolateral white matter of spinal cords treated with PM alone. The arrows show that following treatment with 10 lM MPSS (after 1 h of
PM application), some ﬁbers and cell bodies are present in ventrolateral WM regions, compared to PM alone. Bar = 50 lm. (B) Histograms showing
total number of S100-positive cell bodies in sham, MPSS (10 lM), PM or MPSS after PM toxicity (PM/MPSS 10 lM)-treated spinal cord. Dorsal
(ﬁlled bars), central (gray bars), ventral (open bars) and white matter (WM; dashed bars) regions were analyzed. For all experiments, data are from
six spinal sections from three rats. The Mann–Whitney test was used after performing One-Way Analysis of Variance test; comparison between PM
data vs. sham gave **P< 0.05; comparing PM/MPSS 10 lM vs. PM alone also gave **P< 0.05.
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was observed. Nonetheless, there was a slight reduction
in pyknosis in the white matter ROI for both concentra-
tions of MPSS (4.0 ± 1% with 6 lM, and 3.1 ± 1% with
10 lM) compared to kainate alone (6.9 ± 2%)
(Fig. 4A, B).
We also quantiﬁed the number of NeuN-positive
neurons in dorsal, central and ventral ROIs after kainate
washout and treatment with MPSS (6 or 10 lM).
Table 2 lists neuronal loss elicited by excitotoxicity and
the unchanged outcome 24 h after MPSS administration.
In the ventral horn ROI, motoneurons analyzed with
ChAT (ACh synthetic enzyme) immunopositivity were
highly vulnerable to kainate and not rescued by MPSS
(Table 2).
Eﬀects of MPSS on electrophysiological network
properties
To further verify any neuroprotective eﬀect by MPSS from
a functional viewpoint, we investigated whether this drug
could protect against neuronal damage evoked by
kainate (0.1 mM) or PM. Kainate or PM was applied for
1 h followed by washout and subsequent administration
of MPSS for 24 h. The electrophysiological responses
were recorded 24 h later (Taccola et al., 2008;
Margaryan et al., 2009).
Fig. 5 summarizes data related to monosynaptic (A) or
polysynaptic (B) reﬂexes elicited by DR stimulation.
These responses were largely depressed 24 h after
either kainate or PM application with no signiﬁcant
recovery in peak amplitude after MPSS administration
(Fig. 5C, D). Nevertheless, a signiﬁcant improvement in
the area of polysynaptic reﬂexes was detected in KA or
PM solution followed by MPSS (P=<0.001;
P= 0.015, respectively) (Fig. 5B, E).
We next tested DR pulse trains to induce ﬁctive
locomotion expressed as alternating oscillations
superimposed on cumulative depolarization (Marchetti
et al., 2001). These eﬀects were severely depressed by
kainate or PM (Fig. 6A). As illustrated in Fig. 6A–D, sub-
sequent application of MPSS had little impact on the
electrophysiological outcome. In fact, just minimal oscilla-
tions were seen in 5 out 11 preparations treated with
MPSS after kainate solution (P< 0.001) (Fig. 6A, B).
Fig. 4. Limited neuroprotection by MPSS after kainate-mediated excitotoxicity. (A) Micrographs of DAPI staining showing pyknosis in the ventral
white matter part of the rat lumbar spinal cord. Sham (left), 0.1 mM kainate (KA; middle) or kainate followed by MPSS (KA/MPSS 10 lM; right).
Bar = 50 lm. (B) Histograms showing the percent of pyknotic nuclei counted in dorsal (ﬁlled bars), central (dark gray bars), ventral (open bars) and
ventrolateral white matter (striped bars) regions, in sham, MPSS alone (10 lM), 0.1 mM KA (1 h), or KA followed by 24 h MPSS (6 or 10 lM).
Average from six spinal sections from three rats; the Mann–Whitney test was used after performing One-Way Analysis of Variance test.
Comparisons were KA vs. sham and KA/MPSS 6 lM or KA/MPSS 10 lM vs. KA alone; *P< 0.05 and **P< 0.001.
Table 2. Vulnerability of neurons to kainate-mediated excitotoxicity was
not rescued by MPSS treatment
IR ROI Sham 0.1 mM KA KA/MPSS
6 lM
KA/MPSS
10 lM
NeuN D 197 ± 4 127 ± 6* 125 ± 8 126 ± 8
NeuN C 170 ± 2 143 ± 2* 136 ± 2 134 ± 2
NeuN V 195 ± 6 175 ± 3* 176 ± 5 176 ± 6
ChAT V 30 ± 2 21 ± 1** 21 ± 3 22 ± 2
SMI-32 V 13 ± 2 5± 2** 5 ± 1 5± 2
* Indicates the signiﬁcant diﬀerence (P< 0.001) between kainate 0.1 mM (KA)
vs. sham for NeuN immunoreactivity (IR).
** P< 0.01 for 0.1 mM KA (n= 3) vs. sham for both motoneurons markers
(ChAT and SMI-32). No statistically-signiﬁcant diﬀerence is apparent among
groups treated with kainate followed by methylprednisolone (MPSS 6 or 10 lM)
vs. kainate alone. For all experiments, data are from six spinal cords sections
from three rats; the Mann–Whitney test was used after performing One-way
analysis of Variance test. D, C and V denote dorsal, central and ventral ROIs,
respectively.
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Modest recovery (P= 0.042) in the area of cumulative
depolarization was also detected (Fig. 6A, D).
As indicated in Fig 7A, kainate application (1 h)
blocked rhythmic oscillations induced by NMDA and
5HT. The majority of preparations (8/11 spinal cords)
could not generate any cyclic discharge after
superfusion with kainate (1 h) despite increasing the
NMDA concentration in the 2–6 lM range. In the
remaining three preparations, sporadic oscillatory cycles
without any alternation were observed. These
oscillations were not restored after MPSS (24 h)
treatment (Fig. 7A–C). On the other hand, following
application of PM, few (7–10), slow oscillations without
alternation were recorded in ﬁve out of nine spinal cords
(Fig. 7). This condition was improved after MPSS
administration because rhythmic, alternating oscillations
were present in eight out of nine preparations, even if
they remained slow by comparison with sham spinal
cords (Fig. 7A, C).
Fig. 8A, B summarizes data concerning the spinal
cord intrinsic rhythmicity (disinhibited bursting) studied
after pharmacological block of synaptic inhibition (Bracci
et al., 1996). Kainate application resulted in a compara-
tively lower number of bursts (of smaller size) vs sham
preparations. This condition was not signiﬁcantly amelio-
rated by a 24-h application of MPSS. After PM application
followed by 24-h MPSS, the number of bursts was signif-
icantly reduced because their duration and amplitude had
increased when compared to the spinal cords treated with
PM alone.
DISCUSSION
The principal ﬁnding of this report is that, within the ﬁrst
24 h from an experimental lesion, any neuroprotection
by MPSS was limited in extent and regionally restricted
to the ventrolateral white matter when damaged by PM.
Conversely, MPSS could not contrast excitotoxic
neuronal damage. In either case no good recovery in
locomotor network function was observed.
Regional and cellular speciﬁcity of MPSS protection
The underlying mechanisms of MPSS action against SCI
secondary damage remain unclear. Various suggestions
have been proposed including decrease in oxygen
radical-induced lipid peroxidation of cell membranes,
scavenging of free radicals, attenuation of Ca2+ inﬂux
Fig. 5. Eﬀect of MPSS (10 lM) application on reﬂex responses recorded after 24 h from exposure to kainate (KA) (0.1 mM) or pathological medium
(PM) for 1 h. (A, B) Examples of average monosynaptic (A) or polysynaptic (B) responses recorded from L2 homolateral VRs in control (sham),
kainate (KA, 1 h), kainate followed by MPSS (KA/MPSS) for 24 h, pathological medium (PM, 1 h) and PM followed by MPSS (PM/MPSS) for 24 h.
(C, D) Histograms representing the peak amplitude (mV) of monosynaptic (C) and polysynaptic (D) responses after KA (n= 11), KA/MPSS
(n= 11), PM (n= 9), PM/MPSS (n= 9) treatment compared to sham (n= 10). Note that there is signiﬁcant fall in amplitude of only polysynaptic
reﬂexes (D) in treated preparations as compared to sham (P= 0.006; One Way Analysis of Variance test) but no signiﬁcant change in case of
amplitude of monosynaptic reﬂexes (C). (E) Histograms showing the area (mV ms) of polysynaptic responses of KA- or PM-treated spinal cords.
MPSS application for 24 h signiﬁcantly increases the reﬂex area after kainate or PM vs data after either treatment (***P< 0.001, *P= 0.015,
respectively; t-test). All values of polysynaptic reﬂex area in treated spinal cords were diﬀerent from sham (P< 0.001; One-Way Analysis of
Variance test).
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and enhancement of spinal blood ﬂow (Hall, 2011; Tohda
and Kuboyama, 2011; Bains and Hall, 2012). The ratio-
nale for MPSS use in SCI is based on the destructive pro-
cesses aﬀecting the white matter as consequence of
ischemia, edema and lipid peroxidation (Liu et al., 1997;
Kanellopoulos et al., 2000). Astrocytes and oligodendro-
cytes are very sensitive to injury that induces demyelina-
tion and cell death by apoptosis (Kim et al., 2003;
Kuzhandaivel et al., 2010a). Our standard protocol for
inducing experimental SCI in vitro attempted to mimic a
clinical scenario whereby the initial injury (whether of
mechanical or dysmetabolic nature) is promptly
addressed with emergency care that involves correction
of ongoing metabolic dysregulation and support of life-
critical functions. The use of a neonatal mammalian SCI
in vitro preparation is helpful to investigate neuronal net-
work properties because of its well-deﬁned inputs via
DR ﬁbers and motor output via VR axons. Spinal net-
works can generate, even in the absence of external stim-
uli, a repertoire of rhythmic activities that represent an
advantageous model to explore the delayed action of
excitotoxicity and metabolic perturbation. Additionally,
the model can also be useful for better understanding
the pathological processes related to child SCI, a scarcely
researched ﬁeld. In fact, clinical studies report a relatively
high occurrence of SCI among very young children
(Bilston and Brown, 2007; Pieretti-Vanmarcke et al.,
2009), even at perinatal age (Vialle et al., 2008).
Thus, our protocols used a transient application of a
pathological medium or of the excitotoxic agent kainate
(Kuzhandaivel et al., 2011) followed by a 24-h washout
with oxygenated Kreb’s that, in the present study,
included MPSS (6 or 10 lM that corresponds to the clini-
cal use). Cell protection by MPSS application was mainly
expressed as a signiﬁcant decrease in the number of
pyknotic nuclei in the ventrolateral white matter, although
a substantial number of dead cells remained. In this area
MPSS could reverse the loss of astrocytes, and, to a
lesser extent, the fall in oligodendrocytes. The present
data accord with in vivo studies of the rat-transected
Fig. 6. Eﬀect of MPSS (10 lM) application on ﬁctive locomotion evoked by a train of DR stimuli. Data recorded after 24 h from spinal cords exposed
to kainate (KA) or pathological medium (PM) for 1 h. Same preparations as analyzed in Fig. 5. (A) Representative records of electrically evoked
cumulative depolarization with superimposed oscillations (ﬁctive locomotion) of sham, kainate (KA), kainate followed by MPSS (KA/MPSS), PM and
PM followed by MPSS (PM/MPSS). (B) Histograms depicting number of oscillations evoked by DR stimulation. There is a small, yet signiﬁcant
recovery of DR oscillations in kainate-treated spinal cords after application of MPSS (24 h) (***P< 0.001; t-test). (C) Bar graph showing no
signiﬁcant improvement by MPSS administration (24 h) in cumulative depolarization recorded from kainate- or PM-treated preparations. (D)
Histograms showing signiﬁcant recovery of cumulative depolarization area after kainate followed by MPSS for 24 h (*P= 0.042; t-test). Note the
signiﬁcant change in number of oscillations as well as in the amplitude and area of cumulative depolarization seen in all treated preparations in
comparison to sham (P< 0.001; One-Way Analysis of Variance test).
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spinal cord indicating that MPSS treatment can reduce
spinal tissue loss (Oudega et al., 1999). In particular,
MPSS is reported to attenuate cell death of oligodendro-
cytes in a dose-dependent manner and to inhibit axonal
demyelination (Lee et al., 2008). Several investigations
have targeted oligodendrocytes for protection after exper-
imental SCI (Lee et al., 2008; Sun et al., 2010). The ques-
tion, however, remains whether glial cells within the gray
or white matter are diﬀerentially sensitive to lesion.
Our former investigations have detailed the type and
extent of glial damage evoked by kainate and/or PM
applications to the rat isolated spinal cord or organotypic
spinal slices. Immunohistochemical analysis has
indicated that, within the gray and white matter,
excitotoxicity induced by kainate has rather limited
eﬀects on astroglia and oligodendroglia (Kuzhandaivel
et al., 2010a,b; Mazzone and Nistri, 2011, 2014;
Mazzone et al., 2013), though microglia becomes acti-
vated early (Taccola et al., 2010). Loss of myelination
within 24 h from the insult is scant and is not associated
with a signiﬁcant decrease in action potential generation
by isolated VRs (Taccola et al., 2008). Furthermore, when
the lesion is restricted to one spinal segment, descending
or ascending ﬁbers coursing through it can be electrically
stimulated to generate polysynaptic reﬂexes at segments
above or below the lesion, demonstrating that impulse
propagation via long axons is well preserved (Taccola
et al., 2010). Contusive injury to the rat dorsal spinal cord
in vivo elicits early, patchy demyelination (mainly in cen-
tral laminae) followed by chronic demyelination inter-
rupted by phases of remyelination and variable
functional recovery (Totoiu and Keirstead, 2005).
The PM protocols of the present study evoked
signiﬁcant loss of astroglia and oligodendroglia (and
limited neuronal damage) together with depression of
ﬁctive locomotor patterns in accordance with our former
reports (Taccola et al., 2008; Margaryan et al., 2010;
Kuzhandaivel et al., 2010b). Globally, these observations
validate the functionally-negative consequence of even
moderate neuronal losses, but they also raise the issue
of the impact of glia on locomotor network activity.
Studies of the locomotor circuitry in the lamprey spinal
cord have suggested that glia may play a role in regulating
the eﬃciency of network function (Baudoux and Parker,
2008). In the mouse spinal cord, glial cells are proposed
to dynamically release ATP that is degraded extracellu-
larly to adenosine that, in turn, negatively controls the fre-
quency of locomotor output (Witts et al., 2012; Acton and
Fig. 7. Changes in chemically induced ﬁctive locomotor rhythms after kainate or PM (1 h) followed by MPSS (24 h). (A) Representative records of
oscillatory cycles alternating between left (l) and right (r) L2 VRs in the presence of NMDA and 5-HT. After kainate exposure, ﬁctive locomotion has
irreversibly stopped and no recovery is observed after MPSS application. Only 3 out of 11 preparations show some oscillatory cycles without any
alternation both after kainate and kainate followed by MPSS. Few oscillations (8–12) without any alternation and with longer periodicity are observed
in ﬁve out of nine spinal cords exposed to PM, whereas after MPSS application oscillations with alternations in eight out of nine preparations are
detected. (B, C) Bar graphs summarizing averaged data for peak amplitude and periodicity of ﬁctive locomotion of kainate or PM exposed
preparations followed by MPSS (24 h). Note that a signiﬁcant change in peak amplitude and period of oscillations is observed in treated spinal cords
as compared with sham (P< 0.001; One-Way Analysis of Variance test). MPSS does not alter the eﬀects observed after KA or PM.
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Miles, 2015). In the present report the only partial reten-
tion of locomotor cycles and disinhibited bursting after
PM application suggests that, against a relatively limited
neuronal loss, glia damage might have signiﬁcantly
enhanced the network dysfunction not predicted on the
basis of the quite modest neuronal damage. The small
improvement in astroglia survival with MPSS treatment
was, however, insuﬃcient to restore the standard locomo-
tor output.
Excitotoxic damage is distinct from PM-evoked
damage because the former primarily aﬀects neurons
rather than glia (Kuzhandaivel et al., 2011). In the
kainate-lesioned model, MPSS exerted no neuronal pro-
tection and modest inhibition of the limited white matter
pyknosis. Previous studies have, however, indicated that
motoneurons could be protected by MPSS in SCI in vitro
or in vivo (Guzma´n-Lenis et al., 2009; Yin et al., 2013).
This discrepancy may be attributable to: (i) distinct mod-
els of SCI with diﬀerential distribution and timecourse of
MPSS action; (ii) the degree of excitotoxic stimulation
and the timing of MPSS application; (iii) the diﬀerent out-
come parameters investigated (Wittstock et al., 2015).
These considerations led us to test the electrophysiologi-
cal network activity after experimental lesion and MPSS
administration.
MPSS and functional deﬁcit of spinal networks
In accordance with previous studies (Taccola et al., 2008;
Margaryan et al., 2009), mono and polysynaptic reﬂexes
were partially depressed 24 h after kainate or PM applica-
tion. The same result was obtained when repeated DR
stimuli generated cumulative depolarization that lacked
oscillations. Fictive locomotion induced by NMDA and
5HT was blocked after kainate and consistently
depressed after PM. This functional scenario of network
function inhibition by either lesion protocol was not
accompanied by massive cell loss. In fact, the largest inci-
dence of gray matter pyknosis was observed in the dorsal
horn following kainate application and amounted to less
than 30%. With PM application the damage was even
more limited. These observations suggest that spinal net-
works operate in a condition of criticality (Massobrio et al.,
2015; Valverde et al., 2015) whereby even modest losses
are transduced into major functional deﬁcit. This notion is
consistent with the view of minimal network membership
necessary to express locomotor patterns (Kuzhandaivel
et al., 2011). Once that value is surpassed, no locomotor
activity can be observed anymore.
This adverse condition was only partly changed by
MPSS. Thus, the polysynaptic reﬂex area increased,
Fig. 8. Disinhibited bursting after MPSS (24 h) application. (A) Sample recordings of disinhibited bursts obtained from sham (n= 7), kainate (KA)
(n= 7), kainate followed by MPSS (KA/MPSS) (n= 5), PM (n= 7) and PM- followed by MPSS (PM/MPSS) (n= 9)-treated preparations. (B–D)
Histograms representing signiﬁcant change induced by MPSS in the number of bursts during a 20-min epoch (**P= 0.002; t-test) (B), duration of
bursts (*P= 0.02; t-test) (C), and burst amplitude (*P= 0.02; t-test) (D) after kainate or PM.
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perhaps suggestive of more residual connections left
within the premotoneuron circuitry. Likewise, a small
improvement was observed with the cumulative
depolarization area and superimposed oscillations.
These were minimal gains in the presence of MPSS and
could not be carried over to any strong recovery in
locomotor network function particularly after kainate
application. The outcome appeared more favorable
when ﬁctive locomotion was monitored following PM and
MPSS as slow alternating oscillations could re-emerge.
Studying these network phenomena cannot clarify if a
beneﬁcial, albeit small, eﬀect by MPSS was produced at
the level of discrete elements of the white or gray
matter. Hence, it seemed useful to minimize the size of
the spinal circuitry by blocking synaptic inhibition (Streit,
1993; Bracci et al., 1996; Darbon et al., 2002) and observ-
ing spontaneous rhythmic bursting that reﬂects the intrin-
sic excitability of the ventral area predominantly through
glutamatergic transmission (Bracci et al., 1996). In this
case, MPSS did not change the depression elicited by kai-
nate, although it contrasted PM eﬀects by increasing burst
amplitude and duration (with consequently fewer bursts
per unit of time). The latter observation suggests slightly
improved functional connectivity within the network.
CONCLUSIONS
Management of acute SCI is a diﬃcult task because the
origin, duration and extent of the primary lesion vary
considerably, making it complicated issuing guidelines
for a standard therapeutic treatment. Furthermore, SCI
grows in size and severity in a time-dependent fashion,
thus demanding rapid intervention that so far has been
useful only when performing early neurosurgery
(Fehlings et al., 2012). The beneﬁts of MPSS have been
long debated because of the contrasting results in
human trials (Tohda and Kuboyama, 2011; Bracken,
2012; Harrop, 2014). The present study suggests that
MPSS may exert a modest beneﬁcial action in a
non-excitotoxic lesion of the spinal cord by preserving a
number of glial cells. This phenomenon is not, however,
translated into a rapid functional protection of spinal
networks.
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Abstract
Although neuroprotection to contain the initial damage of spinal cord injury (SCI) is difficult, multicentre studies show that early
neurosurgery under general anaesthesia confers positive benefits. An interesting hypothesis is that the general anaesthetic itself
might largely contribute to neuroprotection, although in vivo clinical settings hamper studying this possibility directly. To further
test neuroprotective effects of a widely used general anaesthetic, we studied if propofol could change the outcome of a rat iso-
lated spinal cord SCI model involving excitotoxicity evoked by 1 h application of kainate with delayed consequences on neurons
and locomotor network activity. Propofol (5 lM; 4–8 h) enhanced responses to GABA and depressed those to NMDA together
with decrease in polysynaptic reflexes that partly recovered after 1 day washout. Fictive locomotion induced by dorsal root stimuli
or NMDA and serotonin was weaker the day after propofol application. Kainate elicited a significant loss of spinal neurons, espe-
cially motoneurons, whose number was halved. When propofol was applied for 4–8 h after kainate washout, strong neuroprotec-
tion was observed in all spinal areas, including attenuation of motoneuron loss. Although propofol had minimal impact on
recovery of electrophysiological characteristics 24 h later, it did not further depress network activity. A significant improvement in
disinhibited burst periodicity suggested potential to ameliorate neuronal excitability in analogy to histological data. Functional
recovery of locomotor networks perhaps required longer time due to the combined action of excitotoxicity and anaesthetic depres-
sion at 24 h. These results suggest propofol could confer good neuroprotection to spinal circuits during experimental SCI.
Introduction
Traumatic spinal cord injury (SCI) produces long-term effects asso-
ciated with severe motor disability (Furlan et al., 2013). Although
acute management of SCI has been improved, only about 5% of
patients with complete SCI will walk again (Dobkin & Havton,
2004). The primary insult triggers a sequence of pathological events
(secondary injury) lasting a few hours or even days (Sekhon &
Fehlings, 2001; Park et al., 2004; Rowland et al., 2008). This time
window creates the opportunity for a potentially successful clinical
intervention to prevent damage expansion.
One major mechanism contributing to cell loss during the sec-
ondary phase is excitotoxicity due to excessive activation of gluta-
mate receptors (Rossignol et al., 2007) with subsequent neuronal
degeneration (Mandir et al., 2000; David et al., 2009; Kuzhandaivel
et al., 2010): this is, thus, an important target for neuroprotection.
To investigate the pathophysiological events occurring after SCI, we
have developed an in vitro model of SCI based on the application
of kainate, a potent glutamate receptor agonist that evokes delayed
neuronal loss especially affecting motor networks (Taccola et al.,
2008; Nasrabady et al., 2011b; Nistri, 2012). One major advantage
of this model is that it allows studying any correlation between elec-
trophysiological activity and histological damage. Although previous
reports indicate limited neuroprotective success with various strate-
gies (Nasrabady et al., 2011a, 2012), more encouraging data have
recently emerged by testing the volatile anaesthetic methoxyﬂurane
(Shabbir et al., 2015). These results raised the question whether
neuroprotection is an intrinsic property of a volatile anaesthetic (less
frequently employed because of toxicity) or whether another general
anaesthetic may produce a similar effect. The present study explored
the potential protection by the intravenous anaesthetic propofol
widely used to induce and maintain general anaesthesia (Acton,
2011). Studies investigating its neuroprotective action on in vitro
and in vivo models of brain ischaemia have provided positive results
(Pittman et al., 1997; Young et al., 1997; Ito et al., 1999; Gelb
et al., 2002; Velly et al., 2003; Engelhard et al., 2004b). Proprofol
pre-treatment also protects against spinal cord ischaemia in vivo
(Sahin et al., 2015). The underlying mechanism of neuroprotection
by propofol is related to potentiation of GABAA-mediated inhibition
of synaptic transmission (Hales & Lambert, 1991; Xu, 1999; Bajrek-
tarevic & Nistri, 2016), direct inhibition of glutamate release (Orser
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et al., 1995) and antioxidant properties (Hans et al., 1997; Ansley
et al., 1998; Stratford & Murphy, 1998). While propofol attenuates
damage to the motoneurons of organotypic spinal slice cultures
(Bajrektarevic & Nistri, 2016), it is unknown what functional impact
on locomotor networks this phenomenon may have. The novel ﬁnd-
ings of the present investigation are that propofol protected spinal
neurons, and motoneurons in particular, from damage even when it
was applied for a few hours after kainate. Recovery in locomotor
network function was not, however, observed probably because of
the lingering depression of circuit activity by the sustained applica-
tion of this anaesthetic. It is noteworthy that this protocol simulates
the clinical setting of acute SCI by applying the anaesthetic agent
only after having provoked the damage.
Materials and methods
Spinal cord preparation
Spinal cords were carefully dissected from 0- to 2-day-old Wistar
rats under terminal anaesthesia with i.p. urethane (0.2 mL i.p. of a
10% w/v solution) according to the guidelines for the care and use
of laboratory animals of National Institute of Health (NIH). Because
urethane produces non-selective depression of excitatory amino acid
or dorsal root-evoked depolarization of isolated spinal cords (Evans
& Smith, 1982) and is not clinically used due to liver toxicity, this
drug was employed only for terminal anaesthesia rather than as a
test agent for neuroprotection. Rats were supplied by the animal
house of the International School for Advanced Studies (SISSA)
through their in-house breeding facility. A total of 87 animals were
used. All experimental protocols were approved by the ethics com-
mittee for animal experimentation of SISSA. All efforts were made
to minimize the number of the animals used for the experiments as
well as their suffering. Once dissected, spinal cords were continu-
ously superfused with Krebs solution (in mM: 113 NaCl, 4.5 KCl, 1
MgCl27H2O, 2 CaCl2, 1 NaH2PO4, 25 NaHCO3, 11 glucose;
gassed with 95% O2 and 5% CO2, pH 7.4 at room temperature at
7.5 mL/min) as described previously (Taccola & Nistri, 2006a).
After dissection, to obtain full functional recovery, spinal cords were
incubated in Krebs solution for about 2 h to recover before proceed-
ing to experimentation. Recovery from urethane is reported to occur
during 30-min washout in vitro (Bagust & Kerkut, 1981; Evans &
Smith, 1982).
Protocol for drug application, lesion and neuroprotection
In order to mimic the in vitro spinal lesion of grey matter, kainate
(100 lM) was applied for 1 h (Taccola et al., 2008; Margaryan
et al., 2010; Mazzone et al., 2010). This concentration was chosen
to fully abolish ﬁctive locomotion elicited by DR train pulses or
NMDA + 5-HT when tested 24 h after injury (Nasrabady et al.,
2011b). Propofol (Frenesius Kabi Italia – SPA, NDC 63323-0270-
50, Verona, Italy) was diluted in Krebs solution and to ensure its
full solubilization, vigorous mixing for at least 3 min was performed
before application. Several studies have demonstrated that propofol
clinical effects are achieved at concentrations from 0.5 to 10 lM
(Gredell et al., 2004; Matute et al., 2004; Wakita et al., 2013; Eckle
et al., 2015). As propofol had never been tested before in this type
of experiment, we chose the mid-range value of 5 lM.
The effect of propofol (5 lM) was ﬁrst studied electrophysiologi-
cally by applying it for 4 h on day 1. The polysynaptic reﬂex activ-
ity was recorded every 10 min during 4 h, and its area and
amplitude were analysed. The same experiments were also done by
doubling the duration of propofol (5 lM) application. Thereafter,
preparations were kept in standard Krebs solution overnight and
recorded on the subsequent day (Fig. S1). Furthermore, we used a
different protocol to ﬁnd out the effect of propofol on the ventral
root (VR) depolarization induced by exogenously applied neuro-
transmitter agents (2 min application): GABA (10 lM, 20 lM, and
30 lM; n = 7); glycine (30 lM and 50 lM; n = 5); AMPA (5 lM,
7.5 lM and 10 lM; n = 5); NMDA (10 lM, n = 5; 20 lM, n = 6,
and 25 lM, n = 6). We also tested responses to GABA or NMDA
after application of tetrodotoxin (TTX; initially 1 lM and then
0.1 lM for maintenance) to pharmacologically isolate motoneuronal
responses from neuronal networks. GABA was applied at 10 lM
and 20 lM (n = 6), while NMDA was at 10 lM (n = 4), 20 lM
(n = 6), 25 lM (n = 6) and 30 lM (n = 8).
The excitotoxic protocol was based on kainate (100 lM) applied
for 1 h and then washout with either Krebs solution or propofol
(5 lM) solution for 4–8 h. These spinal cords were later superfused
for 16–24 h with standard Krebs solution. Electrophysiological and
immunohistochemical data were compared among the following six
groups after 24 h: sham (untreated), kainate 100 lM/1 h, propofol
5 lM/4 h, propofol 5 lM/8 h and the two corresponding kainate
treatments followed by propofol-treated groups (see scheme in
Fig. S1).
Electrophysiological recordings
DC-coupled recordings from lumbar (L) ventral roots (VR) using
Ag/AgCl suction electrodes were employed to study ﬁctive locomo-
tor rhythms from ﬂexor (L2) and extensor (L5) motor pools. Data
were acquired with pClamp software (version 9.2; Molecular
devices, Sunnyvale, CA, USA).
In order to generate polysynaptic responses, single electrical stim-
uli (0.1 ms duration) were applied to an individual ipsilateral
homosegmental dorsal root (DR) once every 1 min. We ﬁrst deter-
mined the minimum stimulus intensity to elicit the VR threshold
response homolaterally. As previously reported by Marchetti et al.
(2001), thrice threshold stimuli were used to produce polysynaptic
responses (Baranauskas & Nistri, 1995). Data were analysed by
averaging three to ﬁve consecutive responses. Cumulative depolar-
ization was induced by stimulating (0.1 ms) a single DR with 30
pulse trains (2 Hz) that elicited a series of alternating discharges
typical of electrically induced ﬁctive locomotion (Marchetti et al.,
2001). Fictive locomotion was also elicited chemically by applying
NMDA (3–6 lM) and 5-HT (10 lM) (Kiehn, 2006). A minimum of
20 VR cycles alternating homolaterally between ﬂexor and extensor
motor pools or from side to side at the same segmental level was
considered as a criterion to observe ﬁctive locomotion evoked by
NMDA and 5-HT (Taccola et al., 2008). Disinhibited bursting was
elicited by co-applying blockers of GABAA and glycine receptors,
bicuculline (20 lM) and strychnine (1 lM) respectively (Bracci
et al., 1996a). All the recorded parameters were digitized and anal-
ysed as previously reported (Samano et al., 2016).
Immunohistochemical procedure
Spinal cords from all experimental groups were ﬁxed in
paraformaldehyde approximately 24 h after dissection, then cryopro-
tected with 30% sucrose and ﬁnally sectioned (30 lm) with a slid-
ing microtome at 20 °C. Immunostaining was performed with a
free-ﬂoating method on T13-L5 segments, which contain the princi-
pal elements of the locomotor networks, in accordance with former
studies from our laboratory (Cifra et al., 2012; Bianchetti et al.,
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2013; Shabbir et al., 2015). As a routine, after incubation in block-
ing solution (5% normal goat serum, 5% bovine serum albumin,
0.3% Triton-X 100, 1% phosphate buffer saline) for 2 h at room
temperature, spinal cord sections were incubated overnight at 4 °C
with one of these primary antibodies: anti-NeuN (neuron-speciﬁc
protein, mouse monoclonal, 1 : 50 dilution; Chemicon, Millipore,
Billerica, MA), anti-SMI32 (speciﬁc non-phosphorylated neuroﬁla-
ment protein, mouse monoclonal, 1 : 200 dilution; Chemicon, Milli-
pore) and anti-ChAT (choline acetyltransferase, goat polyclonal,
1 : 50 dilution; Chemicon, Millipore). Anti-NeuN antibody was
used to identify differentiated neurons, whereas anti-SMI32 and
anti-ChAT antibodies were used to speciﬁcally stain motoneurons
visualized as large (>20 lm) cells in the ventral horn. All these anti-
bodies have been validated for immunostaining with this preparation
in our laboratory (Taccola et al., 2008; Cifra et al., 2012; Bianchetti
et al., 2013; Shabbir et al., 2015). Primary antibodies were visual-
ized using secondary donkey anti-goat Alexa ﬂuor 594 and donkey
anti-mouse Alexa ﬂuor 488 (1 : 500, Invitrogen, Carlsbad, CA,
USA). Sections were ﬁnally incubated with 40,6-diamidino-2-pheny-
lindole (DAPI) for 30 min and analysed as detailed below.
Cell death analysis
The methods for cell counting are the same as used before in our
laboratory and described in detail (Bianchetti et al., 2013; Shabbir
et al., 2015). We used either a Zeiss Axioskop2 epiﬂuorescence
microscope (Oberkochen, Germany) or a confocal Leica TCS SP2
microscope (Wetzlar, Germany) to obtain bidimensional histological
images. Cell counting was performed by an observer blinded to the
experimental protocols after DAPI, NeuN, ChAT and SMI32 stain-
ing, for nuclei, neurons and motoneurons, respectively, using
‘ECELLENCE’ software (Glance Vision Tech., Trieste, Italy) and the
‘cell counter’ plugin for IMAGEJ (Kurt De Vos, University of Shef-
ﬁeld, UK). For neuron counting, the NeuN nuclear antibody enabled
quantifying their number in discrete regions of interest (ROI; dimen-
sions indicated below) regardless of the neuron size: nuclear staining
was conﬁrmed with DAPI staining. Clearly damaged nuclei were
discarded from counting. Pyknosis was readily observed as a change
in nuclear morphology characterized by an intense nuclear conden-
sation with strong refractivity (Burgoyne, 1999; Taccola et al.,
2008) corresponding to type 1 cell death as stated by the interna-
tional Nomenclature Committee on Cell Death (NCCD) classiﬁca-
tion (Galluzzi et al., 2007, 2012).
For each histological section of the spinal cord, three different
ROIs were investigated as previously reported (Mazzone et al.,
2010; Cifra et al., 2012; Bianchetti et al., 2013): dorsal grey matter
(Rexed laminae I–IV), central grey matter (Rexed laminae V–VII
and X) and ventral grey matter (Rexed laminae VIII–IX) (Fig. S2).
In each region, two ﬁelds of 125 9 100 lm were analysed. For
each experimental group, at least three spinal cords were analysed
and, for each spinal cord, at least 10 different sections were exam-
ined.
Statistics
Statistical analysis was done using SIGMA STAT 3.5 software (Systat
Software, Chicago, IL, USA). Electrophysiology and immunohisto-
chemical data are shown as mean  SEM; n is the number of spinal
cord preparations. From each histological experiment that yielded
several sections, we calculated the mean for one spinal cord and
repeated the same approach with the other spinal cords so that we
could ﬁnally calculate the mean of the experimental group.
After applying a normality test to differentiate between parametric
and non-parametric data, the values were evaluated with either a
two-tailed Student’s t-test or a Mann–Whitney test respectively.
Analysis of variance (ANOVA) test was used to compare multiple
groups (through Kruskal–Wallis or Holm–Sidak tests or Dunn’s
method). The acceptance level of signiﬁcance was P < 0.05.
Results
Early changes in responses to exogenously applied
neurotransmitters in the presence of propofol
Previous reports have shown that propofol acts as a positive modu-
lator of GABAA and glycine receptors (Hales & Lambert, 1991; Xu,
1999). Furthermore, propofol can decrease glutamate and NMDA-
mediated responses of mouse cultured hippocampal neurons (Orser
et al., 1995). To validate that these observations are applicable to
the rat spinal cord as well, we tested if propofol differentially
affected network depolarizations evoked by GABA, glycine, AMPA
or NMDA recorded sequentially from lumbar VRs on the ﬁrst day
in vitro as exempliﬁed in Fig. 1A. Thus, propofol (5 lM) potentiated
the GABA (20 lM)-mediated response that was characterized by an
early peak followed by fade presumably due to receptor desensitiza-
tion (Fig. 1A). Responses to glycine or AMPA were not signiﬁ-
cantly changed, while NMDA-mediated depolarization was
decreased (Fig. 1A). Figure 1D (ﬁlled circles) indicates that average
responses to 10–20 lM GABA (F5,34 = 2.657, *P = 0.039; Holm–
Sidak test, calculated from raw data) were enhanced by propofol,
while larger responses were less potentiated. On the same prepara-
tions, propofol had no signiﬁcant effect on glycine (F3,14 = 0.114,
P = 0.950; one-way analysis of variance test, calculated from raw
data) or AMPA (F5,24 = 0.617, P = 0.688; one-way analysis of vari-
ance test, calculated from raw data)-mediated responses (Fig. 1C). A
reduction in depolarization amplitude was observed when NMDA
(10–30 lM) was tested in the presence of propofol (Fig. 1A and E;
F5,24 = 3.747, P = 0.012; Holm–Sidak test, calculated from raw
data). As shown by the sample depolarizations depicted in Fig. 1A,
these network responses had complex origin and time-course arising
from co-activation of premotoneurons and motoneurons. In order to
minimize the indirect network contribution to the observed VR
effects, TTX was pre-applied to block propagated network activity.
Responses, therefore, reﬂected motoneuron population depolarization
as exempliﬁed in Fig. 1B. VR depolarizations of similar amplitude
evoked by GABA or NMDA were differentially modulated by
propofol because the ﬁrst ones were increased and the latter ones
depressed (Fig. 1B,D and E; H(3) = 8.978, P = 0.03 and
H(7) = 24.893, ***P = <0.001; Kruskal–Wallis one-way analysis of
variance on ranks test, respectively, calculated from raw data).
Hence, the present results suggest that, in the rat spinal cord, GABA
receptor-mediated responses were upregulated by propofol that con-
comitantly depressed NMDA-mediated ones.
Delayed application of propofol protected from cell death
evoked by kainate
The protocol to assess whether propofol could be neuroprotective
against kainate-elicited excitotoxicity involved observing the histo-
logical characteristics of three ROIs (see Fig. S2A) of the spinal
cord 24 h after applying kainate (1 h). Thus, we used 100 lM kai-
nate that is damaging neurons (identiﬁed with NeuN immunopositiv-
ity) rather than glia with particular vulnerability of motoneurons
(immunoreactive to ChAT or SMI32; Mazzone et al., 2010; Cifra
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et al., 2013). Figure 2A provides general data concerning the toxic-
ity of kainate and its antagonism by propofol in the three spinal
ROIs. The examples for ventral ROI shown in Fig. 2C indicate a
pyknotic cell (see the arrow in inset pointing to a DAPI-stained cell
with compacted nuclear chromatin) next to a standard neuron, sug-
gesting scattered damage. In general, the % value of pyknotic cells
was signiﬁcantly lower when kainate application was followed by
propofol for 4 or 8 h (Fig. 2A and C). One example of pyknotic
nuclei is shown in Fig. S2B.
By analysing actual neuronal numbers in the three ROIs (Fig. 2B
and C), it became apparent that, 24 h after kainate, the number of
neurons was lowered in all regions as a consequence of kainate toxi-
city (see also Taccola et al., 2008; Mazzone et al., 2010) and that
this effect was signiﬁcantly prevented by propofol applied for 4 or
8 h after washout of kainate. It is noteworthy that propofol per se
applied for the same length of time had no deleterious effect
(Fig. 2A–C). Figure 3A and B shows results for motoneurons
immunolabeled with the ChAT antibody (or SMI32; see Fig. S3):
Fig. 1. Effect of propofol (5 lM) on VR depolarization induced by exogenously applied neurotransmitter agonists. (A) Examples of responses recorded from a
single lumbar VR following superfusion with GABA (20 lM), glycine (30 lM), AMPA (5 lM) or NMDA (20 lM) in standard Krebs solution (control) and sub-
sequently with propofol. Application times are indicated by horizontal bars. (B) Representative records of lumbar VR responses evoked by GABA (20 lM) or
NMDA (20 lM) in TTX solution followed by propofol + TTX. Data exemplify propofol-mediated potentiation of GABA and suppression of NMDA responses.
(C) Bar graph showing per cent change (vs. control) in VR depolarization recorded in the presence of propofol following application of glycine (30 lM, n = 6,
U = 13, P = 0.485 and 50 lM, n = 3, U = 6, P = 0.700; Mann–Whitney test) or AMPA (5 lM, t8 = 0.681, P = 0.515; 7.5 lM, t8 = 0.494, P = 0.635 and
10 lM, t8 = 1.356, P = 0.212; n = 5). No signiﬁcant alteration in such responses was obtained. (D) Line graph depicting per cent increase in GABA-mediated
VR depolarization after application of propofol alone (ﬁlled symbols) (GABA = 10, 20 and 30 lM) in Krebs solution or in TTX solution (open symbols)
(GABA = 10 and 20 lM) when compared with the amplitude detected with GABA alone. Applying the Student’s t-test to raw data, a signiﬁcant increase in
peak amplitude was observed with 10 lM GABA and propofol (n = 7, t12 = 2.634, *P = 0.022) and 10 lM GABA + propofol + TTX (n = 4, t6 = 3.125,
P = 0.02). However, there was no signiﬁcance change in response to 20 and 30 lM GABA with propofol (20 lM, n = 7, t12 = 1.926, P = 0.078; 30 lM,
n = 6, t10 = 1.315, P = 0.218) and 20 lM GABA + propofol + TTX (n = 4, U = 13, P = 0.200; Mann–Whitney test). (E) Line graph illustrating per cent
decrease in NMDA-mediated VR depolarization in the presence of propofol (NMDA = 10, 20, 25; lM) as well as propofol + TTX (NMDA = 10, 20, 25, 30;
lM) vs. responses evoked by NMDA alone. Applying the Student’s t-test to raw data indicated that propofol signiﬁcantly depressed 10 and 20 lM NMDA-
mediated responses in Krebs (10 lM, n = 6, t10 = 2.729, P = 0.021 and 20 lM, n = 5, t8 = 2.649, P = 0.029 respectively), whereas propofol applied with TTX
signiﬁcantly depressed only 10 lM NMDA responses (n = 5, t6 = 3.089, P = 0.021). Responses to 25 lM NMDA applied with propofol (n = 4, t6 = 0.263,
P = 0.801) and 20, 25, 30 lM NMDA + propofol + TTX (20 lM, n = 6, t10 = 0.475, P = 0.645; 25 lM, n = 6, t10 = 0.0673, P = 0.948; 30 lM, n = 8,
t14 = 0.312, P = 0.759) were not signiﬁcantly different from their subsequent control groups.
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against a very strong loss of motoneurons induced by kainate, a sig-
niﬁcant neuroprotection by 4–8 h propofol was observed.
Long-lasting effect of propofol on network synaptic
transmission
While previous studies have reported the relatively early effect of
propofol on spinal dorsal (Jewett et al., 1992) and ventral
(Kungys et al., 2009; Eckle et al., 2015) horn neurons and
reﬂexes (Baars et al., 2006), it was ﬁrst necessary to investigate
what changes in synaptic transmission were caused by administra-
tion of this anaesthetic extended for a few hours even in the
absence of excitotoxicity. Hence, we monitored polysynaptic
reﬂexes over several hours following 4- (Fig. 4A upper row, B)
or 8-h (Fig. 4A lower row, C) application of propofol. During
the 4-h application, the reﬂex amplitude did not signiﬁcantly
change (Jewett et al., 1992), while the area fell with minimal
recovery over the following 3-h washout (Control vs. Prop 4 h,
t9 = 3.587, **P = 0.006; Control vs. Wash, t9 = 2.977,
*P = 0.016; t-test; Fig. 4A and B). When the application of
Fig. 2. Histological neuroprotection by propofol (Prop; 5 lM) against kainate (KA; 100 lM)-evoked excitotoxicity. (A) Histograms showing percentage of
pyknotic cells in the different ROIs (dorsal, central and ventral) after kainate application and/or propofol treatment. Note statistically signiﬁcant decrease of
pyknosis percentage in all three ROIs when anaesthetic propofol was applied (4 or 8 h) after kainate, compared to sham or application of kainate alone. Thus,
using the Mann–Whitney test, the observed signiﬁcance level was for KA + Prop 4 h vs. KA alone was P = 0.0009 (U = 238), P = 0.0003 (U = 835) and
P = 0.0002 (U = 990) for dorsal, central and ventral ROI respectively. For KA + Prop 4 h vs. sham, signiﬁcance levels were: P = 0.0003 (U = 652),
P = 0021 (U = 681) and P = 0.0009 (U = 636) for dorsal, central and ventral ROI respectively. Equivalent results were obtained when Mann–Whitney test
was performed for comparing KA + Prop 8 h vs. KA alone and KA + Prop 8 h vs. sham. All data are the average from 10 to 15 sections of 3–5 rat spinal
cords and are represented as mean  SEM. Likewise symbols represent a signiﬁcant difference between groups (for more details see Material and Methods sec-
tion). (B) Histograms showing number of neurons in the same ROIs after kainate application and/or propofol treatment. Also here, a signiﬁcant neuroprotective
effect of propofol is shown. Thus, using a two-tailed Student’s t-test, the observed signiﬁcance level was for KA + Prop 4 h vs. KA alone: P = 0.048
(t36 = 2.056), P = 0.004 (t52 = 3.076) and P = 0.0008 (t39 = 3.645) for dorsal, central and ventral ROI respectively. For KA + Prop 4 h vs. sham, signiﬁ-
cance levels were: P = 0.2070 (t31 = 1.281), P = 0.135 (t40 = 1.541) and P = 0.002 (t27 = 3.469) for dorsal, central and ventral ROI respectively. Equivalent
results were obtained when a two-tailed Student’s t-test was performed for comparing the number of neurons in KA + Prop 8 h vs. KA alone and KA + Prop
8 h vs. sham. All data are the average from 10 to 15 sections of 3–5 rat spinal cords and are represented as mean  SEM. Likewise symbols represent a signif-
icant difference between groups (for more details see Material and Methods section). (C) Examples of ventral horn NeuN and DAPI staining. In the kainate
group example, the inset shows at larger magniﬁcation an apparently normal neuron next to one pyknotic nucleus (indicated by an arrow). Scales bars: 20 lm
and 2.5 lm. For protocols of drug applications see Fig. S1.
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Fig. 3. Histological neuroprotection of ChAT-positive motoneurons by propofol (Prop; 5 lM) against kainate (KA; 100 lM) evoked excitotoxicity. (A) His-
togram showing number of motoneurons in ventral ROI. Note signiﬁcantly larger number of motoneurons from samples treated with propofol for 4 or 8 h after
kainate vs. sham or kainate alone. Thus, by using a two-tailed Student’s t-test, the observed signiﬁcance level for KA + Prop 4 h vs. KA alone was: P = 0.002
(t18 = 3.729) and for KA + Prop 4 h vs. sham, P = 0.00001 (t28 = 5.321). When compared KA + Prop 8 h vs. KA alone through the same test, the obtained
signiﬁcance was P = 0.004 (t16 = 2.808) and for KA + Prop 8 h vs. sham, P = 0.0001 (t26 = 4.489). All data are the average from 10 to 15 sections of 3–5 rat
spinal cords and are represented as mean  SEM. Star symbols represent a signiﬁcant difference between groups (for more details see Material and Methods
section). (B) Examples of ChAT immunopositive cells using such protocols. Scale bar: 50 lm. For paradigms of drug applications see Fig. S1.
Fig. 4. Long-lasting effect of propofol (5 lM) on polysynaptic responses. (A) Upper row: sample recordings of reﬂex responses evoked by single DR stimula-
tion in Krebs (Control), at 4 h application of propofol (Prop 4 h) and washed out with Krebs for 3 h (Wash). Lower row: sample recordings of responses in
Krebs (Control), at 8-h propofol application (Prop 8 h) and washed out with Krebs for 3 h (Wash). (B, C) Histograms showing the area of average polysynaptic
reﬂex responses at 10 min (B) or 1 h (C) intervals while propofol was continuously applied for 4 h (n = 6) and 8 h (n = 6), respectively, and then washed out
with Krebs solution for further 3 h. Green bars depict superfusion with Krebs, whereas grey bars show propofol application (4 and 8 h). Recordings (A) and
bar graphs (B, C) indicate that the area was reduced after propofol application (4 and 8 h) with modest recovery during wash (Control vs. Prop 4 h, t9 = 3.587,
**P = 0.006; Control vs. Wash, t9 = 2.977, *P = 0.016). No apparent recovery was observed at 3 h washout after 8 h propofol (Control vs. Prop 8 h,
t10 = 2.121, P = 0.060; Control vs. Wash, U = 20, P = 0.114, Mann–Whitney test).
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propofol was extended to 8 h, the response area was persistently
decreased with no apparent recovery over the next 3 h wash
(Fig. 4A lower row, C; Control vs. Prop 8 h, t10 = 2.121,
P = 0.060, t-test; Control vs. Wash, U = 20, P = 0.114, Mann–
Whitney test). Figure 5A–C shows that 24 h later, reﬂex charac-
teristics, when compared with sham preparations, were depressed
after previous exposure to propofol (on the ﬁrst day) especially
in terms of area despite the observation that no histological deﬁcit
was detected (see Figs 2 and 3). These observations suggested
prolonged functional depression by propofol despite washout.
Functional activity of locomotor networks following kainate and
propofol application
We next explored whether propofol depression of synaptic transmis-
sion was additive to any neurotoxic action by kainate or whether it
could actually reverse it, at least in part. Figure 5A–C indicates that
reﬂex depression was more intense after kainate alone than after
propofol per se. Furthermore, although 4–8 propofol administration
was inhibiting reﬂexes, its application after kainate did not intensify
the reﬂex reduction, indeed it either occluded the overall fall in
amplitude or actually counteracted the area shrinkage. This phe-
nomenon was readily apparent with 4-h propofol and less mani-
fested with 8-h propofol (Fig. 5A–C). Nevertheless, no additive
neurodepression caused by excitotoxicity plus propofol was
observed.
We next queried if the propofol-dependent histological preserva-
tion, despite innate decrease in network transmission, could shape
the output of locomotor networks activated by trains of DR stimuli
or NMDA + 5HT. Thus, DR stimulation-evoked ﬁctive locomotion
(expressed as alternating oscillations recorded from pairs of VRs)
was readily apparent in sham preparations 24 h later (Fig. 6A and
B), yet completely absent after kainate with no recovery in the oscil-
lations (bottom traces in Fig. 6A). As expected from previous
reports (Taccola et al., 2008), the cumulative depolarization ampli-
tude and area were severely decreased by the previous kainate appli-
cation (Fig. 6C and D). After application of propofol alone, on the
subsequent day, oscillations could still be elicited by DR stimulus
trains as indicated in Fig. 6A. In fact, the number of oscillations
although decreased was still close to the value detected in sham
preparations (Fig. 6B) (Sham vs. Propofol 4 h, Q = 0.262; Sham
vs. Propofol 8 h, Q = 0.369; Dunn’s method). Despite this preserva-
tion of electrically evoked ﬁctive locomotion, no oscillations were
present when propofol was applied after kainate (Fig. 6A and B).
Fictive locomotion was also tested by co-applying NMDA (3–
6 lM) and 5-HT (10 lM) 24 h after kainate (1 h) followed by
propofol (4 or 8 h). Figure 7 illustrates that alternating oscillations
were observed the day after application of propofol alone even if
their periodicity was longer (Sham vs. Propofol 4 h, U = 66,
P = 0.005) and after the 8-h treatment (U = 61, P = 0.001, Mann–
Whitney test), the cycle amplitude was also decreased (Sham vs.
Propofol 8 h, t14 = 3.313, P = 0.005, Student t-test) (Fig. 7A–C).
When the 4-h propofol application paradigm was employed after 1-
h kainate administration, in 5 out of 10 spinal cords, there was
emergence of sporadic oscillations at slow period as exempliﬁed in
Fig. 7A (middle panels). This effect was not typical of ﬁctive loco-
motion and was absent after 8-h propofol following kainate applica-
tion (Fig. 7A–C).
Fig. 5. Effect of propofol (5 lM) application on polysynaptic reﬂex responses recorded 24 h after exposure to kainate (KA, 100 lM). (A) Examples of polysy-
naptic responses recorded from L5 VRs in sham (control for day 2), propofol applied for 4 h (Prop 4 h), propofol applied for 8 h (Prop 8), kainate applied for
1 h (KA), kainate (1 h) followed by propofol for 4 h (KA/Prop 4 h) and kainate (1 h) followed by propofol for 8 h (KA/Prop 8 h). (B, C) Histograms illustrat-
ing the peak amplitude (B) and area (C) of reﬂex responses after KA (n = 11), KA/Prop 4 h (n = 10), KA/Prop 8 h (n = 14) treatment compared to sham
(n = 8), Prop 4 h (n = 9) and Prop 8 h (n = 8). Note the signiﬁcant fall in peak amplitude (U = 24, **P = 0.004; Mann–Whitney test) of preparations treated
with propofol for 8 h after kainate application as compared to kainate alone. All values of reﬂex peak amplitude and area in treated spinal cords were signiﬁ-
cantly different from sham (H5 = 32.163, P = 0.001; H5 = 30.521, P = 0.001; Kruskal–Wallis one-way analysis of variance on ranks test respectively).
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Figure 8A summarizes the data involving network rhythmicity
that appears when synaptic inhibition is blocked by strychnine and
bicuculline (Bracci et al., 1996b). Figure 8A–C shows persistence
of bursting 1 day after propofol application even though with smal-
ler amplitude and longer period. When kainate application was fol-
lowed by propofol (4 h or 8 h), the burst amplitude remained very
depressed (t13 = 3.087, P = 0.009; U = 4, P = 0.004; Mann–Whit-
ney test), while the periodicity improved in comparison to kainate
alone.
Discussion
The principal ﬁnding of the present study is the novel demonstration
that the anaesthetic propofol induced signiﬁcant neuroprotection of
spinal neurons against excitotoxicity even when administered after
the excitotoxic stimulus (i.e. kainate application) had been
terminated. This protection was also extended to motoneurons as the
number of survivors approached the control level. Using the in vitro
preparation enabled us testing the proof of principle that propofol
might neuroprotect independently from vascular (or peripheral)
effects. While these beneﬁcial effects were observed after 24 h from
excitotoxic stimulation, they were not, however, associated with sig-
niﬁcant recovery in locomotor network output, a phenomenon we
attributed to the rather slow recovery of motor networks from the
depressant effect of propofol.
Effects of propofol per se on spinal networks
In line with previous studies (Kotani et al., 2008), we observed that
the concentration of propofol used in the present investigation partly
depressed polysynaptic transmission (Jewett et al., 1992), potenti-
ated GABA-evoked responses (Adodra & Hales, 1995; Reynolds &
Fig. 6. Changes in electrically induced ﬁctive locomotor oscillations elicited by DR stimuli recorded on day 2 after kainate (1 h) exposure followed by propo-
fol for 4 or 8 h. (A) Representative records of electrically evoked cumulative depolarization of sham (n = 7), propofol applied for 4 h (Prop 4 h, n = 7), propo-
fol applied for 8 h (Prop 8, n = 8), kainate applied for 1 h (KA, n = 11), kainate (1 h) followed by propofol for 4 h (KA/Prop 4 h, n = 10) and kainate (1 h)
followed by propofol for 8 h (KA/Prop 8 h, n = 14) protocols. Traces show typical alternating VR cycles between homolateral L2 and L5 motor pools: these
oscillations are superimposed over the slowly developing cumulative depolarization due to non-linear summation of synaptic responses (Marchetti et al., 2001).
(B) Bar graph representing number of alternating oscillations elicited by DR stimulation. Although propofol alone does not change oscillations, no emergence
of oscillations is observed after kainate with or without subsequent application of propofol for 4 or 8 h. (C) Histogram representing signiﬁcant depression in
cumulative depolarization after treating spinal cords with kainate: this effect was unchanged by 4-h propofol (t19 = 0.792, P = 0.438) and intensiﬁed by 8 h of
the same anaesthetic (U = 31, *P = 0.013; Mann–Whitney test). (D) Histogram depicting a decrease in cumulative depolarization area of the same preparations
shown in C. Note the signiﬁcant change in number of oscillations, cumulative depolarization and area of all treated preparations in comparison to sham
(H5 = 51.806, P = <0.001; H5 = 37.673, P = <0.001; H5 = 41.110, P = <0.001; Kruskal–Wallis one-way analysis of variance on ranks test, respectively).
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Maitra, 1996) and depressed NMDA-mediated ones (Orser et al.,
1995). These effects on GABA or NMDA depolarizations were at
least in part attributable to a direct effect on motoneurons as they
persisted after block of network activity with TTX. Human studies
corroborate this notion as propofol has been shown to reduce spinal
motoneuron excitability (Kakinohana et al., 2002; Kammer et al.,
2002). Long-term effects by propofol on synaptic transmission
investigated over several hours suggested that the reduction in reﬂex
area was perhaps due to a combinatorial phenomenon of facilitated
GABA action (that on neonatal spinal neurons is depolarizing, yet
inhibitory; Vinay & Jean-Xavier, 2008) plus NMDA receptor antag-
onism as these receptors contribute to the late component of excita-
tory transmission onto motoneurons (Evans et al., 1982). It is
noteworthy that even prolonged washout of propofol (for at least
16 h) did not fully restore synaptic transmission, although within
the 24 h timeframe of the present study, ﬁctive locomotion evoked
by DR stimuli or neurochemicals (albeit of slow rate and small
intensity) could still be observed together with lack of histochemical
damage to spinal networks. It is surprising that details of reversibil-
ity of propofol depression on polysynaptic transmission induced by
DR stimulation in the rat spinal cord are lacking, although a former
study seemed to indicate partial recovery (Matute et al., 2004). Pre-
vious experiments have indicated that propofol depresses cumulative
depolarization (Matute et al., 2004), a phenomenon consistent with
the proposed analgesic action of this drug.
Propofol contrasted excitotoxic damage to spinal networks
In accordance with the view that propofol is neuroprotective against
brain ischaemia (Kawaguchi et al., 2005), the present study
observed that delayed application of propofol was an effective strat-
egy to largely prevent the development of neuronal damage in all
three spinal ROIs and was especially striking in the case of
motoneurons. As we found no difference in the histological outcome
when propofol was applied for 4 or 8 h, we propose that its neuro-
protective effect was exerted during the early phase of secondary
injury that involves (within the ﬁrst few hours) activation of non-
apoptotic cell death mechanisms (Kuzhandaivel et al., 2011). The
question then arises about the mode of action of propofol. We
favour the possibility that propofol enhanced GABA-mediated inhi-
bition and thereby decreased network excitability in a persistent
fashion (Jewett et al., 1992). This phenomenon is somewhat remi-
niscent of the action by the anaesthetic methoxyﬂurane that
depresses network activity by activating background K+ conduc-
tances (Elliott et al., 1992; Sirois et al., 2000) and thus, protects
spinal neurons from injury (Shabbir et al., 2015).
Hence, the simplest interpretation is that, regardless of the cellular
mode of action of the general anaesthetic drug, intense network
depression elicited by either a gas or an i.v. anaesthetic drug can exert
largely beneﬁcial actions on spinal networks even when administered
following the excitotoxic insult. This notion accords with the
Fig. 7. Changes in chemically induced ﬁctive locomotion after exposure to kainate (1 h) followed by propofol (4 or 8 h). Data recorded on day 2 after treat-
ment. (A) Sample recordings of ﬁctive locomotion induced by NMDA and 5-HT in sham (n = 8), propofol applied for 4 h (Prop 4 h, n = 9), propofol applied
for 8 h (Prop 8 h, n = 8), kainate applied for 1 h (KA, n = 6), kainate (1 h) followed by propofol for 4 h (KA/Prop 4 h, n = 10) and kainate (1 h) followed
by propofol for 8 h (KA/Prop 8 h, n = 11). Traces show typical alternating VR cycles between homolateral L2 and L5 motor pools. Although smaller in ampli-
tude and slower, these cycles are still present the day after treatment with propofol alone (4 or 8 h). (B, C) Bar graphs illustrate the peak amplitude of oscilla-
tory cycles (B) whose amplitude was decreased after application of propofol (8 h) in comparison to sham (t14 = 3.313, **P = 0.005; Student t-test), and period
of oscillations (C) has increased by application of propofol for 4 h (U = 66, P = 0.005; Mann–Whitney test) and for 8 h (U = 61, ***P = 0.001; Mann–Whit-
ney test). After kainate application, alternating oscillatory cycles irreversibly stopped in most cases. However, 5–15 sporadic oscillations (typically limited to a
single VR) could be detected in spinal cord preparations (5/10) after propofol administration for 4 h. No recovery in the preparations treated with propofol for
8 h after kainate exposure (1 h) was found. Note a signiﬁcant change in all the values of amplitude and period vs. sham (B and C) (H5 = 38.038, P = <0.001
and H5 = 40.923, P = 0.001; Kruskal–Wallis one-way analysis of variance on ranks test respectively).
© 2016 Federation of European Neuroscience Societies and John Wiley & Sons Ltd
European Journal of Neuroscience, 1–13
Propofol against excitotoxic injury 9
observations that neuronal damages after kainate are not immediately
caused by necrotic death as they emerge during the ﬁrst few hours
after washout of this excitotoxic drug and concern a certain popula-
tions of neurons only (Kuzhandaivel et al., 2010). Testing other gen-
eral anaesthetics like chloralose or barbiturates that are not clinically
used would also pose problems of data interpretation due to the rather
slow recovery of the in vitro spinal cord from their effects even when
applied for relatively short times (Bagust & Kerkut, 1981).
It is also noteworthy that pharmacological block of GABA-
induced inhibition largely aggravates kainate-evoked damage
(Bajrektarevic & Nistri, 2016). The propofol-mediated antagonism
of NMDA responses was less likely to contribute to neuroprotection
because we have previously shown that NMDA receptor blockers
per se are not efﬁcacious in this model (Margaryan et al., 2010).
The present results suggest that depression of network excitability is
an important strategy for damage limitation even after the excito-
toxic stimulus has been removed. Conversely, decrease in the
release of the excitatory transmitter glutamate by applying for
instance riluzole is far less effective (Samano et al., 2012) perhaps
because signiﬁcant background release of glutamate continues (Maz-
zone & Nistri, 2011) to support ongoing cell death processes.
Network function after kainate and propofol
Twenty-four hours after kainate followed by propofol application,
there was no recovery in integrated network function, in particular
cumulative depolarization evoked by DR stimuli, or ﬁctive locomo-
tion induced by electrical pulses or NMDA + 5-HT. This was not
totally unexpected in view of the long-lasting depression evoked by
propofol per se: there was, however, no additive depression by kai-
nate and propofol on synaptic transmission, indicating that further
deterioration had been blocked. In fact, disinhibited bursting that
reﬂects the intrinsic rhythmicity of spinal networks (Streit, 1993;
Bracci et al., 1996a) showed improved periodicity when 4-h propo-
fol administration followed kainate washout. The simplest interpreta-
tion is that, when network output required activation of a limited
circuitry (Bracci et al., 1996b), the protective action of propofol was
manifested more efﬁciently than over a very wide locomotor net-
work with complex connections extending over several segments
(Kiehn, 2006, 2016) and, therefore, with a much higher probability
of failure. These observations are consistent with our view (Samano
et al., 2016) that spinal networks operate in a condition of criticality
(Massobrio et al., 2015; Valverde et al., 2015), so that even moder-
ate cell losses trigger a major functional deﬁcit. Thus, we propose
that there is a minimal network membership necessary to express
locomotor patterns (Kuzhandaivel et al., 2011) below which loco-
motor output is lost.
Following the pioneer clinical work by Kay & Rolly (1977) who
used propofol for rapid induction of anaesthesia in man, this drug is
widely used in surgery because of the relatively fast recovery of
patient’s consciousness after the end of i.v. administration (Grund-
mann et al., 2001): this phenomenon is normally assessed as aware-
ness (“eye opening”) rather than locomotor function, and is
apparently due to the drug fast redistribution to body fat stores
rather than metabolic inactivation (Mirski et al., 1995). In fact, in
humans, the propofol plasma half-life is about 5 h, indicating slow
drug elimination with delayed concentration peaks perhaps responsi-
ble for potential changes in cardiovascular activity (Kay et al.,
Fig. 8. Disinhibited bursts recorded on day 2 after kainate (1 h) followed by propofol (4 or 8 h) treatment. (A) Sample recordings obtained from sham
(n = 8), propofol applied for 4 h (Prop 4 h; n = 9), propofol applied for 8 h (Prop 8; n = 7), kainate applied for 1 h (KA; n = 7), kainate (1 h) followed by
propofol for 4 h (KA/Prop 4 h; n = 9), and kainate (1 h) followed by propofol for 8 h (KA/Prop 8 h; n = 9). After kainate or propofol alone bursts are smaller,
although no further decrease is observed when these two treatments were sequentially applied (A–C). Note signiﬁcant recovery in number of bursts during 20-
min epoch after kainate followed by propofol treatment both for 4 and 8 h (t14 = 3.622, **P = 0.003 and t14 = 2.793, *P = 0.014 respectively) in compar-
ison to kainate alone, although their corresponding amplitude was signiﬁcantly reduced after propofol for 4 and 8 h (t13 = 3.087, P = 0.009; U = 4, P = 0.004;
Mann–Whitney test respectively). Note a signiﬁcant change in number of bursts (in 20 min) and burst amplitude in treated preparations in comparison to sham
(F5,43 = 4.100, P = 0.004, one-way analysis of variance test; H5 = 36.563, P = <0.001, Kruskal–Wallis one-way analysis of variance on ranks test, respec-
tively).
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1986). Earlier investigations report that patients may experience side
effects even 24–48 h after a single 10-min administration of propo-
fol (Sanders et al., 1991). Anaesthesiological studies also demon-
strate that full motor recovery in humans is incomplete for many
hours after propofol (M€unte et al., 2001; Haavisto & Kauranen,
2002), leading to the general advice that dizziness and drowsiness
may persist for 24 h and to caution against driving (http://
www.rxlist.com/diprivan-drug/patient-images-side-effects.htm). Thus,
our interpretation is that poor recovery of in vitro network function
after kainate and propofol was not due to neuronal damage but to
lingering consequences of long-lasting propofol administration. One
limitation of the present model is the length of in vitro survival that
is restricted to 24 h, as at later times, tissue deterioration and loss of
locomotor network activity emerge as earlier reported by Kerkut &
Bagust (1995). This condition makes it difﬁcult to extend the time-
frame of our experimental observations to support our view about
the late consequences of propofol administration.
In conclusions, recent clinical reports suggest that general anaes-
thetics may be neuroprotective for the spinal cord especially during
aortic surgery when blood supply to the spinal cord is compromised
(Kakinohana, 2014). Our current data support the notion that a gen-
eral anaesthetic applied even after an excitotoxic stimulus to the
in vitro spinal cord can provide large neuroprotection of locomotor
networks (Shabbir et al., 2015; Bajrektarevic & Nistri, 2016), whose
functional recovery might depend on the actual pharmacokinetic
characteristics of the anaesthetic used. It should be interesting to
extent these studies to in vivo animals to better identify their transla-
tional impact. Furthermore, multicentre clinical trials will be
required to ﬁnd out whether propofol should be the preferred drug
of choice for early management of traumatic SCI apart from its use
for spinal cord ischaemia (Kakinohana, 2014).
Supporting Information
Additional supporting information can be found in the online ver-
sion of this article:
Fig. S1. Scheme of experimental procedures.
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Abstract 
Activation of neuronal nicotinic acetylcholine receptors (nAChRs) by nicotine is reported to 
protect brain neurons from glutamate excitotoxicity. We inquired whether a similar phenomenon 
can occur in the rat isolated spinal cord (or spinal slice culture) challenged by a transient (1 h) 
application of kainate (a powerful glutamate receptor agonist) to induce excitotoxicity 
mimicking spinal injury in vitro. We recorded spinal reflexes and fictive locomotion generated 
by the locomotor central pattern generator before and 24 h after applying kainate. We also 
monitored network activity with Ca
2+
 imaging and counted neurons and glia with 
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immunohistochemical methods. In control conditions nicotine (1 µM; 4 h) depressed reflexes 
and fictive locomotion with slow recovery and no apparent neurotoxicity at 24 h although 
synchronous Ca
2+
 transients appeared in slice cultures. Kainate nearly halved neuron numbers 
(while sparing glia), decreased reflexes and Ca
2+
 transients, and suppressed fictive locomotion. 
When nicotine was applied (4 h) after washout of kainate, fictive locomotor cycles appeared 24 h 
later though with low periodicity, and significant protection of neurons, including motoneurons, 
was observed. Nicotine applied together with kainate and maintained for further 4 h yielded 
better neuroprotection, improved fictive locomotion expression, and reversed the depression of 
Ca
2+
 transients. nAChR antagonists did not intensify kainate neurotoxicity and inhibited the 
neuroprotective effects of nicotine. These data suggest that nicotine was efficacious to limit 
histological and functional excitotoxic damage probably because it activated and then 
desensitized nAChRs on excitatory and inhibitory network neurons to prevent triggering 
intracellular cell death pathways. 
Introduction 
The functional role of neuronal nicotinic acetylcholine receptors (nAChRs) was first observed at 
the motoneuron-Renshaw cell synapse, thus making the spinal cord exemplary for investigating 
the expression of nAChRs previously studied on peripheral tissues only (Eccles et al., 1954). 
nAChRs (α4β2 and α7 subtypes) are widely expressed in the dorsal (Kiyosawa et al., 2001; Khan 
et al., 2003; Genzen & McGehee, 2003; 2005; Takeda et al., 2007) and ventral horns (Roth & 
Berg, 2003; Nakamizo et al., 2005). These receptors mediate cation fluxes responsible for 
depolarization and firing, although these phenomena are attenuated by receptor desensitization 
(Fenster et al., 1999). There are also similar intracellular nAChRs on the outer membrane of 
mitochondria to control mitochondrial activity and energy supply (Skok et al., 2016). 
Mitochondrial receptors can be activated by nicotine that readily passes across cell membranes. 
From a functional viewpoint, spinal nAChRs are involved in physiological responses like pain 
(Khan et al., 1998) and locomotion (Perrins and Roberts, 1995; Nishimaru et al., 2006) to which 
motoneuron/Renshaw cell synapses make an important contribution (Lamotte d'Incamps et al., 
2012; Enjin et al., 2017).  
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nAChRs are implicated in neuroprotection mechanisms against acute cell distress (Bencherif, 
2009) induced by excitotoxicity, namely a process of over-activation of glutamate receptors 
considered as a paradigm of neurodegeneration (Choi 1992; 1994). Nicotine mediated 
neuroprotection has been reported in vitro (Garrido et al., 2003), in vivo (Xue et al., 2014) and in 
epidemiological studies (Quik et al., 2012), suggesting potential strategies to contrast neuronal 
death. On brainstem motoneurons nicotine protects against excitotoxicity by activating nAChRs 
that trigger intracellular pathways to block reactive oxygen species (ROS) and by normalizing 
mitochondrial metabolism (Corsini et al., 2016; Tortora et al., 2017). Since nicotine depolarizes 
rat spinal motoneurons via direct and indirect effects (Blake et al., 1987), this drug might be 
neuroprotective for the spinal cord by acting on a broad spectrum of targets. To explore this 
issue, we used an excitotoxic model of the isolated rat spinal cord kept in vitro for up to 24 h 
(Taccola et al., 2008). We measured the output of locomotor networks as fictive locomotion by 
recording oscillatory patterns from lumbar ventral roots (VRs), and investigated locomotor 
network activity and neuronal survival after excitotoxicity and nicotine application. For this 
purpose, we initially analyzed the acute and delayed effects of nicotine on synaptic transmission, 
fictive locomotion and cell composition to identify the most suitable concentration of nicotine. 
Thereafter, we applied the excitotoxic protocol based on a transient application of kainate, a 
potent glutamate analogue, to find out the best regimen of nicotine administration for functional 
and structural neuroprotection of spinal networks. Since the neurotoxicity evoked by kainate 
peaks after its washout (Kuzhandaivel et al., 2010), we investigated the impact of nicotine 
administration applied together with kainate or after its washout. Finally, we studied if the 
subtype selective nAChR antagonists Di-hydro-β-erythroidine (DHβE) and methyllycaconitine 
(MLA) (Arias, 1997; Gotti & Clementi, 2004) could change spinal network activity as well as 
influence any beneficial action by nicotine toward excitotoxic damage.  
Materials and methods 
Ethical approval 
All the experimental procedures were approved by SISSA ethical committee (prot. 3599, 28th 
May 2012) and were performed in accordance with the guidelines provided by European Union 
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rules for animal experimentation. All attempts were made to reduce the number of animals used 
and their sufferings.  
Spinal cord preparation and drug application protocol 
Experiments were carried out with in vitro spinal cord preparations from 0-2 day old wistar rats 
(n = 111, where n is the number of animals used in the whole study) by rapidly decapitating 
under anesthesia with urethane (0.2 mL i.p. of a 10% w/v solution). Thoraco-lumbar spinal cord 
preparations were carefully isolated in continuously oxygenated Krebs solution (in mM; 113 
NaCl, 4.5 KCl, 1 MgCl2.7H2O, 2 CaCl2, 1 NaH2PO4, 25 NaHCO3, 11 glucose; gassed with 95% 
oxygen and 5% CO2; pH 7.4 at room temperature at 7.5 mL/min) as previously published 
(Taccola & Nistri, 2006a; Taccola et al., 2008; Margaryan et al., 2009). After dissection, spinal 
cords were kept in Krebs for 2 h to recover functional activity before starting with 
experimentation. To mimic excitotoxic damage of gray matter, kainate was applied at 50 µM 
concentration to partially abolish fictive locomotor rhythms induced by DR train pulses and 
NMDA+5HT when tested the subsequent day. Initially the protocol of nicotine concentration 
was optimized by using different concentrations of nicotine (10, 2, 1, 05; µM) for 4 h on day 1 
and recorded polysynaptic reflex responses and fictive locomotor patterns every 15-20 min 
during 4 h. After all concentrations trails, on an in vitro spinal cord preparation, nicotine with 1 
µM concentration was selected for further continuing experimentation with spinal lesion and 
neuroprotection protocols. Thereafter, spinal cords were kept in Krebs overnight and recorded 
monosynaptic reflexes, polysynaptic reflexes, electrically induced and chemically induced fictive 
locomotion 24 h after wash.   
Excitotoxicity was induced by bath application of kainate (for 1 h; 50 µM, from Tocris), 
glutamate agonist, followed by either Krebs or nicotine (1 µM) administered for 4 h on day 1. 
These preparations were then superfused with Krebs solution overnight and reflexes and fictive 
locomotion were recorded on subsequent day. Electrophysiological and immunohistochemical 
data were compared among the following 5 groups; Sham (day 2 control), nicotine 1 µM applied 
for 4 h (N, from Sigma-Aldrich), kainate administered for 1 h, kainate (1 h) followed by nicotine 
for 4 h (KA/N 4h), kainate co-applied with nicotine for 1 h followed by nicotine for 4 h 
(KA+N/N 4h) (see supplemental fig. 1).  
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To further ensure the neuroprotective effect of nicotine and the involvement of specific nicotinic 
acetylcholine receptors i.e. α4β2 and α7 in spinal neuroprotection, nAChR antagonists, dihydro-
β-erythroidine, 10 µM (DHβE, from Tocris) and methyllycaconitine, 10 nM (MLA, from Sigma-
Aldrich, Saint Louis, MO, USA), were applied in the following 9 combinations; DHβE applied 
alone for 4 h (D), DHβE co-applied with kainate for  1 h (KA+D), DHβE administered with 
kainate and nicotine for 1 h followed by DHβE and nicotine for 4 h (KA+D+N/D+N 4 h), MLA 
applied for 4 h (M), MLA co-administered with kainate for  1 h (KA+M), MLA administered 
with kainate and nicotine for 1 h followed by MLA and nicotine for 4 h (KA+M+N/M+N 4 h), 
DHβE and MLA were co-applied for 4 h (D+M), DHβE+MLA coapplied with kainate for  1 h 
(KA+D+M), DHβE and MLA were administered with kainate and nicotine for 1 h followed by 
DHβE+MLA+nicotine for 4 h (KA+D+M+N/D+M+N 4 h) (supplemental fig. 1).   
Electrophysiological recordings  
By using tight fighting monopolar suction Ag/AgCl electrodes, DC coupled recordings were 
acquired from L2 and L5 ventral roots (VRs) which carry flexor and extensor motor pools to 
hind limbs (Taccola & Nistri, 2006a; Taccola et al., 2008). VR responses were elicited (at 10 
KHz) by delivering electrical square pulses with 0.1 ms duration to the dorsal root (L) through 
bipolar suction electrodes. Initially, minimum stimulus threshold was estimated by applying 
graded electrical stimuli and detecting the minimal response in ipsi-lateral and ispi-segmental 
VRs, equivalent to 1x threshold to induce monosynaptic reflex responses. 3x stimulus threshold 
was used to evoke polysynaptic reflexes.  3x threshold intensity to evoke DR induced fictive 
locomotion by stimulating 30 pulses of DR train at 2 Hz frequency (15 s) (Marchetti et al., 
2001). Chemically induced fictive locomotion was evoked by bath application of N-methyl-D-
aspartate (NMDA) (3-6 µM) and 5-hydroxytryptamine (5-HT) (10 µM) (Kiehn & Kjaerulff, 
1998; Kiehn 2006). Disinhibited bursts were evoked by applying γ-aminobutyric acid (GABA)-
A and glycine receptors blockers, bicuculline (20 µM) and strychnine (1 µM) respectively. 
Signal records were acquired and processed with pClamp software 9.2, (Molecular Devices, 
Sunnyvale, CA, USA). Fictive locomotor rhythms and burst activity was measured in accordance 
with Taccola et al. (Taccola et al., 2008) and Bracci et al. (Bracci et al.,1996a,b) respectively. 
Immunofluorescence, microscopy and analysis 
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Immunohistochemical experiments were performed in accordance with previous reports (Cifra et 
al. 2012; Sámano et al., 2016; Kaur et al., 2016). After electrophysiology recordings, spinal 
cords were fixed in 4% paraformaldehyde and then cryoprotected with 30 % (w/v) sucrose. 30 
µm thick transverse sections of spinal cords were cut from T13-L5 segment of spinal cord with 
sliding microtome at –20 
°
C and preserved in phosphate buffer saline (PBS) until use. Free 
floating immuno-fluorescence procedure was used where the sections were preincubated for 2 h 
with blocking solution (5% normal goat serum, 5% bovine serum albumin, 0.3 % Tritox X 100, 
1% PBS) at room temperature. Spinal cords were immunolabelled with primary antibodies 
namely, anti-Neu N (Neuron specific neuronal marker; rabbit polyclonal; 1:500 dilution; Merck 
Millipore, Milan, Italy), anti-SMI 32 (specific non phosphorylated neurofilament H in spinal 
motoneurons; mouse monoclonal; 1:1000 dilution; Chemicon, Millipore, Milan, Italy), anti-S100 
(specific for S100 protein, belongs to family of Ca
2+
 binding proteins in nuclei and cytoplasm of 
astrocytes, rabbit polyclonal; 1:1000; DAKO, Glostrup, Denmark) and anti-GFAP (specific for 
Glial fibrillary acidic protein (GFAP), m mber of class III intermediate filament protein family, 
expressed in astrocytes and certain other astroglia in the central nervous system; mouse 
monoclonal; 1:500; Sigma Aldrich) in antibody solution (containing 1% NGS, 1% BSA, 0.1 % 
Triton-X 100), kept overnight at 4 
°
C. Sections were washed with 1x PBS and incubated with 
appropriated secondary antibodies, anti-mouse Alexa Flour 488 or 594, or anti-rabbi Alexa Fluor 
488 or 594 and DAPI for 2 h. Finally they were mounted on glass and imaged with Leica 
DM6000 (20x magnification). Images were obtained from 3 to 6 spinal sections (5-10 
sections/preparation) by selecting 3 regions of interest (ROIs); dorsal, central (D, C; 350x350 
µm
2
) and ventral (V; 300x230 µm
2
) (Mazzone et al; 2010; Cifra et al., 2012; Sámano et al., 
2016).  Quantification (of cells, pyknotic nuclei, motoneurons and neurons) and immuno-
fluorescence intensity (AU, of astrocytes and glia) was measured by ImageJ software.  
Preparation of organotypic slice cultures 
Organotypic spinal cultures were prepared from spinal cords of E13 day rat embryos as 
previously reported (Avossa et al., 2003; Mazzone et al., 2010; Mazzone and Nistri, 2011). Thus, 
275 µm transverse slices were cut and fixed on a glass coverslip (Kindler, EU) with reconstituted 
chicken plasma clotted with 1 drop of thrombin (200 U/mL). The coverslips with spinal sections 
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were inserted into plastic tubes with 1 mL of medium comprised 82 % Dulbecco’s modified 
eagle’s medium, 8% sterile water with tissue culture, 10 % fetal bovine serum, osmolarity 300 
mOsm, pH 7.35. About 40 slices (from thoraco-lumbar part) were prepared from single 
dissection. The tubes were kept for culturing for 22 days in vitro (DIV) in roller drum (120 x g/h) 
at 36.5 
°
C, with 5% CO2. Dulbecco’s modified eagle’s medium was applied with high glucose 
(DME/HIGH), penicillin and streptomycin (Euroclone, Devon, UK). Fetal calf serum (FBS) was 
purchased from Invitrogen (Carlsbad, CA, USA), nerve growth factor (NGF) from D.A.B Italia 
(Segrate, Italy), chicken plasma from Innovative (Novi, MI, USA) and thrombin from Merck 
(Darmstadt, Germany). Organotypic spinal cultures were treated after 22 days of culturing. There 
were four selected paradigms used on 22
nd
 day, namely sham, nicotine 1 µM, kainate 50 µM and 
kainate coapplied with nicotine for 1 h followed by nicotine for 4 h (KA+N/N 4h). All the 
treatments were washed out with culture medium for 24 h before using the cultures for Ca
2+
 
imaging experiments.   
Ca
2+
 Imaging    
In accordance with previous protocols for Ca
2+
 imaging (Fabbro et al., 2004; Sharifullina & 
Nistri, 2006; Corsini et al., 2017), organotypic spinal slices grown in-vitro for 3 weeks were 
incubated with fluorescent calcium dye Fluo 3-AM (4 µM, Molecular Probes, Invitrogen, 
Carlsbad, CA, USA) for 1 h at room temperature in Dulbecco’s modified eagle’s medium. The 
fluorescent dye was washed out with the same medium (Dulbecco’s modified eagle’s medium) 
containing strychnine and bicuculline for 30 min. Spinal cultures were then transferred to a 
recording chamber of the Nikon Eclipse T1 microscope (Nikon, Tokyo, Japan) and replaced the 
medium with 2 mL of oxygenated Krebs comprising strychnine (1 µM) and bicuculline (20 µM). 
We recorded Ca
2+
 signals from ventrally located neurons (somatic diameter > 20 µm; Fabbro et 
al., 2007). For each slice, only one region was analyzed, and 8 ± 3 number of fluorescent ventral 
neurons was selected (focused in the most superficial plane) to investigate changes in 
intracellular Ca
2+
 concentration. Ca
2+
 fluorescent emission was excited at a fixed wavelength of 
488 nm generated by a Nikon intensilight C-HGFI lamp (Nikon) and detected with the digital 
CMOS camera ORCA-Flash 4.0 (Hamamatsu Photonic, Hamamatsu City, Japan). Images were 
acquired with the Fiji software (ImageJ, Wayne Rasband, National Institued of Health, USA; 62) 
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with 200 ms exposure time. Traces extrapolated with Igor Pro software (version 6.37, 
Wavemetrics, Lake Oswego, OR, USA) were analyzed with the software Clampfit 10.0 
(Molecular Devices Corporation, Sunnyvale, CA, USA). Ca
2+
 transients were expressed as ∆F/F0 
(the amplitude fractional increase), where ∆F is the fluorescence rise over baseline, and F0 the 
baseline fluorescence level; [Ca
2+
]i elevations were considered significant when they exceeded 5 
times the noise standard deviation (Bosi et al., 2015; Rauti et al., 2016). The correlation between 
the Ca
2+
 events among active cells recorded from the same field was assessed by cross-
correlation analysis. The value of cross correlation factor (CCF) was used to measure the 
strength of the correlation between cells, i.e. the relative probability that the peaks of calcium 
transients took place at the same time in all the cells. These values range between 1 (maximal 
correlation) and −1 (maximal anti-correlation), and were obtained using Igor Pro. 
Statistical analysis 
Electrophysiological, immuno-histochemical and calcium imaging data were statistically 
analyzed with SigmaStat 3.5 (Stat Software, Chicago, IL, USA). Values were expressed as 
mean±SEM, where n is the number of spinal cords or spinal slices used. As directed by software, 
normality test was applied to distinguish between parametric and non-parametric data, the values 
were evaluated by Student’s t-test or Mann-Whitney test respectively. One-way Analysis of 
variance test (ANOVA) was applied for multiple comparisons (via Kruskal-Wallis or Holm 
Sidak tests). The acceptance significance level was P < 0.05.  
Results 
Acute effects of nicotine on reflexes, fictive locomotion and motoneuron depolarization of 
the rat spinal cord 
Because the effects of nicotine are complex and could be manifested as either neuroprotective or 
toxic, initial experiments were performed to identify the most suitable time course and 
concentration of nicotine for experiments which spanned over several hours. Fig. 1 A shows 
changes in average polysynaptic reflexes recorded from a lumbar VR following homosegmental 
DR stimulation. While the response peak was stable for several h in Krebs solution, in the 
presence of nicotine there was a sustained depression of the amplitude with partial recovery at 1 
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h wash. Nicotine was applied continuously for 4 h since this would be the most suitable time to 
contrast the delayed onset of kainate excitotoxicity that starts within the first h and is fully 
expressed over the next 4 h (Kuzhandaivel et al., 2010). The largest depression by nicotine was 
observed with 2 µM (**P = 0.007, area; P = 0.006, amplitude; Control vs N 20 min, Student’s t-
test) or 10 µM (***P = 0.001, area; *P = 0.017, amplitude; Control vs N 20 min, Mann 
Whitney-test) concentrations of nicotine (Fig. 1 B, C). Fig. 1 B shows that the polysynaptic 
response area became smaller with anyone of the nicotine concentrations used however not 
significant with 1 and 0.5 µM nicotine (P = 0.089 and P = 0.838, Mann Whitney-test). The acute 
effect of nicotine was associated with depolarization recorded from VRs as shown in Fig. 2. 
Thus, by comparison with kainate (50 µM), depolarization evoked by 10 µM nicotine was 
clearly smaller (P = 0.001, KA vs N 10 µM; Student’s t-test) and almost undetectable when 1µM 
was applied (P = 0.001, KA vs N 1 µM; Student’s t-test) (Fig 2 A). Fig. 2 B summarizes average 
data indicating that depolarization evoked by nicotine was less than 1/3
rd
 of the one evoked by 
kainate, and that it was only modestly dependent on the drug concentration, probably indicating 
that most effects had indirect origin within spinal networks. To minimize network depression and 
to avoid concentrations likely to produce toxicity, these data suggested the use of 1 µM nicotine 
for further, even longer tests.    
Delayed effects by nicotine on spinal networks 
Fig. 3 shows responses recorded on the second experimental day after spinal cords had been 
treated on day 1 with 1 µM nicotine (4 h) followed by washout (see scheme in supplementary 
Fig. 1). Monosynaptic reflexes were largely depressed by comparison with sham preparations (P 
= 0.003, Student’s t-test) (Fig. 3 A, E). A similar effect was also detected when recording 
polysynaptic reflexes from the same preparations (P = 0.027, amplitude, Mann Whitney-test; P = 
0.029, area, Student’s t-test; sham vs N) (Fig. 3 B, F, G). We next tested trains of DR stimuli 
applied to a single DR to elicit cumulative depolarization with superimposed alternating VR 
oscillations reflecting the activation of the locomotor central pattern generator (Marchetti et al., 
2001). Fig 3 C, H-J shows that cumulative depolarization amplitude and area values were similar 
after nicotine pretreatment and retained their ability to generate oscillations. FL cycles induced 
by the standard method of co-application of NMDA and 5-HT to elicit alternating VR 
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oscillations (Kiehn, 2006) had slightly slower periodicity and smaller amplitude (P = 0.001, 
Student’s t-test) after prior day treatment with nicotine (Fig. 3 D, K). 
These data suggested that, despite extensive wash, nicotine had left a functional signature on the 
activity of spinal networks which were operative at near normal level only when subjected to 
strong, sustained stimulation (DR trains or NMDA + 5-HT). This realization raised the issue of 
whether nicotine could replicate its effects when reapplied on the second day or whether 
nAChRs might have been inactivated or lost. Supplemental Fig. 2 A, B shows that nicotine 
retained its depressant effect on polysynaptic reflexes (amplitude: P = 0.002, H(2) = 12.244, 
Kruskal-Wallis one way analysis of variance on ranks test; area: P = 0.001, F2,26 = 12.385, one 
way analysis of variance test). When compared to Fig. 1 A, B the action of nicotine was even 
stronger and was associated with a larger decrease in the area (P = 0.011, F2,21 = 5.714, one way 
analysis of variance test) of cumulative depolarization and associated oscillations (P = 0.013, 
H(2) = 8.636, Kruskal-Wallis one way analysis of variance on ranks test) (Supplemental Fig. 2 C, 
D). 
Fig. 4 shows that prior application of nicotine on day 1 did not significantly change cell 
populations within the lumbar spinal cord. Thus, as exemplified in Fig. 1 A for a section of the 
dorsal horn, good immunopositivity to NeuN was retained, an observation applicable to all three 
ROIs investigated (Dorsal: P = 0.001, t16 = –5.406; Central: P = 0.859, U = 43, Mann Whitney 
test; Ventral: P = 0.104, t16 = 1.726, respectively, sham vs nicotine, N) (Fig. 4 D). Similar data 
were obtained for SMI32 positive motoneurons (P = 0.001; t24 = –3.798, sham vs N) (Fig. B, E) 
and astroglia immunostained with S100 (Dorsal, P = 0.562; Central, P = 0.276; Ventral, P = 
0.265) or GFAP (Dorsal: P = 0.715; Central: P = 0.675; Ventral: P = 0.801, respectively, sham 
vs N) antibodies (Fig. 4 C, F, G). 
Neuroprotection by delayed application of nicotine 
The potential translation value of pharmacological treatment should, inter alia, include 
administration of the drug under test after the excitotoxic stimulus. Thus, as indicated in 
Supplemental Fig. 1, we applied kainate on day 1 followed by washout and immediate 
application of 1 µM nicotine for 4 h. Extensive washout was then performed with Krebs solution 
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for the next 24 h when testing commenced. Fig. 5 A-D shows sample record of mono-, 
polysynaptic responses, cumulative depolarization and chemically-induced fictive locomotion 24 
h after kainate alone or kainate followed by nicotine. While kainate consistently decreased all 
these responses (see control sham values in Fig. 3) in accordance with previous reports (Taccola 
et al., 2008; Mazzone et al., 2010), delayed application of nicotine attenuated the kainate-induced 
toxicity as depression of polysynaptic responses was less intense (amplitude: P = 0.002, U = 23; 
area: P = 0.014, U = 37, Mann Whitney-test, respectively; KA vs KA/N 4h) (Fig. 5 B, F, G), 
some recovery in cumulative depolarization (P = 0.005, t22 = –3.092) (Fig. 5 C, I, J) and 
oscillations (P = 0.001; U = 0, Mann Whitney-test) (Fig. 5 H) was detected, and small VR 
alternating cycles were present (amplitude, P = 0.001; t19 = –6.563; period, P = 0.001, U = 28, 
Mann Whitney-test) (Fig. 5 D, K). No change in monosynaptic responses was apparent (Fig. 5 A, 
E).  
Histological data validated the partial neuroprotection by the delayed application of nicotine as 
shown in Fig. 6. Thus, pyknosis was less frequent (P = 0.001, U = 108, Mann Whitney-test) (Fig. 
6 C), neuronal numbers were better preserved (P = 0.001, t16 = –11.612) especially in the dorsal 
ROI (Fig. 6 A, D), and more numerous motoneurons (P = 0.001, U = 3, Mann Whitney-test) 
were observed (Fig. 6 B, E). In line with our previous results, we found no significant damage by 
kainate to astroglia in the three ROIs and, therefore, no effect by subsequent application of 
nicotine (Supplemental Fig. 3, A, C, D).  
Advancing the timing of nicotine application to improve neuroprotection 
We wondered if better neuroprotection could be obtained by applying nicotine earlier, i.e. 
together with kainate (Supplemental Fig. 1). While this procedure would not confer much 
translational value to the data, we felt it would probably serve another purpose, namely to clarify 
if the intracellular pathways triggered by nicotine operate more slowly than the death pathways 
triggered by kainate. This approach has been employed with some success with the PARP-1 
inhibitor PJ34 (Nasrabady et al., 2011).  
Fig. 7 summarizes our observations with co-application of kainate and nicotine for 1 h, followed 
by 4 h nicotine and then washout with Krebs up to the next day. Thus, while monosynaptic 
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reflexes were similarly depressed by kainate alone or with the nicotine protocol (Fig. 7 A, E), 
improvement in polysynaptic reflexes was stronger when nicotine had been co-applied 
(amplitude: P = 0.001; area: P = 0.001, Mann Whitney-test, respectively; KA vs KA+N/N 4h) 
(Fig. 7 B, F, G). Likewise, the cumulative depolarization was larger (P = 0.001, U = 5, Mann 
Whitney-test) with the latter protocol (Fig. 7 C, H, I, J) and, in particular VR cycles evoked by 
NMDA plus 5HT emerged at slow periodicity (amplitude: *P = 0.012 and periodicity: P = 0.004, 
Mann Whitney-test) (Fig. 7 D, K).  These data suggested that network excitability strongly 
lowered by kainate was better preserved with this nicotine protocol. One functional test in 
support of this hypothesis was the demonstration that the spontaneous disinhibited bursting, 
arising after pharmacological block of inhibition and relying on network glutamatergic 
transmission (Bracci et al 1996), was characterized by significantly larger burst amplitude (P = 
0.027, Students t-test; KA vs KA+N/N 4h) (Fig. 8 A, B) when nicotine was co-applied even if 
the burst frequency remained unchang d (P = 0.356) (Fig. 8 C).   
While isolated preparations of the spinal cord offer the advantage of studying the integrated 
network output in terms of reflexes and fictive locomotion, they are not well suited to provide 
data on the distribution of bursting and their long-term sensitivity to kainate and/or nicotine. 
With the aim of studying long-term spontaneous bursting as an index of distributed network 
activity, we recorded Ca
2+
 transients from neurons in spinal slice cultures (Fabbro et al., 2007; 
Sibilla et al., 2009) as exemplified in Fig. 9 A. Fig. 9 A shows the spatial resolution of ventral 
neurons that could be simultaneously traced within the same field of view, with single cell 
resolution. At 22 DIV Ca
2+
 oscillations elicited during disinhibited bursting were typically very 
slow by comparison to electrophysiological bursts and detected over a wide area (Fig. 9 B, top 
left; see also Fabbro et al., 2007; Sibilla et al., 2009; Streit, 1993). By simultaneous recording 
from distinct neurons, it was clear that these Ca
2+
 oscillations were synchronous as evaluated 
with their cross-correlation factor even when the cells were spaced 300 µm apart (Fig. 9 A, B, 
E). Nicotine applied at 1 µM concentration for 4 h (in analogy to the protocol earlier reported; 
Supplemental Fig. 1) largely enhanced the frequency of bursting (P = 0.001, F3,19 = 38.639, 
Holm sidak-test) recorded the day after with preserved synchronicity (Fig. 9 B, C, E). This 
delayed effect of nicotine was accompanied by a significant decrease in the length of single 
transients (Fig. 9 D) (P = 0.002, H(3) = 15.009, Kruskal-Wallis one way analysis of variance on 
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ranks test). Kainate application was followed by a strong decrement in oscillatory activity and 
prolongation of Ca
2+
 transients, effects that were significantly and persistently reversed by 
nicotine that did not decrease their synchronicity (Fig. 9 B-D).  
Histochemical experiments with the isolated spinal cord preparation showed that early nicotine 
administration together with kainate followed by nicotine for 4 h strongly blocked pyknosis (Fig. 
10 A, C), and left the motoneuronal number nearly normal (P = 0.001, U = 3, Mann Whitney-
test, KA vs KA+N/N 4h) (B, E), while the neuronal number was significantly improved vs 
kainate treatment for all three ROI, especially in the case of dorsal horn (P = 0.001, t16 = –
14.761, Student’s t-test) (Fig. 10 D). With this protocol the number of neurons in the dorsal ROI 
was similar to the one observed when nicotine had been applied only after kainate (P = 0.705, t16 
= 0.385, Student’s t-test; KA/N 4h vs KA+N/N 4h) (see Fig. 6 D). The protocol with nicotine + 
kainate followed by nicotine conferred additional protection to neurons in central (P = 0.001, t16 
= - 6.036, Student’s t-test; KA/N 4h vs KA+N/N 4h) and ventral (P = 0.003, U = 75, Mann 
Whitney-test, KA/N 4h vs KA+N/N 4h) ROI when compared (see Fig. 6 D) with the delayed 
nicotine application after kainate. Conversely, no difference was observed in 
immunofluorescence intensity for S100 and GFAP signals between the protocols of kainate 
followed by nicotine and kainate+nicotine followed by nicotine (Supplemental Fig. 3 A-C).  
Changes in spinal reflexes and fictive locomotion by nAChR antagonists 
We next investigated whether application of nAChR antagonists might induce delayed changes 
in network function recorded on the second day in vitro. Fig 11 A, B shows sample averaged 
traces of monosynaptic and polysynaptic reflexes recorded 24 h after earlier application of 
antagonists alone (for 4 h). When compared to sham preparations at 24 h, monosynaptic reflexes 
were depressed after DHβE or MLA or DHβE+MLA (P = 0.045, F3,26 = 3.314; Holm-Sidak-test) 
(Fig. 11 A, E). Vice-versa, polysynaptic reflexes, while retaining peak amplitude (P = 0.281, 
F3,22 = 1.373; one way analysis of variance test) similar to sham, were strongly enhanced in area 
(P = 0.043, U = 8; P = 0.043, U = 8; P = 0.03, t12 = –2.469; D vs sham; M vs sham; D+M vs 
sham, respectively) (Fig. 11 B, F, G). The amplitude and area of cumulative depolarization 
evoked by DR trains were not significantly increased (Fig. 11 C, I, J), while the number of 
superimposed oscillations were reduced (P = 0.043, H3 = 8.416; Kruskal-Wallis one way analysis 
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of variance on ranks test) (Fig. 11 C, H). Chemically-induced fictive locomotion was present on 
the second day after antagonist application (Fig. 11 D), although the cycle amplitude was 
depressed with unchanged periodicity when both antagonists were applied (P = 0.006, F3,26 = 
5.279, one way analysis of variance test, sham vs D; P = 0.009, H3 = 11.580, sham vs M, 
Kruskal-Wallis one way analysis of variance on ranks test) (Fig. 11 K).  
Can antagonists change the severity of KA toxicity? 
We next examined if DHβE or MLA or DHβE+MLA application together with kainate for 1 h 
could modify the outcome of network activity caused by the excitotoxic challenge. No antagonist 
(alone or in combination) altered the severe decrease in monosynaptic (Fig. 12 A, E) and 
polysynaptic reflexes (Fig. 12 B, F, G) associated with kainate toxicity. Cumulative 
depolarization remained largely depressed in amplitude and area values (Fig. 12 C, H, I) with 
significant change in amplitude of cumulative depolarization (H) in case of DHβE+MLA when 
co-applied with KA in comparison to KA alone (P = 0.042, U = 10; Mann Whitney test). 
Interestingly, chemically-induced VR patterns were, however, observed (Fig. 12 D, J), even 
though with smaller amplitude in comparison to kainate alone (P = 0.024, F3,17 = 4.296; one way 
analysis of variance test). (Fig. 12 D, J) and of slow periodicity. Interestingly, co-application of 
kainate with DHβE and MLA improved neuronal survival in the dorsal and central ROI with no 
improvement in the ventral ROI (Dorsal: P = 0.001, F2,28 = 35.058, Holm Sidak test; Central: P = 
0.001, H(2) = 20.031, Kruskal Wallis test; Ventral: P = 0.001, H (2) = 17.757, Kruskal Wallis test) 
(Supplemental Fig. 4).   
nAChR antagonists and neuroprotection by nicotine 
Former observations indicated that the most useful neuroprotective protocol with nicotine was to 
apply this alkaloid together with kainate and maintained it for 4 h during the kainate washout. To 
find out if this action by nicotine was dependent on nAChR activation, we also co-applied 
nAChR antagonists either in combination or as single drug application (Supplemental Fig. 1).  
Fig. 13 summarizes data with such protocols. Thus, monosynaptic reflexes remained thoroughly 
depressed (P = 0.215, F3,22 = 1.631; one way analysis of variance test) (Fig. 13 A), while the 
protective effect by nicotine on polysynaptic reflex amplitude and area was antagonized by 
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DHβE alone (P = 0.013, F3,22 = 4.653 and P = 0.05, F3,23 = 3.087, respectively; one way analysis 
of variance test) (Fig. 13 B, C). The cumulative depolarization amplitude (improved by nicotine 
plus kainate followed by nicotine vs kainate alone) was significantly depressed by nAChR 
antagonist DHβE when co-applied with KA+N/N (P = 0.047, t12 = 2.212, Student’s t-test; 
KA+N/N 4 h vs KA+D+N/D+N 4 h), the protective role of nicotine on the size of the area was 
remained lost with DHβE application (P = 0.044, t12 = 2.248, Student’s t-test; KA+N/N 4h vs 
KA+D+N/D+N 4h)  (Fig. 13 D, E), and oscillations remained absent. On the other hand, the 
moderate recovery in fictive locomotion evoked by nicotine was maintained in terms of cycle 
amplitude and periodicity when the antagonists were co-applied together or in isolation (P = 
0.684. F3,23 = 0.504 and P = 0.746, F3,23 = 0.4, respectively; one way analysis of variance test) 
(Fig. 13 F). 
We next investigated how nAChR antagonists might affect the histological neuroprotection 
elicited by nicotine. Fig. 14 shows average distribution of neuronal damage in three ROI (see 
sample image of dorsal ROI in A). Thus, in comparison with data with kainate+nicotine followed 
by nicotine, a significant deterioration in the number of NeuN-positive neurons was detected 
when the antagonists were applied alone or in combination (Dorsal: P = 0.001, t16 = 4.660; 
Central: P = 0.001, U = 0; Ventral: P = 0.001, U = 0.5; KA+N/N 4 h vs KA+D+N/D+N 4 h), 
(Dorsal: P = 0.001, t16 = 8.649; Central: P = 0.003, t16 = 3.541; Ventral: P = 0.001, U = 0;  
KA+N/N 4 h vs KA+M+N/M+N 4 h), (Dorsal: P = 0.001, U = 0; Central: P = 0.001, t16 = 4.360; 
Ventral: P = 0.001, U = 0;  KA+N/N 4 h vs KA+D+M+N/D+M+N 4 h) (Fig. 14 C). This 
observation was further validated by counting the number of motoneurons (Fig. 14 B, D) as their 
protection by nicotine was largely impaired by DHβE, while it was left unchanged by MLA (P = 
0.001, H(3) = 35.347; Kruskal-Wallis one way analysis of variance on ranks test).  
Discussion  
The principal finding of the present report is the demonstration that nicotine could protect spinal 
networks from kainate-evoked excitotoxicity with good histological preservation and moderate 
recovery in circuitry activities including fictive locomotion. The effects of nicotine were 
dependent on nAChRs that are widely expressed in the spinal cord. These data, therefore, 
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indicate nicotine as a pharmacological agent that, at least in an in vitro model of spinal cord 
injury, was beneficial to limit cell death and related dysfunction. 
nAChRs in the mammalian spinal cord 
In the central nervous system (CNS), cholinergic transmission acts via nAChRs to modulate cell 
excitability and neurotransmitter release with control over physiological functions like cognition, 
pain, anxiety, fatigue, reward, learning, memory (Changeux and Edelstein, 2001; Hogg et al., 
2003; Christie et al., 2008). CNS nAChRs mainly belong to α7 nAChRs and α4β2 subtypes 
(Whiting & Lindstrom, 1986a,b; Whiting & Lindstrom, 1987).   
Although various nAChR subunits have been identified in the rat spinal cord (Wada et al., 1989, 
1990; Khan et al., 2003), α4β2 and α7 are the prominent receptor assemblies (Hsu et al., 1997; 
Berg & Conroy, 2002). Furthermore, α4β2 and α7 receptors play a role in nAChR mediated 
neuroprotection against excitotoxicity reported with rat dissociated spinal cultures (Nakamizo et 
al., 2005; Shimohama, 2009) and spinal neurons of chick embryos (Roth & Berg, 2003). Thus, 
antagonists for α4β2 and α7 receptors, DHβE and MLA respectively, were used in the present 
excitotoxicity model.  
As the physiological role of spinal nAChRs is complex, it is no surprise that nicotine application 
can activate excitatory as well as inhibitory neurons (Cordero-Erausquin et al., 2004). Within the 
dorsal horn, nicotinic cholinergic transmission can control, in an inhibitory fashion, nociceptive 
inputs (Matsumoto et al., 2007). Yet at network level, nAChR synaptic activity can depress 
GABA (Genzen & McGehee, 2005) and glycine (Kiyosawa et al., 2001) mediated inhibition, 
thus leading to disinhibition. The latter phenomenon may account for the present observation that 
co-application of DHβE and MLA enhanced polysynaptic reflexes. nAChR antagonists per se, 
however, decreased monosynaptic responses, perhaps implying that presynaptic nAChRs were 
regulating fast synaptic transmission (Khan et al., 2003) from primary afferent fibres whose 
neurotransmitter is glutamate (Pook et al., 1992; Kerkut & Bagust, 1995). Of course, nicotine is 
expected to rapidly activate nAChRs and desensitize them (Khiroug et al., 1997, Sokolova et al., 
2005), making difficult to dissect out, over an extended experimental protocol, which of these 
processes was the principal contributor to the delayed responses to nicotine. The present study, 
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therefore, reports the delayed histological and functional outcome of nicotine application rather 
than its complex mechanisms. 
Nicotine for experimental neuroprotection 
Although previous preclinical studies have indicated that nicotine can protect neurons against 
insults like excitotoxicity, or oxygen/glucose deprivation (Gahring et al., 2003; More and Dong, 
2016), the present investigation was prompted by the recent observation of nicotine protection 
against excitotoxicity applied to rat brainstem motoneurons (Corsini et al., 2016, 2017). There 
was, however, no report of similar effects on the rat spinal cord, an issue that was explored by 
using an in vitro model of spinal cord injury fully validated in our laboratory. Although the 
model relies on a neonatal spinal cord preparation (or organotypic slice preparations), it should 
be borne in mind that acute spinal injuries are frequent in infants with profound consequences in 
terms of disability (Betz e al., 2004; Parent et al., 2011). The in vitro model based on 1 h 
application of kainate to evoke excitotoxicity followed by extensive wash with oxygenated Krebs 
attempts to mimic clinical settings when an acute spinal injury is usually treated after 1-2 h in 
life-saving intensive care to arrest the primary cause of damage. Furthermore, as the secondary 
injury develops slowly over a matter of hours through complex intracellular metabolic pathways 
(Oyinbo, 2011; Zhang et al., 2012), our model offers the opportunity to explore the potential for 
neuroprotection by drugs applied during/after the injury and to follow up the functional and 
histological evolution during the first 24 h. The present study required a lengthy phase of 
protocol design because, in addition to the choice of nicotine concentration, it was necessary to 
identify delayed effects by nicotine itself and the timing of nicotine application. This led us to 
testing various protocols with nicotine to be applied late or during the excitotoxic stimulation. 
Early and late effects of nicotine on spinal networks 
In the present experiments the motoneuron depolarization produced by bath-applied nicotine (at 
µM concentrations) was modest by comparison to the one by kainate, indicating that it probably 
originated within the network (Blake et al., 1987) and that desensitization was likely curtailing it. 
The overall impact of nicotine on spinal reflexes was a depressant one with slow recovery on 
washout. While the multiple expression of nAChRs and their kinetics on distinct neurons can be 
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probably responsible for this phenomenon, the present data clearly showed that applying nicotine 
for 4 h (a time that corresponds to the strong activation of cell death pathways in the excitotoxic 
protocol; Kuzhandaivel et al., 2010) was tolerated and reversible even though some depression 
of mono and polysynaptic reflexes was apparent the day after. Nonetheless, application of 
nicotine on the first experimental day led to delayed increased network excitability observed as 
widespread Ca
2+
 transients, indicating that there was no generalized network depression. 
Following earlier treatment with nicotine, spinal cords in vitro did retain their ability to express 
fictive locomotor patterns elicited by DR stimulation or neurochemicals like NMDA plus 5HT. 
In keeping with these results, neurons and motoneurons were histologically preserved, even 
better than in sham conditions perhaps because nicotine had delayed the deterioration of 
preparations maintained in vitro for sustained time.  
The mechanisms underlying effects by nicotine are difficult to be resolved with the present 
preparation because we measured network responses (which by their nature are nonlinear and 
integrated) and neuronal numbers that provide only an endpoint for the neurotoxic phenomenon 
24 h later. Delayed network hyperactivity evoked by nicotine was associated with decreased 
reflexes perhaps because of facilitation of inhibitory circuits and/or persistent desensitization of 
excitatory nAChRs. One further target for nicotine might have been mitochondrial nAChRs that, 
although not mediating cationic fluxes, are important for the correct functioning of cell energy 
metabolism. Thus, the present protocols were not designed to clarify the molecular processes 
responsible for the nicotine action (a subject for future work) rather to delineate a scenario to 
achieve histological and functional neuroprotection. 
Nicotine and excitotoxicity 
Kainate (50 µM) is a validated agent to elicit irreversible degeneration in the rat spinal cord in 
vitro (Taccola et al., 2010) and in vivo (Sun et al., 2006). Although at least 50 % neurons survive 
the initial insult, severe inhibition of reflexes and arrest of fictive locomotion ensue (Mazzone et 
al., 2010). When the 1 h application of kainate was followed by 4 h application of nicotine, 
significant improvement in polysynaptic reflexes was observed together with some recovery in 
oscillatory VR patterns induced by DR stimuli or NMDA plus 5HT. Histological preservation of 
neurons, including motoneurons, provided the structural substrate for functional protection. We 
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further attempted to improve nicotine neuroprotection by applying nicotine together with kainate. 
This protocol has been used before with our model on the assumption that drug access to 
neuronal structures located deeply within the spinal cord, like for example lamina X neurons 
believed to be important for the central pattern generator of locomotion (Kiehn, 2006; 2016), 
may be too slow to block the wave of excitotoxic depolarization spreading through spinal 
segments (Taccola et al., 2008, 2010). Indeed, when nicotine was co-applied with kainate, better 
functional and structural neuroprotection was detected. 
Since early treatment with nicotine could restore at least in part the amplitude and frequency of 
disinhibited bursts or Ca
2+
 transients, these results indicate that certain elementary circuits 
relying on glutamatergic transmission for intrinsic rhythmicity (Bracci et al., 1996b) had been 
protected by nicotine and retained their connectivity because synchronicity was preserved even 
over a substantial distance. It was of particular interest to note that motoneuron numbers were 
rather close to control and that preservation of neurons had been attained throughout the three 
ROI. In this scenario the depression of monosynaptic reflexes was the only phenomenon not 
reversed by nicotine. While extracellular recording is not well suited to demonstrate the 
monosynaptic nature of excitatory transmission, former experiments have demonstrated that this 
protocol can actually generate monosynaptic excitatory potentials on motoneurons (Ostroumov 
et al., 2007). Hence, it seems likely that, despite near normalization of motoneuron numbers by 
nicotine, their ability to respond to weak inputs had remained impaired after kainate application. 
nAChR antagonists, nicotine and excitotoxicity 
The outcome of experiments based on co-application of antagonists with kainate (and nicotine) 
was complicated by the fact that, in the isolated spinal cord, effects due to administration of 
multiple drugs depend on individual drug kinetics, targets and intra-tissue distribution which are 
unavoidably dissimilar. Nonetheless, the broad depression of spinal responses by kainate was not 
arrested by either nAChR antagonist with only one exception, namely a partial preservation of 
chemically-induced fictive locomotion. We hypothesize that kainate-mediated excitation had led 
to release of endogenous ACh and that this phenomenon partly contributed to excitotoxicity at 
the level of the central pattern generator network. This suggestion is compatible with the modest 
protection by DHβE and it alludes to the possibility that at least part of the neuroprotection 
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exerted by nicotine itself was caused by its dual action on nAChRs, namely rapid activation and 
desensitization. In the presence of the antagonists and nicotine, the protection by nicotine toward 
fictive locomotion remained while the number of surviving neurons was intermediate between 
kainate toxicity and full protection. Furthermore, any protection of spinal reflexes was inhibited 
by the antagonists (with DHβE more efficacious than MLA).   
We have formerly proposed that the locomotor central pattern generator operates according to 
the principle of “minimal membership”, i.e. a critical number of neurons below which no 
function is generated (Kuzhandaivel et al., 2011). Hence, whenever nAChRs were inhibited by 
antagonists or nicotine-dependent desensitization, we might surmise that locomotor network 
membership remained just above threshold fictive locomotion (elicited by NMDA plus 5HT 
acting broadly on spinal neurons). Conversely, since electrically-evoked mono and polysynaptic 
reflexes depended on a lower number of activated neurons, in this instance losses induced by 
kainate had consistently larger impact on electrophysiological responses.       
Conclusions 
Attempts to obtain early spinal neuroprotection with pharmacological agents have been reported 
earlier with mixed results (Lee et al., 2003; Bagriyanik et al., 2008). Thus, among glutamate 
release inhibitors, riluzole is the only present-day treatment for motoneuron disease with a rather 
limited lifespan of clinical efficacy (Wokke, 1996; Cheah et al., 2010). In our experimental 
model, this drug cannot effectively contrast the excitotoxicity induced by kainate (Sámano et al., 
2012). Another controversial drug is the glucocorticoid methylprednisolone sodium succinate 
(MPSS) that, in our tests, provides limited neuroprotection to the white matter only (Sámano et 
al., 2016). The poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor PJ34 inhibits a non-
apoptotic cell death process, yet it does not confer full functional protection to locomotor 
networks in vitro (Nasrabady et al., 2011). A more favourable outcome is observed with delayed 
application of the volatile anaesthethic methoxyflurane (Shabbir et al., 2015), and less efficiently 
with the i.v. anaesthetic propofol (Kaur et al., 2016). Hence, the present data suggest that 
modulation of spinal nAChRs is a potentially useful new tool to prevent neurodegeneration and 
should prompt further studies to devise novel pharmacological approaches in vitro and in vivo to 
limit the damage associated with spinal cord injury. 
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Figure Legends 
Fig. 1. Dose dependent effect of nicotine on day 1 on the isolated spinal cord. (A) Sample 
records of polysynaptic reflexes during application of 10 µM (upper panel) and 1 µM (lower 
panel) nicotine (N) for 4 h followed by 1 h wash with standard Krebs solution. Plots of changes 
in polysynaptic reflex area (B) and amplitude (C) with respect to control (at 0 min) by 
application of different concentrations (10, 2, 1, 0.5; µM; n = 3, 4, 5, 3 respectively) of nicotine 
for 4 h (240 min) followed by 1 h wash. Note decline in polysynaptic area and amplitude with 10 
µM (***P = 0.001, U = 1 and *P = 0.017, U = 10, respectively; Mann Whitney-test; Control vs 
N 20 min) and 2 µM (**P = 0.007, t12 = 3.278 and P = 0.006, t12 = 3.314, respectively; Control 
vs N 20 min) of nicotine applied for 20 min, whereas there was no significant change in 
polysynaptic area and amplitude with 1 and 0.5 µM nicotine after 20 min of application (P = 
0.089, U = 27; P = 0.058, t22 = 2.004 and P = 0.838, U = 42; P = 0.775, U = 49; Mann Whitney-
test, respectively; Control vs N 20 min). No recovery in reflex area and amplitude during wash 
after 10 and 2 µM nicotine (P = 0.075, t14 = 1.921; P = 0.218, t14 = –1.291 and P = 0.059, U = 39; 
0.563, t12 = 0.595, respectively; Control vs Wash). Reflex area was significantly recovered 
during wash after 1 µM nicotine (4h) (P = 0.027, U = 23; Mann Whitney-test; Control vs wash).  
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Fig. 2. VR depolarization evoked by kainate (KA) or nicotine administration. (A) Sample record 
of depolarization induced by 50 µM KA or nicotine (10 and 1 µM). (B) Histograms depict 
maximum depolarization induced by KA (n = 10) or nicotine (10, 2, 1, 0.5 µM; n = 5, 4, 6, 4, 
respectively). No significant depolarization was evoked by 2, 1 and 0.5 µM nicotine (P = 0.343, 
t8 = –1.009, 2N vs 1N; P = 0.432, t6 = 0.842, 2N vs 0.5N; P = 0.749, t8 = –0.332; Student’s t-
test). However, 10 µM nicotine induced a signficant depolarization in comparison to 2, 1 and 0.5 
µM nicotine (***P = 0.001, t7 = –5.211, 10 N vs 2 N; **P = 0.005, t9 = 3.738, 10 N vs 1 N; P = 
0.005, t7 = –4.033, 10 N vs 0.5 N; µM; Student’s t-test).  
Fig. 3. Changes in DR stimulation evoked synaptic transmission and fictive locomotion after 24 
(day 2) in vitro. (A-D) Representative records of monoynaptic (A), polysynaptic (B) reflexes, 
DR induced (C) and NMDA+5HT evoked (D) fictive locomotion in sham and 1 µM nicotine (N) 
solution (applied for 4 h on the preceding day). (E-G) Bar graphs showing significant depression 
of monosynaptic (**P = 0.003, t20 = 3.334; Student’s t-test) (E) and polysynaptic reflex 
amplitude (F) and area (G) (*P = 0.027, U = 15, Mann Whitney-test; P = 0.029, t16 = 2.391, 
respectively; sham vs N; n = 10, sham; n = 7 for nicotine). (H-J) Histograms representing 
number of oscillations induced by DR stimulus trains in spinal cords treated with nicotine for 4 h 
(P = 0.013, U = 87.5, Mann Whitney-test; sham vs N). No change in cumulative depolarization 
and area of fictive locomotion was observed (P = 0.343, t19 = 0.973; P = 0.993, t19 = 0.00936, 
respectively; sham vs N). (K) Plot showing significant decline in amplitude (***P = 0.001, t15 = 
5.410; sham vs N) and with no increase in periodicity (P = 0.430, t15 = –0.811, respectively; 
sham vs N) of chemically induced fictive locomotion by nicotine application for 4 h. 
Fig. 4. Changes in neurons (identified with NeuN positivity, red), and motoneuron number 
(SMI32 staining, green) and immunofluorescence intensity of glia (immunolabeled with S100, 
green or GFAP, red) induced by previous (24 h earlier) 1 µM nicotine (4 h) treatment. DAPI 
(blue) was used as cell nuclear marker. (A-C) Histochemical examples of dorsal horn neurons 
(A), motoneurons (B), and dorsal horn glia (C). (D) Bar graphs quantify increased number of 
neurons in the dorsal horn after application of N (4 h) (***P = 0.001, t16 = –5.406; sham vs N), 
whereas no significant change was observed in central and ventral horn (P = 0.859, U = 43, 
Mann Whitney test; P = 0.104, t16 = 1.726, respectively, sham vs N). (E) Histograms illustrate 
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increase in number of motoneurons after N  treatment (4 h) (P = 0.001; t24 = –3.798; sham vs N). 
(F, G) Bar graphs show no change in immunofluorescence intensity (AU) of glia after N (4h) 
treatment in all three ROI (GFAP- D: P = 0.715, t8 = –0.379; C: P = 0.675, t8 = –0.435; V: P = 
0.801, t8 = –0.260 and S100- D: P = 0.562, t9 = 0.601; C: P = 0.276, t9 = 1.159; V: P = 0.265, t8 
= 1.199, respectively, sham vs N) (n = 3-6 spinal cords; 3-10 sections/preparation). Scale bar = 
100 µm. 
Fig. 5. Reflexes and fictive locomotion recorded 24 h in vitro after KA or KA followed by 
nicotine for 4 h (KA/N 4 h). (A-D) Sample records of mono-, polysynaptic reflexes, electrically 
and chemically induced fictive locomotion after application of KA (n = 8) or KA/N 4 h (n = 8). 
(E) shows no change in monosynaptic responses (P = 0.874, U = 70, Mann Whitney-test), 
whereas a measurable rise in polysynaptic reflex amplitude and area (F,G) was detected after KA 
followed by N (**P = 0.002, U = 23; *P = 0.014, U = 37, Mann Whitney-test, respectively; KA 
vs KA/N 4h). (H-K) Significant increase in electrically (H-J) (number of oscillations, ***P = 
0.001; U = 0, Mann Whitney-test; cumulative depolarization, P = 0.005, t22 = –3.092) and 
chemically induced (K) (amplitude, P = 0.001; t19 = –6.563; period, P = 0.001, U = 28, Mann 
Whitney-test) fictive locomotion. There was no significant change in the area of DR evoked 
cumulative depolarization (P = 0.081, U = 35) after N application to KA treated spinal cords. 
Fig. 6. Histochemical damage 24 h after KA (1 h) or KA followed by nicotine (N, 4 h).  (A, B) 
Micrographs depicting examples of high pyknosis (A, staining with DAPI, blue), low neuronal 
(A, NeuN, red) and motoneuronal numbers (B, green) after KA application: this effect was 
prevented by KA/N 4h (DAPI- Dorsal: ***P = 0.001, U = 108; Central: P = 0.001, U = 0; 
Ventral: P = 0.001, U = 189, Mann Whitney-test;  NeuN- Dorsal: P = 0.001, t16 = –11.612; 
Central: **P = 0.01, t16 =  –2.944; Ventral: *P = 0.05, t16 =  –2.05; SMI32- P = 0.001, U = 3; 
comparisons were between KA vs KA/N 4h), n = 3-5 spinal cords; 3-10 sections/preparation. 
Scale bar = 100 µm. 
Fig. 7. Improved neuroprotection recorded at day 2 in vitro after former pretreatment with 
nicotine and KA (n = 8). Sample records representing changes in reflex activity and fictive 
locomotor patterns by excitotoxicity, effects prevented by co-application of nicotine with kainate 
followed by nicotine alone for further 4 h (KA+N/N 4h, n =8). (E-G) Histograms illustrating 
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recovery in polysynaptic reflex amplitude (F) and area (G) (***P = 0.001, U = 3 and P = 0.001, 
U = 10, Mann Whitney-test, respectively; KA vs KA+N/N 4h), despite no improvement in 
monosynaptic reflex activity (P = 0.864, U = 80, Mann Whitey-test) (E). (H-K) Bar plots show 
presence of DR evoked (number of oscillations: P = 0.001, U = 0; cumulative depolarization: P 
= 0.001, U = 5 and area: P = 0.001, U = 11, Mann Whitney-test) and chemically evoked fictive 
locomotion (amplitude: *P = 0.012, U = 24 and periodicity: **P = 0.004, U = 32, Mann 
Whitney-test). 
Fig. 8. Effect of co-application of nicotine with KA on disinhibited bursts recorded on day 2 in 
vitro. (A) Representative records obtained after KA (n = 8) or KA+N/N 4h (n = 8) application on 
the day before. (B, C) Histograms depicting raised burst amplitude after KA+N/N 4h treatment 
(*P = 0.027, t14 = –2.794; KA vs KA+N/N 4 h) with no change in the number of bursts (P = 
0.356, t14 = 0.989).  
Fig. 9. Changes in Ca
2+
 transients evoked by application of strychnine and bicuculline (Sham, n 
= 6; nicotine, N, n = 4; kainate, KA, n = 6 and KA+N/N 4h, n = 4; n is the number of slices, 
where 6-12 neurons analysed/slice) on day 2 in organotypic spinal cord slices in vitro. (A, B) In 
A snapshot of representative field of ventral horn neurons. Numbers indicate two representative 
cells whose Ca
2+
 transients are shown in B. Scale bar = 100 µm. In B representative Ca
2+ 
events 
recorded in Sham, Nicotine, Kainate and KA+N/N 4h conditions (two sample neurons were 
selected from the same field). (C-E) KA induced a significant decrease in bursts number (C) 
(**P = 0.007, t10 = 3.353, sham vs KA; ***P = 0.001, t8 = 7.822, N vs KA) and increased single 
burst duration (D) (*P = 0.03, U = 3, sham vs KA; P = 0.016, U = 20, N vs KA; Mann Whitney-
test) without affecting cross-correlation factor (CCF) (E): this phenomenon was reversed by 
applying nicotine with KA(burst number: P = 0.001, t8 = –10.055; burst duration: P = 0.016, U = 
20, KA vs KA+N/N, Mann Whitney-test, respectively). 
Fig. 10. Histological neuroprotection induced by co-application of nicotine with KA. (A, C, D) 
Example (A) and bar graphs show large reduction in excitotoxicity by co-application of nicotine 
with KA followed by nicotine for 4 h, and observed 24 h later. Note minimal pyknosis (A, C) 
when staining with DAPI (blue)  (Dorsal: ***P = 0.001, U = 108; Central = P = 0.001, U = 0; 
Ventral: P = 0.001, U = 189, Mann Whitney-test; KA vs KA+N/N 4h). (A, D) shows good 
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preservation of neurons stained with NeuN antibody (red) (Dorsal: P = 0.001, t16 = –14.761; 
Central: P = 0.001, t16 = –7.122; Ventral: P = 0.001, t16 = –7.445) in all three ROI. (B, E) 
Sample images (B) and histograms (E) illustrate significant survival of motoneurons (tsained 
with SMI32; green) in ventral horn of spinal cord (P = 0.001, U = 3, Mann Whitney-test, KA vs 
KA+N/N 4h). Scale bar = 100 µm, n = 3-5 spinal cords; 3-10 sections/preparation. 
Fig. 11. Effect of nAChR antagonists on VR reflexes and fictive locomotion after 24 h in vitro. 
(A-D) Representative records of alterations in reflexes (A, B) and fictive locomotion (C, D) 
produced by 4 h co-application of DHβE (10 µM, n = 5) and MLA (10 nM, n = 5) in comparison 
to sham. (A, E) DHβE, MLA or DHβE+MLA (n = 4) application depressed monosynaptic reflex 
which was significant with DHβE alone (*P = 0.035, t16 = 2.304, DHβE vs sham). (B, F, G) The 
polysynaptic area (G) has increased (P = 0.043, U = 8; P = 0.043, U = 8; P = 0.03, t12 = –2.469; 
D vs sham; M vs sham; D+M vs sham, respectively) with no significant change in amplitude (F) 
in comparison to sham (n = 13). (C, H-J) The number of oscillations (C, H) during electrically 
induced fictive locomotion was reduced by DHβE+MLA co-application in comparison to sham 
(**P = 0.006, U = 45.5; Mann Whitney-test, DHβE+MLA vs sham), with no significant change 
in the area and amplitude of cumulative depolarization. (D, K) The cycle amplitude of 
chemically induced fictive locomotion was significantly depressed in MLA and DHβE+MLA 
treated preparations (P = 0.02, t16 = 2.590; P = 0.004, t15 = 3.411, respectively, MLA vs sham, 
DHβE+MLA vs sham) while the periodicity was increased in MLA treated spinal cords (P = 
0.001, t16 = -6.696, MLA vs sham).  
Fig. 12. Effect of application of nAChR antagonists on spinal cord preparations studied in vitro 
on day 2 after kainate application. (A-D) Sample recordings of reflex responses (A, B) and 
fictive locomotor rhythms (C, D) following co-application of DHβE+MLA (1 h) together with 
KA or of KA alone. (E-J) Histograms representing no change in monosynaptic (E), and 
polysynaptic (F, G) reflexes and DR evoked fictive locomotion (H-J) in KA+D (n = 5), KA+M 
(n = 6) and KA+D+M (n = 4) treated preparations in comparison to KA (n = 8) alone. Note 
significantly larger amplitude of cumulative depolarization with KA+D+M treatment vs KA 
alone (*P = 0.042, U = 10; Mann Whitney test). (D, J) emergence of chemically induced fictive 
locomotor rhythms the day after application of antagonists with KA (cycle amplitude: ***P = 
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0.024, F3,17 = 4.296; one way analysis of variance test). There was no significant difference in 
periodicity among various treatments while no cycles appeared after KA alone (D, J).  
Fig. 13. Effects of nAChR antagonists on neuroprotection evoked by nicotine on spinal cords 
after 24 in vitro. (A-C) Despite no variation in monosynaptic responses, DHβE (4 h) depressed 
amplitude of polysynaptic reflexes when co-applied with nicotine+KA (*P = 0.019, t11 = 2.756, 
KA+N/N 4 h vs KA+D+N/D+N 4 h). Likewise, the combination of DHβE+MLA suppressed 
nicotine evoked neuroprotection in terms of polysynaptic amplitude (P = 0.05, t9 = 2.203, 
KA+N/N 4 h, vs KA+D+M+N/D+M+N 4 h). MLA alone could not prevent the effect of 
nicotine+KA. (C) Significant change in reflex area was observed with DHβE was applied with 
nicotine+KA with no significant change with combination of DHβE+MLA (*P = 0.049, t12 = 
2.190, KA+N/N 4h vs KA+D+N/D+N 4 h; P = 0.136, t9 = 1.635, KA+N/N 4h vs 
KA+D+M+N/D+M+N 4 h). (D, E)  In the presence of KA+nicotine, DHβE (4h) alone 
significantly reduced the amplitude and area (E) (P = 0.047, t12 = 2.212 and P = 0.044, t12 = 
2.248, respectively; KA+N/N 4h vs KA+D+N/D+N 4h) of cumulative depolarization (that did 
not generate oscillations). (K) Chemically induced fictive locomotor patterns were observed in 
all preparations without any significant difference (amplitude: P = 0.684. F3,23 = 0.504; Period: P 
= 0.746, F3,23 = 0.4; one way analysis of variance test). n = 8, 6, 6, 4; KA+N/N 4 h, 
KA+D+N/D+N 4h, KA+M+N/M+N 4h, KA+D+M+N/D+M+N 4 h, respectively. 
Fig. 14. Histological damage evoked by co-application of nAChR antagonists with KA and 
nicotine. (A, C) Co-application of DHβE and MLA with KA+N/N 4 h treatment exaggerated the 
neuronal loss detected with NeuN staining (red) (D: ***P = 0.001, F3,36 = 20.527; C: P = 0.001, 
F3,35 = 32.380; V: P = 0.001, H(3) = 29.851; one way analysis of variance test; KA+N/N 4 h vs 
KA+D+N/D+N 4 h; KA+N/N 4 h vs KA+M+N/M+N 4 h; KA+N/N 4 h vs 
KA+D+M+N/D+M+N 4 h). (B, D) DHβE (4 h) and DHβE+MLA when co-applied with 
KA+N/N 4h enhanced motoneuronal loss detected with SMI32 staining (green) (P = 0.001, t29 = 
4.736; *P = 0.028, t28 = –2.314; P = 0.001, t28 = 6.197, respectively; KA+N/N 4 h vs 
KA+D+N/D+N 4 h; KA+N/N 4 h vs KA+D+M+N/D+M+N 4 h), whereas MLA co-application 
with KA+N/N 4h did not change the effect of KA+nicotine (D). Scale bar = 100 µm, n = 3-5 
spinal cords; 3-10 sections/preparation. 
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Supplemental Fig. 1. Schematic representation of experimental procedures used. (A-I) 
Diagram of different protocols used for drug administration where kainate (KA) was the 
excitotoxic stimulus and nicotine (1 µM) was applied for 4 h. Two nAChR antagonists, 
DHβE and MLA alone or in combination (DHβE+MLA) were used for 4 h. 
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Supplemental Fig. 2. Changes in polysynaptic reflexes and electrically evoked fictive 
locomotion evoked by 1 µM nicotine reapplied on the second day in vitro after first 
application of nicotine (4 h) on the previous day. N0 indicates response immediately prior to 
second application of nicotine while sham indicates naïve preparations.(A, C) Sample records 
of changes in polysynaptic responses (A) and DR evoked fictive locomotion (C) by re-
applying nicotine on day 2 for 15 min. (B) Bar graphs show further decrease in polysynaptic 
reflex amplitude and area by re-application of nicotine for 15 min (n = 4) in comparison to 
sham (n = 9) (**P = 0.002, U = 68; ***P = 0.001, t16 = 4.949, respectively ; sham vs N 15 
min) and to nicotine 4 h treated spinal cords on day 1 (*P = 0.012, t14 = 2.877; P = 0.030, U = 
59, respectively; N 0 min vs N 15 min). Fig. D shows depression in number of oscillations (P 
= 0.019, U = 42, sham vs N 15 min), cumulative depolarization amplitude (P = 0.041, t13 = 
2.274, sham vs N 15 min) and area (P = 0.007, U = 36, sham vs N 15 min; P = 0.039, t11 = 
2.345, N 0 min vs N 15 min) of DR evoked fictive locomotion. 
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Supplemental Fig. 3. (A-C) No significant change in immunofluorescence intensity (AU) of 
astrocytes (green; S100 staining) and general glia (red; GFAP staining) by KA together with 
or followed by nicotine for 4 h (KA/N 4 h and KA+N/N 4 h, respectively). n = 3-6 spinal 
cords; 3-10 sections/preparation. Scale bar = 100 µm. 
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Supplemental Fig. 4. Example (A) of dorsal horns showing neurons (stained with NeuN, 
red) and cells (stained with DAPI, blue) 24 h after application of KA or KA plus nAChR 
antagonists.  Histograms (B) show average neuronal numbers calculated after 24 h in 
vitro in sham condition (no treatment) or after 1 h application of kainate alone or with 
KA+DHβE+MLA (Dorsal: ***P = 0.001, t16 = 11.736; Central: P = 0.001, U = 0; 
Ventral: P = 0.001,t16 = 11.034,sham vs KA; Dorsal: P = 0.001, t18 = –3.927; Central: *P 
= 0.012, t16 = –2.828; Ventral; P = 0.429, t16 = 0.812, KA vs KA+D+M; Dorsal: P = 
0.001, t18 = –4.044; Central: P = 0.001, U = 81; Ventral: P = 0.001, U = 0, sham vs 
KA+D+M). n = 3-5 spinal cords; 3-10 sections/preparation. Scale bar = 100 µm. 
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6 DISCUSSION 
 
The principal findings of the present study reported in this thesis are summarized as: 
 The neuroprotection produced by Methylprednisolone sodium succinate (MPSS; 
after 24 h in vitro SCI) was confined to white matter when damaged by providing 
dysmetabolic/hypoxic conditions with pathological medium (PM) applied for 1 h. 
 
 MPSS could not reverse the excitotoxic damage evoked by kainate (100 µM) 
applied for 1 h. 
 
 Histologically, delayed application of propofol has arrested neuronal and 
motoneuronal damage by kainate (50 µM). 
 
 No good recovery in fictive locomotor patterns by propofol treatment, whereas 
disinhibited rhythmicity was improved. 
 
 Nicotine (10 µM) was toxic.  
 
 Nicotine (1 µM) administration has shown neuroprotective effects to spinal 
locomotor networks from excitotoxic damage induced by kainate (50 µM). 
 
 Good histological recovery of motoneurons and neurons by nicotine (1 µM) after 
excitotoxic insult. 
 
 Pre-treatment of celastrol has shown substantial neuroprotective effects against 
kainate-induced excitotoxicity.  
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1. In vitro spinal injury model 
Current data were acquired by using an in vitro neonatal rat SCI model based on transient 
(1 h) application of kainate or pathological medium (PM). Although the in vitro 
preparations are immature, they possess a number of advantages such as giving an 
opportunity to study synaptic transmission, fictive locomotor oscillatory cycles recorded 
from lumbar ventral roots (Kiehn, 2006), intrinsic rhythmicity (Bracci et al., 1996a, b; 
Taccola & Nistri, 2007), and motoneuronal properties. Furthermore, these preparations 
provide an insight into pediatric SCI, show limited tissue damage which resembles actual 
new SCI cases (Jain et al., 2015), and allow studying delayed drug application with 
survival time up to 24 h (Shabbir et al., 2015; Nasrabady et al., 2012). In addition to in 
vivo animal models of SCI (Onifer et al., 2007), in vitro models provide useful data as 
they reduce the complexity of pathophysiology of in vivo SCI and help to identify 
particular injury processes without interference by general anaesthesia or blood pressure 
changes (Kuzhandaivel et al., 2011). 
 
2. Excitotoxicity produces structural and functional 
deficits during spinal insult 
 
In the past decades, excitotoxicity, a type of neurotoxicity produced by over-activation of 
glutamatergic system, has been at the centre stage of stroke research. Glutamate is the 
primary neurotransmitter in the adult CNS. Glutamate plays important roles in various 
physiological processes such as rapid synaptic transmission, neuronal growth and axon 
guidance, brain development and maturation etc. In order to investigate glutamate 
transport dysfunction as a primary excitotoxic event in neurodegenerative diseases, 
several models have been developed. It has previously been reported that blocking 
glutamate uptake is toxic to cortical and spinal motor neurons, through NMDA or non-
NMDA receptor-dependent mechanisms respectively (Rothstein et al., 1993; Carriedo et 
al., 1996; Velasco et al., 1996).  
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Subsequent studies have demonstrated that kainate is a non-degradable analogue 
of glutamate and a potent neurotoxin (Vincent & Mulle, 2009). KA employs its neuro-
excitotoxic and epileptogenic characteristics by acting on kainate receptors which 
ultimately lead to cell death (Wang et al., 2005). Kainate has extensively been used as an 
excitotoxic agent as it mimics the effect of glutamate in neurodegenerative disease 
models (Choi, 1992 a; Lipton & Rosenberg, 1994; Shaw, 1994; King et al., 2016). 
Kainate receptors mediate kainate-induced seizures and excitotoxic neuronal death, 
thereby serving as a model for neurodegeneration. In addition to kainate, other agents 
could be ibotenic acid (IBO) and NMDA, however, they are nonspecific in acting on 
different cell types and usually they do not cause seizures. In contrast, focal injection of 
KA leads to hippocampal damage (Jarrard, 2002). It has been reported that systematic 
administration of kainate results in a well-characterized seizure syndrome in rodents 
(Ben-Ari, 1985; Mulle et al., 1998). One h after kainate administration limbic motor 
seizures emerge and develop into status epilepticus lasting 1-2 h (Chuang et al., 2004). 
Electrophysiological recordings have suggested there is a critical threshold for 
excitotoxicity mediated by kainate which could fully suppress fictive locomotion. Ten 
µM kainate enables onset of locomotor patterns in the spinal cord although with smaller 
amplitude and slower periodicity than sham preparations. However, ≥ 50 µM is sufficient 
to evoke irreversible fictive locomotor damage and reflex suppression (Mazzone et al., 
2010) 24 h after insult. Hence, we used 50 or 100 µM kainate application for 1 h to study 
its effect on spinal locomotor networks via electrophysiological recordings, histology 
(Taccola et al, 2008) as well as calcium imaging techniques. 
 
With 50 or 100 µM kainate fictive locomotion disappeared and mono- and 
polysynaptic reflexes were highly depressed, while disinhibited bursts evoked by 
strychnine and bicuculline were still present despite increased periodicity and lower 
amplitude (Taccola et al., 2008; Margaryan et al., 2010). One possibility is that a primary 
targets for kainate are inhibitory interneurons important for fictive locomotion (Morin et 
al., 1998; Cossart et al., 2001). After kainate application, spinal networks retained their 
intrinsic rhythmicity supported via recurrent excitatory collaterals (Ballerini et al., 1999; 
Tscherter et al., 2001) because disinhibited bursting requires a circuitry simpler than 
fictive locomotion. 
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Histologically, neuronal numbers were highly reduced and pyknotic nuclei 
appeared in all three regions of gray matter (Taccola et al., 2008, Margaryan et al., 2009; 
Kuzhandaivel et al., 2010) observed 24 h after kainate application. Motoneurons were 
halved in the ventral horn of gray matter probably because they lack the calcium binding 
protein and remain very vulnerable to consequences of calcium overload evoked by 
kainate (Dekkers et al., 2004). Our data are in analogy with the previous reports (Bracci et 
al., 1996b; Taccola et al., 2008; Mazzone et al., 2013). Extensive production of poly-
ADP-ribose (PAR) by hyperactivation of the poly (ADP-ribose) polymerase-1 (PARP-1) 
enzyme has recently been proposed as a novel programmed cell death, termed 
―parthanatos‖ (Andrabi et al., 2006, 2008) and applicable to excitotoxic death in the 
spinal cord. 
 
3. Dysmetabolic perturbation induced spinal damage 
 
Another protocol was based on dysmetabolic spinal lesion evoked by a toxic solution 
named as pathological medium (PM) that mimics the conditions (hypoxic/aglycemic) 
occurring shortly after acute SCI (Taccola et al., 2008). This kind of condition causes 
delayed cell death of oligodendrocytes by apoptosis (Shuman et al., 1997; Emery et al., 
1998; Li et al., 1999; Springer et al., 1999) which is infrequent in SCI cases. Interestingly, 
in other models of neurodegeneration such as brain ischemia, Alzheimer’s disease, etc, 
apoptotic cell death is not frequent and mainly involves glial cells (oligodendroglia, 
microglia and astrocytes; Jellinger & Stadelmann, 2000; Shibata et al., 2000; Narkilahti et 
al., 2003). Previous studies on neonatal spinal cord have shown that pyknosis occurs 24 h 
after the hypoxic conditions and it maximally damages the ventrolateral white matter of 
spinal cord (Kuzhandaivel et al., 2010). Similar results were observed in our case after 
treating the preparations with PM for 1 h (Sámano et al., 2016). This kind of apoptotic 
cell death was mediated by activation of caspase pathways (Kuzhandaivel et al., 2010). 
Despite white matter lesion occurred after 1 h application of PM, spinal locomotor 
networks retained their activity even though the oscillatory patterns were slower than 
those chemically evoked by NMDA+5HT (Taccola et al., 2008; Kuzhandaivel et al., 
2010). However, dorsal root evoked locomotor patterns were absent (Taccola et al., 
2008).  Therefore, in this case, in spite of having intrinsic ability to induce locomotor 
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patterns, the sensory feedback, necessary to support locomotion, had been lost (Barbeau 
et al., 1999).  
 
4.  Neuroprotective effects of MPSS on histological and 
functional outcome 
 
MPSS is a widely used GC for the treatment of neurological diseases (in a dose-
dependent manner) due to its anti-inflammatory (Gold et al., 2001) and anti-oxidant 
properties. However, treatment with MPSS has become controversial because of modest 
neurological improvement and a number of serious side-effects (Bracken et al., 1984; 
Gerndt et al., 1997; Pointillart et al., 2000; Matsumoto et al., 2001) in patients with SCI. 
This drug is still in use for clinical trials (Nicholas et al., 2009; Bracken, 2012; Druschel 
et al., 2013; Miekisiak et al., 2014; Cheung et al., 2015) as the first approach to SCI. 
These observations raised the issue if distinct types of SCI might have more positive 
outcome than other cases. Therefore we tried two different toxic conditions, kainate (100 
µM, completely abolished fictive locomotion) induced excitotoxicity or PM (applied for 1 
h). Thereafter, we applied 6 or 10 µM MPSS (24 h application, Fehling et al., 2017) based 
on published clinical guidelines (Sauerland et al., 2000) and in vitro SCI models 
(Guzmán-Lenis et al., 2009; Sun et al., 2010). Histologically, neuroprotection induced by 
MPSS after PM application was restricted to ventrolateral white matter, as MPSS 
reversed the loss of astrocytes and to lesser extent oligodendrocytes. Functionally, the 
polysynaptic response area was increased after MPSS (10 µM) despite no changes in 
monosynaptic reflexes. Moreover, small improvements were observed in the area of 
cumulative depolarization and oscillations.  A more positive outcome (slow alternating 
oscillations) was observed in chemically evoked fictive locomotion after PM followed by 
MPSS treatment. Basic network rhythmicity was also studied after pharmacological block 
of inhibition. Here MPSS was not able to change the period depression induced by 
kainate, however, it potentiated burst amplitude, which suggested little improvement in 
functional network connectivity.  All these observations were in analogy to previous in 
vitro rat SCI reports which suggested MPSS had not efficiently protected neurons (Xu et 
al., 1998a; Liu et al., 1997; Lee et al., 2008).  
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5. Neuroprotection by propofol  
 
As neurosurgery is performed under general anaesthesia, it seemed plausible that at least 
some positive contribution might come from the administration of general anaesthesia. 
Recently Shabbir et al. have reported in our lab that a volatile anaesthetic, 
methoxyflurane, could confer strong functional and histological neuroprotection in an in 
vitro rat SCI model (Shabbir et al., 2015). These results raised the issue whether a widely 
used i.v. anaesthetic such as propofol could also produce the same effects or it is an 
intrinsic property of gas anaesthetics only (which are less frequently used because of their 
toxic effects). It has been demonstrated that propofol has neuroprotective effects on 
various in vitro and in vivo models of brain injury (Velly et al., 2003; Kawaguchi et al., 
2005; Rossaint et al., 2009; Vasileiou et al., 2009; Zhang et al., 2014; Fan et al., 2015). 
While propofol attenuates motoneuronal damage in spinal organotypic slice cultures 
(Bajrektarevic & Nistri, 2016), it is unknown what impact propofol poses on functional 
locomotor networks.  Various studies have demonstrated that the clinically relevant 
concentration of propofol ranges from 0.5 to 10 µM (Gredell et al., 2004; Matute et al., 
2004; Wakita et al., 2013; Eckle et al., 2015). As the drug has never been tested before for 
these spinal cord experiments, therefore we decided to use the mid value of 5 µM. The 
timing of propofol administration was chosen according to previous observations that 
maximum excitotoxic cell death pathways are activated within the first few hours of 
secondary insult (Kuzhandaivel et al., 2011). Also according to Bajrektarevic & Nistri 
(2016), propofol was administered for 8 h and good neuroprotection was achieved on 
spinal cultures. Thus, we applied propofol for 4 or 8 h after kainate (100 µM) and tested 
its effects the day after.  
 
Propofol, when applied alone for 4 h, partially depressed network synaptic 
transmission (Jewett et al., 1992) and fictive locomotion. This depression was further 
exaggerated by propofol 8 h application. This phenomenon is in line with our observation 
that propofol potentiates GABAA (Adodra & Hales, 1995; Reynolds & Maitra, 1996) and 
depressed the NMDA mediated (Orser et al., 1995) receptor responses. Propofol (4 or 8 
h) when applied after kainate structurally preserved neurons and motoneurons in all the 
regions (dorsal, central and ventral) of the spinal cord. Therefore, the simplest 
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interpretation might be that the drug has exerted its beneficial effects by suppressing the 
network excitability (Jewett et al., 1992). It could not attenuate the depression of synaptic 
transmission and cumulative depolarization caused by kainate; however, it arrested 
further damage by suppressing network excitability. In chemically induced fictive 
locomotion (recorded 24 h later), there was the emergence of some fictive locomotor 
cycles after 4 h propofol after kainate: this response was absent after 8 h propofol. This 
was not unexpected in line with the long-lasting depression evoked by the drug. In fact, 
disinhibited bursting that reflects the intrinsic rhythmicity of spinal networks (Streit, 
1993; Bracci et al., 1996a) showed improved periodicity when 4-h propofol 
administration followed kainate washout. These results illustrate that when network 
output required activation of a limited circuitry (Bracci et al., 1996b), the protective 
action of propofol was manifested more efficiently than over a very wide locomotor 
network with complex connections (Kiehn, 2006, 2016). Anesthesiological studies 
demonstrate that full locomotor recovery in humans is incomplete for several h after 
propofol (Münte et al., 2001; Haavisto & Kauranen, 2002). The general advice is to be 
cautious against driving since dizziness and drowsiness may persist for 24 h 
(http://www.rxlist.com/diprivan-drug/patient-images-side-effects.htm). Thus, these 
observations are consistent with our depressed functional results which occur due to long-
lasting network depression effect induced by this anaesthetic.  
 
6. Effects of nicotine  
Nicotine-mediated neuroprotection has been reported previously in several models such 
as in vitro (Garrido et al., 2003), in vivo (Xue et al., 2014) and in epidemiological studies 
(Quik et al., 2012), suggesting potential strategies to contrast neuronal death. Recently 
our lab has shown the neuroprotective effect of nicotine on brainstem motoneurons 
against excitotoxicity by activating nAChRs that triggered intracellular pathways to block 
reactive oxygen species (ROS) and regulated mitochondrial metabolism (Corsini et al., 
2016; Tortora et al., 2017). These intriguing results motivated us to investigate the role of 
nicotine and nAChRs in neuroprotection against SCI. As Corsini et al. have achieved 
neuroprotective effects with 10 µM nicotine (Corsini et al., 2016), it seemed a good initial 
concentration to start the experiments. Unexpectedly, nicotine (10 µM) exerted minimal 
protection after excitotoxic damage by kainate (refer supplemental data, appendix I 
enclosed in the thesis). When tested histologically, the neuronal number was significantly 
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improved after kainate (50 µM) followed by nicotine or kainate+nicotine application (1 or 
4 h) only in the dorsal horn with no change in the central and ventral horn of spinal cord. 
Similarly, the motoneuron numbers were not significantly increased with this 
concentration except in case where nicotine was applied for 1 h after kainate. These 
results indicated that nicotine (10 µM) might be toxic for spinal neurons and 
motoneurons. This assumption was confirmed by examining the effects by nicotine per 
se.  
  
 The next goal was to examine 0.5 or 1 or 2 µM nicotine (4 h) concentration 
and investigated its functional and structural effects alone and after or together with 
kainate (1 h). Electrophysiologically, nicotine 0.5 µM was not much effective to reverse 
the excitotoxic effect evoked by kainate, whereas 2 µM was suppressing the polysynaptic 
reflexes and fictive locomotion. Thus, I chose nicotine 1 µM to continue the project 
further. Nicotine 1 µM showed promising recovery in polysynaptic reflex, fictive 
locomotion, neuronal and motoneuron numbers in all the three ROIs. Since early 
treatment with nicotine could restore at least in part the amplitude and frequency of 
disinhibited bursts or Ca
2+
 transients (achieved by calcium imaging experiments with 
spinal organotypic cultures), these results indicate that certain elementary circuits relying 
on glutamatergic transmission for intrinsic rhythmicity (Bracci et al., 1996b) had been 
protected by nicotine and retained their connectivity because synchronicity was preserved 
even over a substantial distance. The only parameter not reversed by nicotine was 
monosynaptic reflexes. Hence, it seems likely that, despite near normalizing the 
motoneuron numbers by nicotine, their ability to respond to weak inputs had remained 
impaired after kainate application.  
  
 The subsequent step was to explore which nAChRs are important for spinal 
neuroprotection. Although various nAChR subunits have been identified in the rat spinal 
cord (Wada et al., 1989, 1990; Khan et al., 2003), α4β2 and α7 remain the prominent 
receptor assemblies (Hsu et al., 1997; Berg & Conroy, 2002). Furthermore, α4β2 and α7 
receptors play a role in nAChR mediated neuroprotection against excitotoxicity in rat 
dissociated spinal cultures (Nakamizo et al., 2005; Shimohama, 2009). Thus, antagonists 
for α4β2 and α7 receptors, DHβE and MLA respectively, were used in the present 
excitotoxicity model. The experiments were performed by co-application of 
kainate+antagonists (+nicotine) to examine which receptors are involved in nicotine-
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mediated neuroprotection. Antagonists’ application with kainate did not modulate 
network depression evoked by kainate with only one exception namely, a partial 
preservation of chemically-induced fictive locomotion.  We hypothesize that kainate-
mediated excitation had led to release of endogenous ACh and that this phenomenon 
partly contributed to excitotoxicity at the level of the CPG network, though the exact 
locus of action remains unclear and needs future experiments. This suggestion is 
compatible with the modest protection by DHβE and it implies the possibility that at least 
part of the neuroprotection exerted by nicotine itself was caused by its dual action on 
nAChRs, namely rapid activation and desensitization.  
 
7. Neuroprotective effect of celastrol 
 
Several studies have investigated the effects of HSPs by over-expressing them or 
activating the heat shock response (HSR) in rodent models (Muchowski & Wacker, 2005; 
Neef et al., 2011; Leak, 2014; Duncan et al., 2015; Pratt et al., 2015; Bose & Cho, 2017; 
Calderwood & Murshid, 2017). Determining which HSR elements are effective in 
inhibiting protein aggregation and subsequent neurotoxicity is a crucial step in 
exemplifying targets for the development of therapeutics to combat neurodegenerative 
diseases. It has previously been reported that upregulation of HSR by treatment with 
drugs such as withaferin A, celastrol or arimoclomol resulted in increasing motoneuronal 
numbers and lifespan of mSOD1 expressing mice (Kieran et al., 2004; Kiaei et al., 2005; 
Lin et al., 2013; Patel et al., 2014). As celastrol is a potent HSP70 inducer and also 
possess anti-inflammatory and anti-oxidant properties (Westerheide et al., 2004), 
therefore in the present study of an in vitro SCI model, celastrol is used to investigate the 
neuroprotective effect of induced HSP70 by pre-treating the preparations with celastrol 
for 6 h followed by application of kainate for 1 h. Primarily the effective dose of celastrol, 
which is 0.75 µM was optimized by my colleague Priyadarshini Veeraraghavan. The 
further neuroprotective effect was studied by me by performing extracellular recordings 
(see supplemental data, appendix II). When celastrol was applied alone for 6 h on day 1 
and recorded on a subsequent day showed depression of monosynaptic reflexes. 
However, the polysynaptic reflexes and DR evoked fictive locomotion were recovered 
back to normal. It is noteworthy that the amplitude of NMDA+5HT induced fictive 
locomotion was reduced to less than half and the periodicity was increased to double as 
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compared to sham preparations. Then kainate (50 µM) was applied after pre-treating the 
preparations with celastrol (6 h), which showed strong recovery in polysynaptic reflexes, 
electrically induced fictive locomotion and NMDA+5HT induced fictive locomotion even 
though with smaller amplitude and slower periodicity of oscillatory cycles. As this project 
is a part of collaboration with Antonela Petrović and Miranda Mladinić at the University 
of Rijeka, Department of Biotechnology, Croatia, therefore Petrović will continue the 
project by further performing molecular biology experiments. 
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7   CONCLUSIONS AND FUTURE PERSPECTIVES  
 
The novel findings discussed in the present thesis are intriguing. Several attempts have 
been made earlier to examine the neuroprotective role of distinct pharmacological agents 
(Lee et al., 2003; Bagriyanik et al., 2008; Shabbir et al., 2015; Bajrektarevic & Nistri, 
2017). Among glutamate release inhibitors, riluzole is the only present-day treatment for 
motoneuron disease with a rather limited lifespan of clinical efficacy (Wokke, 1996; 
Cheah et al., 2010). In our lab’s experimental model, this drug cannot effectively contrast 
the excitotoxicity induced by kainate (Sámano et al., 2012) while it does act by 
decreasing glutamatergic transmission and voltage-activated Na
+
 conductances (Cifra et 
al., 2013). MPSS has shown limited neuroprotection to spinal white matter against 
dysmetabolic/hypoxic conditions in our experimental model (Sámano et al., 2016). More 
promising neuroprotective results were obtained with propofol (Kaur et al., 2016), 
nicotine and celastrol against excitotoxic insult in our in vitro rat spinal cord model. 
These encouraging observations will require further experiments in vivo before 
considering their translational implications.  
  
 One limitation of our model is that the survival time of our preparation is 24 
h: beyond this, it is not currently feasible to test whether any protection remains over 
longer times or emerges with an unexpected delay. Hence, in the future, further in vivo 
and clinical attempts are necessary to verify whether these drugs are effectively able to 
attenuate the excitotoxicity evoked after SCI. It is, however, important to reiterate that the 
present data offer proof of principle that pharmacological neuroprotection is indeed 
possible against experimental SCI.   
 
 
 
 
 
Page 155 
 
 
8 REFERENCES 
 
Abdin AA, & Hasby EA (2014) Modulatory effect of celastrol on Th1/Th2 cytokines 
profile, TLR2 and CD3C T-lymphocyte expression in a relapsingremitting model of 
multiple sclerosis in rats. Eur. J. Pharmacol. 742:102-112. 
Alaynick WA, Jessell TM, Pfaff SL (2011) SnapShot: spinal cord development. Cell 146: 
178-178.e1. 
Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. (2009) Mammalian nicotinic 
acetylcholine receptors: from structure to function. Physiol. Rev. 89:73-120.  
Alexander JK, DeVries AC, Kigerl KA, Dahlman JM, Popovich PG (2009) Stress 
exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. Brain, 
Behavior and Immunity 23:851-860. 
Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent 
antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. 
Prog. Neuropsychopharmacol. Biol. Psychiatry 25:1341-1357.  
Anderson DK, Hall ED (1989) Pathophysiology of spinal cord trauma. Ann. Emerg. Med. 
22:987-992.  
Anderson RE, Jakobsson JG (2004) Entropy of EEG during anaesthetic induction: a 
comparative study with propofol or nitrous oxide as sole agent. Br. J. Anaesth. 92:167-
170.  
Andrabi SA, Dawson TM, Dawson VL (2008) Mitochondrial and nuclear cross talk in 
cell death: parthanatos. Ann. N. Y. Acad. Sci. 1147:233-241.  
Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, Klaus JA, Otsuka T, Zhang 
Z, Koehler RC, Hurn PD, Poirier G G, Dawson VL, Dawson TM (2006) Poly(ADP-
ribose) (PAR) polymer is a death signal. Proc. Natl. Acad. Sci. U.S.A. 103:18308-18313. 
 
 
Page 156 
 
Aoki F, Wannier T, Grillner S (2001) Slow Dorsal-Ventral Rhythm Generator in the 
Lamprey Spinal Cord. Journal of Neurophysiology 85:211-218. 
Aoki H, Mizobe T, Nozuchi S, Hiramatsu N (1998) In vivo and in vitro studies of the 
inhibitory effect of propofol on human platelet aggregation. Anesthesiology 88:362-370. 
Bajrektarevic D, Nistri A
 
(2016) Delayed application of the anesthetic propofol contrasts 
the neurotoxic effects of kainate on rat organotypic spinal slice cultures. Neurotoxicology 
54:1-10. 
Ballerini L, Galante M, Grandolfo M, Nistri A (1999) Generation of rhythmic patterns of 
activity by ventral interneurones in rat organotypic spinal slice culture. J. Physiol. 
517:459-475. 
Bannatyne BA, Edgley SA, Hammar I, Jankowska E, Maxwell DJ (2003) Networks of 
inhibitory and excitatory commissural interneurons mediating crossed reticulospinal 
actions. Eur. J. Neurosci. 18:2273-2284. 
Bao FP, Zhang HG, Zhu SM (2017) Anesthetic considerations for patients with acute 
cervical spinal cord injury. Neural Regen. Res. 12:499-504. 
Baranović S, Maldini B, Cengić T, Kolundzić R (2014) Anesthetic management of acute 
cervical spinal cord injury in pregnancy. Acta. Clin. Croat. 53:98-101. 
Baraznenok IL, Jonsson E, Claesson A (2005) 3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy) 
pyridines: synthesis and analgesic activity. Bioorg. Med. Chem. Lett. 15:1637-16340. 
Barbeau H, McCrea DA, O’Donovan MJ, Rossignol S, Grill WM, Lemay MA (1999) 
Tapping into spinal circuits to restore motor function. Brain Res. Brain Res. Rev. 30:27-
51. 
Barnard EA, Skolnick P, Olsen RW, et al (1998) International Union of Pharmacology. 
XV. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit 
structure and receptor function. Pharmacol. Rev. 50:291-313. 
Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. 
Clin. Sci. (Lond). 94:557-572.  
Beato M, Nistri A (1999) Interaction between disinhibited bursting and fictive locomotor 
patterns in the rat isolated spinal cord. J. Neurophysiol. 82:2029-2038. 
 
 
Page 157 
 
Becker DE (2013) Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 
Spring 60:25-31. 
Belelli D, Lambert JJ, Peters JA, et al (1997) The interaction of the general anesthetic 
etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single 
amino acid. Proceedings of the National Academy of Sciences of the United States of 
America 94:11031-11036.  
Bellardita C, Kiehn O (2015) Phenotypic characterization of speed-aasociated gait 
changes in mice reveals modular organization of locomotor networks. Curr. Biol. 
25:1426-1436. 
Ben-Ari Y (1985) Limbic seizure and brain damage produced by kainic acid: mechanisms 
and relevance to human temporal lobe epilepsy. Neuroscience 14:375-403. 
Bohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behavioral 
Brain Research. 221:564-573. 
Bonner TI (1989) The molecular basis of muscarinic receptor diversity. Trends 
Neurosci. 12: 148-151.  
Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of 
muscarinic acetylcholine receptor genes. Science 237:527-532.  
Bonner TI, Young AC, Brann MR, Buckley NJ (1988) Cloning and expression of the 
human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403-410.  
Bose S & Cho J (2017) Targeting chaperones, heat shock factor-1, and unfolded protein 
response: promising therapeutic approaches for neurodegenerative disorders. Ageing Res. 
Rev. 35:155-175. 
Bracci E, Ballerini L, Nistri (1996b) A Localization of rhythmogenic networks 
responsible for spontaneous bursts induced by strychnine and bicuculline in the rat 
isolated spinal cord. J. Neurosci. 16:7063-7076. 
Bracken MB (2012) Steroids for acute spinal cord injury. Cochrane Database Syst. Rev. 
18:1-51. 
Bracken MB, Collins WF, Freeman DF et al (1984) Efficacy of methylprednisolone in 
acute spinal cord injury. JAMA 251:45-52. 
 
 
Page 158 
 
Brown GT (1911) The intrinsic factors in the act of progresson in the mammal. Proc. R. 
Soc. Lond. 84:309-319. 
Brown GT (1914) On the nature of the fundamental activity of the nervous centres; 
together with an analysis of the conditioning of rhythmic activity in progression, and a 
theory of the evolution of function in the nervous system. J. Physiol. 48:18-46. 
Brown IR, Rush S, Ivy GO (1989) Induction of a heat shock gene at the site of tissue 
injury in the rat brain. Neuron 2:1559-1564. 
Bunnelle WH, Dart MJ, Schrimpf MR (2004) Design of ligands for the nicotinic 
acetylcholine receptors: the quest for selectivity. Curr. Top. Med. Chem. 4:299-334. 
Calderwood SK, Murshid A (2017) Molecular chaperone accumulation in cancer and 
decrease in Alzheimer's disease: the potential roles of HSF1. Front. Neurosci. 11:192. 
Campagna JA, Miller KW, Forman SA. Mechanisms of Actions of Inhaled Anesthetics. 
New 
Carmel JB, Kakinohana O, Mestril R, Young W, Marsala M, Hart RP (2004) Mediators 
of ischemic preconditioning identified by microarray analysis of rat spinal cord. Exp. 
Neurol. 185:81-96. 
Carriedo SG, Yin HZ, Weiss JH (1996) Motor neurons are selectively vulnerable to 
AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. 16:4069-4079. 
Caulfield MP, Birdsall NJM (1998) International Union of Pharmacology. XVII. 
Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50:279-290.  
Cazalets JR, Sqalli-Houssaini Y, Clarac F (1992) Activation of the central pattern 
generators for locomotion by serotonin and excitatory amino acids in neonatal rat. J. 
Physiol. (Lond.) 455:187-204. 
Changeux J, Edelstein SJ (2001) Allosteric mechanisms in normal and pathological 
nicotinic acetylcholine receptors. Curr. Opin. Neurobiol. 11:369-377. 
Changeux JP, Edelstein SJ (1998) Allosteric receptors after 30 years. Neuron 21:959-980. 
 
 
Page 159 
 
Cheung V, Hoshide R, Bansal V, Kasper E, Chen CC (2015) Methylprednisolone in the 
management of spinal cord injuries: Lessons from randomized, controlled trials. Surg. 
Neurol. Int. 6:142. 
Choi D W (1992a) Bench to bedside: the glutamate connection. Science 258:241-243. 
Christie DF, Michael AA, and Paul JK (2008) Subtypes of nicotinic acetylcholine 
receptors in nicotine reward, dependence, and withdrawal: Evidence from genetically 
modified mice. Behav. Pharmacol. 19:461-484. 
Chuang YC, Chang AY, Lin JW, Hsu SP, Chan SH (2004) Mitochondrial dysfunction 
and ultrastructural damage in the hippocampus during kainic acid-induced status 
epilepticus in the rat. Epilepsia. 45:1202-1209. 
Cizkova D, Carmel JB, Yamamoto K, Kakinohana O, Sun D, Hart RP, Marsala M (2004) 
Characterization of spinal HSP72 induction and development of ischemic tolerance after 
spinal ischemia in rats. Exp. Neurol. 185:97-108. 
Clements JR, Grant S (1990) Glutamate-like immunoreactivity in neurons of the 
laterodorsal tegmental and pedunculopontine nuclei in the rat. Neurosci. Lett. 120:70-73. 
Cleren C, Calingasan NY, Chen J, Beal MF (2005) Celastrol protects against MPTP- and 
3-nitropropionic acid-induced neurotoxicity. Journal of Neurochemistry 94:995-1004. 
Corringer PJ, Le Novere N, Changeux JP (2000) Nicotinic receptors at the amino acid 
level. Annu. Rev. Pharmacol. Toxicol. 40:431-458. 
Cossart R, Dinocourt C, Hirsch JC, Merchan-Perez A, De Felipe J, Ben-Ari Y, Esclapez 
M, Bernard C (2001) Dendritic but not somatic GABAergic inhibition is decreased in 
experimental epilepsy. Nat. Neurosci. 4:52-62. 
Cowley KC, Schmidt BJ (1995) Effects of inhibitory amino acid antagonists on reciprocal 
inhibitory interactions during rhythmic motor activity in the in vitro neonatal rat spinal 
cord. J. Neurophysiol. 74:1109-1117. 
Crone S A, Zhong G, Harris-Warrick R, Sharma K (2009) In mice lacking V2a 
interneurons, gait depends on speed of locomotion. J. Neurosci. 29:7098-7109. 
 
 
Page 160 
 
Crone SA, et al (2008) Genetic ablation of V2a ipsilateral interneurons disrupts left-right 
locomotor coordination in mammalian spinal cord. Neuron 60:70-83.  
Dafny N (1999) Chapter 3: Anatomy of spinal cord, Section 2: Sensory Systems, 
Neuroscience Online. Website: http://neuroscience.uth.tmc.edu/s2/chapter03.html. 
Dajas-Bailador FA et al (2000) The a7 nicotinic acetylcholine receptor subtype mediates 
nicotine protection against NMDA excitotoxicity in primary hippocampal cultures 
through a Ca2þ dependent mechanism. Neuropharmacology 39:2799-2807. 
Dale HH (1914) The action of certain esters of choline and their relation to muscarine. J. 
Pharmacol. Exp. Ther. 6:147-190. 
Dale HH, Dudley HW (1929) The presence of histamine and acetylcholine in the spleen 
of the ox and horse. J Physiol. 68:97-123. 
Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic 
mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 47:699-729.  
Darwin C (1859) On the origin of species by natural selection, or the preservation of 
favoured races in the struggle for life. London, UK: John Murray 
Datson NA, Morsink MC, Meijer OC, de Kloet ER (2008) Central corticosteroid actions: 
search for gene targets. European Journal of Pharmacology 583:272-289. 
Delcomyn F (1980) Neural basis of rhythmic behaviour in animals. Science 210:492–498.  
Donnelly DJ, Popovich PG (2008) Inflammation and its role in neuroprotection, axonal 
regeneration and functional recovery after spinal cord injury. Exp. Neurol. 209:378-388. 
Donnelly-Roberts DL et al (1996) In vitro neuroprotective properties of the novel 
cholinergic channel activator (ChCA), ABT-418. Brain Res. 719:36–44 
Dougherty KJ, et al (2013) Locomotor rhythm generation linked to the output of spinal 
Shox2 excitatory interneurons. Neuron 80:920-933.  
Druschel C, Schaser KD, Schwab JM (2013) Current practice of methylprednisolone 
administration for acute spinal cord injury in Germany: a national survey. Spine 38:e669-
e677. 
 
 
Page 161 
 
Dubovsky AN, Arvikar S, Stern TA, Axelrod L (2012) The neuropsychiatric 
complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics 53:103-
115. 
Duncan EJ, Cheetham ME, Chapple JP, van der Spuy J (2015) The role of Hsp70 and its 
co-chaperones in protein misfolding, aggregation and disease. Subcell. Biochem. 78:243-
273.  
Edgerton VR, Tillakaratne NJ, Bigbee AJ, de Leon RD, Roy RR (2004) Plasticity of the 
spinal neural circuitry after injury. Annu. Rev. Neurosci. 27:145-167. 
Emery E, Aldana P, Bunge MB, Puckett W,Srinivasan A, Keane RW, Bethea J, Levi AD 
(1998). Apoptosis after traumatic human spinal cord injury. J. Neurosurg. 89:911-920. 
Endo T, Kiehn O (2008) Asymmetric operation of the locomotor central pattern generator 
in the neonatal mouse spinal cord. J. Neurophysiol. 100:3043-3054. 
Evaniew N, Belley-Côté EP, Fallah N, Noonan VK, Rivers CS, Dvorak MF (2016) 
Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A 
Systematic Review and Meta-Analysis. J. Neurotrauma. 33:468-481.  
Fehlings MG, Wilson JR, Tetreault LA, Aarabi B, Anderson P, Arnold PM, Brodke DS, 
Burns AS, Chiba K, Dettori JR, Furlan JC, Hawryluk G, Holly LT, Howley S, Jeji T, 
Kalsi-Ryan S, Kotter M, Kurpad S, Kwon BK, Marino RJ, Martin AR, Massicotte E, 
Merli G, Middleton JW, Nakashima H, Nagoshi N, Palmieri K, Skelly AC, Singh A, Tsai 
EC, Vaccaro A, Yee A, Harrop JS (2017) A Clinical Practice Guideline for the 
Management of Patients With Acute Spinal Cord Injury: Recommendations on the Use of 
Methylprednisolone Sodium Succinate. Global Spine Journal 7:203S-211S. 
Ferchmin PA et al (2003) Nicotinic receptors differentially regulate N-methyl-D-aspartate 
damage in acute hippocampal slices. J. Pharmacol. Exp. Ther. 305:1071-1078. 
Forman SA, Chin VA (2008) General Anesthetics and Molecular Mechanisms of 
Unconsciousness. Int. Anesthesiol. Clin. 46:43-53. 
Geisler FH, Dorsey FC, Coleman WP (1991) Recovery of motor function after spinal 
cord injury—a randomized, placebo-controlled trial with GM-1 ganglioside. N. Engl. J. 
Med. 324:1829-1838.  
 
 
Page 162 
 
Gerndt SJ, Rodriguez JL, Pawlik JW et al (1997) Consequences of high-dose steroid 
therapy for acute spinal cord injury. J. Trauma. 42:279-284. 
Ghosh M, Pearse DD (2014) The role of the serotonergic system in locomotor recovery 
after spinal cord injury. Front. Neural Circuits. 8:151. 
Glen JB (1980) Animal studies of the anaesthetic activity of ICI 35 868. Br. J. Anaesth. 
52: 731-742. 
Glen JB, Hunter SC (1984) Pharmacology of an emulsion formulation of ICI 35 868. Br. 
J. Anaesth. 56:617-626. 
Gold R, Buttgereit F, Toyka KV (2001) Mechanism of action of glucocorticosteroid 
hormones: possible implications for therapy of neuroimmunological disorders. J. 
Neuroimmunol. 117:1-8. 
Gonzalez-Correa JA, Cruz-Andreotti E, Arrebola MM, Lopez-Villodres JA, Jodar M, De 
La Cruz JP (2008) Effects of propofol on the leukocyte nitric oxide pathway: in vitro and 
ex vivo studies in surgical patients. Naunyn-Schmiedeberg's Arch. Pharmacol. 376:331-
339. 
Goto T, Nakata Y, Saito H, et al (2000) Bispectral analysis of the electroencephalogram 
does not predict responsiveness to verbal command in patients emerging from xenon 
anaesthesia. Br. J. Anaesth. 85:359-363.  
Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology 
Progress in Neurobiology 74:363-396. 
Goulding M (2009) Circuits controlling vertebrate locomotion: moving in a new 
direction. Nat. Rev. Neurosci. 10:507-518. 
Grasshoff C, Rudolph U, Antkowiak B (2005) Molecular and systemic mechanisms of 
general anaesthesia: the 'multi-site and multiple mechanisms' concept. Current Opinion in 
Anaesthesiology 18:386-391.  
Grillner S (1985) Neurobiological bases of rhythmic motor acts in vertebrates. Science 
228: 143-149. 
Grillner S (1986) Interaction between sensory signals and the central networks controlling 
locomotion in lamprey, dogfish and cat. In: Grillner S, Stein PSG, Stuart DG, Forssberg 
 
 
Page 163 
 
F, Herman RM, editors. Neurobiology of vertebrate locomotion. Wenner Gren 
international symposium series. London: Macmillan. 45:505-512. 
Grillner S (2003) The motor infrastructure: from ion channels to neuronal networks. Nat. 
Rev. Neurosci. 4:573-586. 
Grillner S (2006) Biological Pattern Generation: The Cellular and Computational Logic 
of Networks in Motion. Neuron 52:751-766. 
Grillner S, Hellgren J, Ménard A, Saitoh K, Wikström MA (2005) Mechanisms for 
selection of basic motor programs-roles for the striatum and pallidum. Trends Neurosci. 
28:364-370.  
Grillner S, Kozlov A, Kotaleski JH (2005c) Integrative neuroscience: linking levels of 
analyses. Curr. Opin. Neurobiol. 15:614-621. 
Grouzmann E, Borgeat A, Fathi M, Gaillard RC, Ravussin P (2000) Plasma and 
cerebrospinal fluid concentration of neuropeptide Y, serotonin, and catecholamines in 
patients under propofol or isoflurane anaesthesia. Can. J. Physiol. Pharm. 78:100-107. 
Grundmann U, Silomon M, Bach F, Becker S, Bauer M, Larsen B, Kleinschmidt S (2001) 
Recovery profile and side effects of remifentanil-based anaesthesia with desflurane or 
propofol for laparoscopic cholecystectomy. Acta. Anaesth. Scand. 45:320-326. 
Guandalini L, Martini E, Gratteri P, Ghelardini C, Varani K, Romanelli MN (2006) 
Design, synthesis and binding affinity of new nicotinic ligands. Issue Italian-Swiss 
Medicinal Chemistry Meeting ARKIVOC VIII:50-65. 
Guertin PA (2009) The mammalian central pattern generator for locomotion. Brain 
Research Reviews 62:45-56. 
Guzma´ n-Lenis MS, Navarro X, Casas C (2009) Drug screening of neuroprotective 
agents on an organotypic-based model of spinal cord excitotoxic damage. Restor. Neurol. 
Neurosci. 27:335–349. 
Ha KY, Carragee E, Cheng I, Kwon SE, Kim YH (2011) Pregabalin as a neuroprotector 
after spinal cord injury in rats: biochemical analysis and effect on glial cells. J. Korean 
Med. Sci. 26:404-411. 
 
 
Page 164 
 
Ha KY, Kim YH, Rhyu KW, Kwon SE (2008) Pregabalin as a neuroprotector after spinal 
cord injury in rats. Eur. Spine J. 17:864-872. 
Häggström M, Stannered, Hoffmeier, Settersr, Richfield D (2014) Diagram of the 
pathways of human steroidogenesis. WikiJournal of Medicine 1:5.   
Ham AW, Cormack DH (1987) Histology, Edn. 8th , J.B. Lippincott company, 
Philadelphia and Torronto 485-517.  
Heise C, Kayalioglu G (2009) Cytoarchitecture of the spinal cord. In: Watson C, Paxinos 
G, Kayalioglu G, editors. The spinal cord. A Christopher and Dana Reeve foundation text 
and atlas. San Diego: Elsevier Academic Press. 64-80. 
Henneman E (1974) Spinal reflexes and the control of movement in Medical Physiology, 
13
th
 Edn, ed.V.B.Mount castle (StLouis: Mosby) 1:651-667. 
Herman JP, Patel PD, Akil H, Watson SJ (1989) Localization and regulation of 
glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal 
formation of the rat. Molecular Endocrinology 3:1886-1894. 
Hikosaka O, Nakamura K, Nakahara H (2006) Basal ganglia orient eyes to reward. J 
Neurophysiol. 95:567-584.  
Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from 
structure to brain function. Rev. Physiol. Biochem. Pharmacol. 147:1-46.  
Hultborn H (1976) Transmission in the pathway of reciprocal Ia inhibition to 
motoneurones and its control during the tonic stretch reflex. Prog. Brain Res. 44:235-255. 
Hurlbert RJ, Hadley MN, Walters BC, Aarabi B, Dhall SS, Gelb DE, Rozzelle CJ, Ryken 
TC, Theodore N (2013) Pharmacological Therapy for Acute Spinal Cord Injury. 
Neurosurgery 72:93-105.  
Ishii H, Arai T, Segawa H, Morikawa S, Inubushi T, Fukuda K (2002) Effects of propofol 
on lactate accumulation and oedema formation in focal cerebral ischaemia in 
hyperglycaemic rats. Br. J. Anaesth. 88:412-417. 
Ishikawa T, Suzuki H, Ishikawa K, Yasuda S, Matsui T, Yamamoto M, Kakeda T, 
Yamamoto S, Owada Y, Yaksh TL (2014) Spinal Cord Ischemia/Injury. Current 
Pharmaceutical Design 20:5738-5743. 
 
 
Page 165 
 
Jarrard LE (2002) Use of excitotoxins to lesion the hippocampus: update. Hippocampus 
12:405-414. 
Jellinger KA, & Stadelmann CH (2000) The enigma of cell death in neurodegenerative   
disorders. J. NeuralTransm. Suppl. 60:21-36. 
Jensen AA, Frølund B, Liljefors T, Krogsgaard-Larsen P (2005) Neuronal nicotinic 
acetylcholine receptors: structural revelations, target identifications, and therapeutic 
inspirations. J. Med. Chem. 48:4705-4745. 
Jessell TM (2000) Neuronal specification in the spinal cord: inductive signals and 
transcriptional codes. Nat. Rev. Genet. 1:20-29. 
Joyce DA, Steer JH, Abraham LJ (1997) Glucocorticoid modulation of human 
monocyte/macrophage function: control of TNF-alpha secretion. Inflammation Research: 
Official Journal of the European Histamine Research Society 46:447-451. 
Kandel ER, Schwartz JH, Jessell TM (2000) Principles of neural science (4
th
 ed.). New 
York: McGraw-Hill, Health Professions division. 
Kannaiyan R, Shanmugam MK, Sethi G (2011) Molecular targets of celastrol derived 
from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and 
cancer. Cancer Lett. 303:9-20. 
Kaur J, Flores Gutiérrez J, Nistri A (2016) Neuroprotective effect of propofol against 
excitotoxic injury to locomotor networks of the rat spinal cord in vitro. Eur J Neurosci. 
44:2418-2430. 
Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF (2005) Celastrol blocks 
neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral 
sclerosis. Neurodegener. Dis. 2:246-254. 
Kiehn O (2006) Locomotor circuits in the mammalian spinal cord. Annu Rev 
Neurosci. 29:279-306. 
Kiehn O (2016) Decoding the organization of spinal circuits that control locomotion. Nat. 
Rev. Neurosci.  17:224-238. 
Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L (2004) 
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease 
progression in ALS mice. Nat. Med. 10:402–405. 
 
 
Page 166 
 
Kihara T, Shimohama S, Sawada H, Honda K, Naamizo T, Shibasaki H,  Kume T, 
Akaike A, (2001) α7 nicotinic receptors transduces signals to phosphatidylinositol 3 
kinase to block a β amyloid induced neurotoxicity. J. Biol. Chem. 276:13541-13546. 
Kim YH, Ha KY, Kim SI (2017) Spinal Cord Injury and Related Clinical Trials. Clin. 
Orthop. Surg. 9:1-9. 
King AE, Woodhouse A, Kirkcaldie MT, Vickers JC (2016) Excitotoxicity in ALS: 
Overstimulation, or overreaction? Experimental Neurology 275:162-171. 
Kissin I (1997) A concept for assessing interactions of general anesthetics. Anesth.. 
Analg. 85:204-210.  
Kremer E, Lev-Tov A (1997) Localization of the spinal network associated with 
generation of hindlimb locomotion in the neonatal rat and organization of its transverse 
coupling system. J. Neurophysiol. 77:1155-1170. 
Kudo N, Yamad T (1987) N-methyl-D,L-aspartate–induced locomotor activity in a spinal 
cord– hindlimb muscles preparation of the newborn rat studied in vitro. Neurosci. Lett. 
75: 43-48. 
Kuizenga K, Wierda JM, Kalkman CJ (2001) Biphasic EEG changes in relation to loss of 
consciousness during induction with thiopental, propofol, etomidate, midazolam or 
sevoflurane. Br. J. Anaesth. 86:354-360.  
Kurt M, Bilge SS, Kukula O, Celik S, Kesim Y (2003) Anxiolytic-like profile of 
propofol, a general anaesthetic, in the plus-maze test in mice. Pol. J. Pharmacol. 55: 973-
977. 
Kushida A, Inada T, Shingu K (2007) Enhancement of antitumor immunity after propofol 
treatment in mice. Immunopharmacol. Immunotoxicol. 29:477-486. 
Kuzhandaivel A, Nistri A, Mazzone GL, Mladinic M (2011) Molecular mechanisms 
underlying cell death in spinal networks in relation to locomotor activity after acute injury 
in vitro. Front. Cell. Neurosci. 5:9. 
Kuzhandaivel A, Margaryan G, Nistri A, Mladinic M (2010) Extensive glial apoptosis 
develops early after hypoxic-dysmetabolic insult to the neonatal rat spinal cord in vitro. 
Neuroscience 169:325-338. 
Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR (2004) Pathophysiology and 
pharmacologic treatment of acute spinal cord injury. Spine J. 4:451-464. 
 
 
Page 167 
 
L. Baraznenok, E. Jonsson, A. Claesson, Bioorg. Med. Chem. Lett. 2005, 15, 1637 – 
1640. 
Laitio RM, Kaskinoro K, Särkelä MOK, Kaisti KK, Salmi E, Maksimow A, Långsjö JW, 
Aantaa R, Kangas K, Jääskeläinen S, Scheinin H (2008) Bispectral Index, Entropy, and 
Quantitative Electroencephalogram during Single-agent Xenon Anesthesia. 
Anesthesiology 108:63-70. 
Lapchak PA, Araujo DM, Song D, et al (2001) Neuroprotection by the selective 
cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits 
induced by reversible spinal cord ischemia. Stroke 32:1220-1225.  
Laviolette SR, van der Kooy D (2004) The neurobiology of nicotine addiction: bridging 
the gap from molecules to behaviour. Nat. Rev. Neurosci. 5:55-65. 
Lavoie B, Parent A (1994) Pedunculopontine nucleus in the squirrel monkey: distribution 
of cholinergic and monoaminergic neurons in the mesopontine tegmentum with evidence 
for the presence of glutamate in cholinergic neurons. J Comp Neurol. 344:190-209. 
Le Novere N, Changeux JP (1995) Molecular evolution of the nicotinic acetylcholine 
receptor: an example of multigene family in excitable cells. J. Mol. 40:155-172. 
Le Ray D, Juvin L, Ryczko D, Dubuc R (2011) Chapter 4 - Supraspinal control of 
locomotion: the mesencephalic locomotor region. Progress in Brain Research. 188:51-70. 
Leak RK (2014) Heat shock proteins in neurodegenerative disorders and aging. J. Cell 
Commun. Signal. 8:293-310. 
Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CY, Xu J (2008) Methylprednisolone 
protects oligodendrocytes but not neurons after spinal cord injury. J. Neurosci. 28:3141-
3149. 
Li GL, Farooque M, Holtz A, Olsson Y (1999) Apoptosis of oligodendrocytes occurs for 
long distances away from the primary injury after compression trauma to rat spinal cord. 
Acta. Neuropathol. 98, 473-480. 
Li S, Mealing GA, Morley P, Stys PK (1999) Novel injury mechanism in anoxia and 
trauma of spinal cord white matter: glutamate release via reverse Na+-dependent 
glutamate transport. J. Neurosci. 19:RC16. 
 
 
Page 168 
 
Li S, Stys PK (2000) Mechanisms of ionotropic glutamate receptormediated 
excitotoxicity in isolated spinal cord white matter. J. Neurosci. 20:1190-1198. 
Lin P-Y, Simon SM, Koh WK, Folorunso O, Umbaugh CS, Pierce A (2013) Heat shock 
factor 1 over-expression protects against exposure of hydrophobic residues on mutant 
SOD1 and early mortality in a mouse model of amyotrophic lateral sclerosis. Mol. 
Neurodegener. 8:43. 
Lindstrom J (2000) The structures of neuronal nicotinic receptors. In: Clementi F, 
Fornasari D, Gotti C (Eds.), Handbook of Experimental Pharmacology Vol. Neuronal 
Nicotinic Receptors. Springer, Berlin. 101-162. 
Lipton SA & Rosenberg PA (1994) Excitatory amino acids as a final common pathway 
for neurologic disorders. N. Engl. J. Med. 330:613-622. 
Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, 
Cohen A, Kim H (2013) A practical guide to the monitoring and management of the 
complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol. 9:30.  
Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, 
Jacquin MF, Hsu CY, Choi DW (1997) Neuronal and glial apoptosis after traumatic 
spinal cord injury. J. Neurosci. 17:5395-5406. 
Loewi O (1921) Uber humorale Ubertragbarkeit der Herznervenwirkung. Pflügers. 
189:239-242. 
Lu GB, Niu FW, Zhang YC, Du L, Liang ZY, Gao Y, Yan TZ, Nie ZK, Gao K (2016) 
Methylprednisolone promotes recovery of neurological function after spinal cord injury: 
association with Wnt/β-catenin signaling pathway activation. Neural Regen. Res. 
11:1816-1823. 
Maiarù M, Tochiki KK, Cox MB et al (2016) The stress regulator FKBP51 drives chronic 
pain by modulating spinal glucocorticoid signalling. Science Translational Medicine 8:1-
11. 
Malenka RC, Nestler EJ, Hyman SE (2009) Chapter 9: Autonomic Nervous System. In 
Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical 
Neuroscience (2nd ed.). New York: McGraw-Hill Medical. 234.  
 
 
Page 169 
 
Margaryan G, Mattioli C, Mladinic M, Nistri A (2010) Neuroprotection of locomotor 
networks after experimental injury to the neonatal rat spinal cord in vitro. Neuroscience 
165:996-1010. 
Margaryan G, Mladinic M, Mattioli C, Nistri A (2009) Extracellular magnesium enhances 
the damage to locomotor networks produced by metabolic perturbation mimicking spinal 
injury in the neonatal rat spinal cord in vitro. Neuroscience 163:669-682. 
Mashour GA, Forman SA, Campagna JA (2005) Mechanisms of general anesthesia: from 
molecules to mind. Best Pract. Res. Clin. Anaesthesiol. 19:349–364.  
Matsumoto T, Tamaki T, Kawakami M, Yoshida M, Ando M, Yamada H (2001) Early 
complications of high-dose methylprednisolone sodium succinate treatment in the follow-
up of acute cervical spinal cord injury. Spine (Phila Pa 1976) 26:426-430. 
Matsusue Y, Horii-Hayashi N, Kirita T, Nishi M (2014) Distribution of corticosteroid 
receptors in mature oligodendrocytes and oligodendrocyte progenitors of the adult mouse 
brain. The Journal of Histochemistry and Cytochemistry 62:211-226. 
Matthews PB (1972) Mammalian Muscle Receptors and their Central Actions. Baltimore: 
Williams and Wilkins. 1-95.  
Matthews PB (1991) The human stretch reflex and the motor cortex. Trends Neurosci. 
14:87-90. 
Mazze RI (2006) Methoxyflurane Revisited: Tale of an Anesthetic from Cradle to 
Grave. Anesthesiology 105:843-846. 
Mazzone GL, Margaryan G, Kuzhandaivel A, Nasrabady SE, Mladinic M, Nistri A 
(2010) Kainate-induced delayed onset of excitotoxicity with functional loss unrelated to 
the extent of neuronal damage in the in vitro spinal cord. Neuroscience 168:451-462. 
Mazzone GL, Mladinic M, Nistri A (2013) Excitotoxic cell death induces delayed 
proliferation of endogenous neuroprogenitor cells in organotypic slice cultures of the rat 
spinal cord. Cell Death Dis. 4:e902. 
McEwen BS, Weiss JM, Schwartz LS (1968) Selective retention of corticosterone by 
limbic structures in rat brain. Nature 220:911-912. 
McKinley WO, Seel RT, Hardman JT (1999) Nontraumatic spinal cord injury: incidence, 
epidemiology, and functional outcome. Arch. Phys. Med. Rehabil. 80:619-623. 
 
 
Page 170 
 
Mena-Segovia J, Winn P, Bolam JP (2008) Cholinergic modulation of midbrain 
dopaminergic systems. Brain Res. Rev. 58:265-271. 
Mesulam MM, Geula C (1988) Nucleus basalis (Ch4) and cortical cholinergic innervation 
in the human brain: observations based on the distribution of acetylcholinesterase and 
choline acetyltransferase. J. Comp. Neurol. 275:216-240. 
Mesulam MM, Geula C, Bothwell MA, Hersh LB (1989) Human reticular formation: 
cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some 
cytochemical comparisons to forebrain cholinergic neurons. J. Comp. Neurol. 283:611-
633. 
Miekisiak G, Kloc W, Janusz W, Kaczmarczyk J, Latka D, Zarzycki D (2014) Current 
use of methylprednisolone for acute spinal cord injury in Poland: survey study. Eur. J. 
Orthop. Surg. Traumatol. 24:S269-273. 
Mirski, M.A., Muffelman, B., Ulatowski, J.A. & Hanley, D.F. (1995) Sedation for the 
critically ill neurologic patient. Crit. Care Med., 23, 2038-2053. 
Molander C, Xu Q, Grant G (1984) The cytoarchitectonic organization of the spinal cord 
in the rat. I. The lower thoracic and lumbosacral cord. J. Comp. Neurol. 230:133-141. 
Molander C, Xu Q, Rivero-Melian C, Grant G (1989) Cytoarchitectonic organization of 
the spinal cord in the rat: II. The cervical and upper thoracic cord. J. Comp. Neurol. 
289:375-385. 
Morin F, Beaulieu C, Lacaille JC (1998) Selective loss of GABA neurons in area CA1 of 
the rat hippocampus after intraventricular kainate. Epilepsy Res. 32:363-369. 
Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular 
chaperones. Nat. Rev. Neurosci. 6:11-22. 
Mulle C, Sailer A, Pérez-Otaño I, Dickinson-Anson H, Castillo PE, Bureau I, Maron C, 
Gage FH, Mann JR, Bettler B, Heinemann SF (1998) Altered synaptic physiology and 
reduced susceptibility to kainate- induced secures in GluR6-deficient mice. Nature 
392:601-605. 
 
 
Page 171 
 
Nakamizo T, Kawamata J, Yamashita H, Kanki R, Kihara T, Sawada H, Akaike A, 
Shimohama S (2005) Stimulation of nicotinic acetylcholine receptors protects 
motoneurons . Biochemical and biophysical research communications 330:1285-1289. 
Narkilahti S, Pirttilä TJ, Lukasiuk K, Tuunanen J, Pitkänen A (2003) Expression and 
activation of caspase 3 following status epilepticus in the rat. Eur. J. Neurosci. 18:1486-
1496. 
Nasrabady SE, Kuzhandaivel A, Akrami A, Bianchetti E, Milanese M, Bonanno G, Nistri 
A (2012) Unusual increase in lumbar network excitability of the rat spinal cord evoked by 
the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake. Neuropharmacology. 
63:415-426.  
National Spinal Cord Injury Statistical Center, Facts and Figures at a Glance (2014) 
Birmingham, AL: University of Alabama at Birmingham.   
Neef DW, Jaeger AM, Thiele DJ (2011) Heat shock transcription factor 1 as a therapeutic 
target in neurodegenerative diseases. Nat. Rev. Drug Discov. 10:930-944. 
Netter FH (2006) Atlas of Human anatomy. Philadelphia, PA: Saunders/Elsevier. 
Newton R (2000) Molecular mechanisms of glucocorticoid action: what is important? 
Thorax 55:603-613. 
Nicholas JS, Selassie AW, Lineberry LA, Pickelsimer EE, Haines SJ (2009) Use and 
determinants of the methylprednisolone protocol for traumatic spinal cord injury in South 
Carolina acute care hospitals. J. Trauma. 66:1446-1450. 
Nicotinic acetylcholine receptors: Introduction (2014) IUPHAR Database. International 
Union of Basic and Clinical Pharmacology.  
Nishiyama T, Matsukawa T, Hanaoka K (2004) Intrathecal propofol has analgesic effects 
on inflammation-induced pain in rats. Can. J. Anaesth. = Journal canadien d'anesthesie 
51:899-904. 
Nowak TS, Bond U, Schlesinger MJ (1990) Heat shock RNA levels in brain and other 
tissues after hyperthermia and trasient ischemia. J. Neurochem. 54:451-458. 
Nuland SB (1988) Doctors: the biography of medicine. 1st ed. New York: Knopf.   
 
 
Page 172 
 
Oakley RH, Cidlowski JA (2011) Cellular processing of the glucocorticoid receptor gene 
and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. 
The Journal of Biological Chemistry 286:3177-3184. 
Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new 
signaling mechanisms in health and disease. The Journal of Allergy and Clinical 
Immunology 132: 1033-1044. 
Onifer SM, Rabchevsky AG, Scheff SW (2007) Rat models of traumatic spinal cord 
injury to assess motor recovery. ILARJ 48:385-395. 
Pain L, Oberling P, Launoy A, Di Scala G (1999) Effect of nonsedative doses of propofol 
on an innate anxiogenic situation in rats. Anesthesiology 90:191-196. 
Pallavicini M, Moroni B, Bolchi C, Clementi F, Fumagalli L, Gotti C, Vailati S, Valoti E, 
Villa L (2004) Synthesis and alpha4beta2 nicotinic affinity of 2-
pyrrolidinylmethoxyimines and prolinal oxime ethers. Bioorg. Med. Chem. Lett. 14:5827-
5830. 
Park E, Velumian AA, Fehlings MG (2004) The role of excitotoxicity in secondary 
mechanisms of spinal cord injury: a review with an emphasis on the implications for 
white matter degeneration. J. Neurotrauma. 21:754-774. 
Patel P, Julien JP, Kriz J (2014) Early-stage treatment with withaferin A reduces levels of 
misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic 
lateral sclerosis. Neurotherapeutics. 12:217-233. 
Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon 
DJ (1987) Distinct primary structures, ligand binding properties and tissue-specific 
expression of four human muscarinic acetylcholine receptors. EMBO J. 6:3923-3929.  
Pointillart V, Petitjean ME, Wiart L et al (2000) Pharmacological therapy of spinal cord 
injury during the acute phase. Spinal Cord 38:71-76. 
Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP (2015) Targeting Hsp90/Hsp70- based 
protein quality control for treatment of adult onset neurodegenerative diseases. Annu. 
Rev. Pharmacol. 55:353-371. 
 
 
Page 173 
 
Prendergast MA et al (2001) Chronic nicotine exposure reduces N-methyl-D-aspartate 
receptor-mediated damage in the hippocampus without altering calcium accumulation or 
extrusion: evidence of calbindin-D28K overexpression. Neuroscience 102:75-85. 
Quinlan KA, Kiehn O (2007) Segmental, synaptic actions of commissural interneurons in 
the mouse spinal cord. J. Neurosci. 27:6521-6530.  
Rampil IJ, Kim JS, Lenhardt R, et al (1998) Bispectral EEG index during nitrous oxide 
administration. Anesthesiology 89:671-677.  
Restrepo CE, et al (2009) Transmitter-phenotypes of commissural interneurons in the 
lumbar spinal cord of newborn mice. J. Comp. Neurol. 517:177-192. 
Revollo JR, Cidlowski JA (2009) Mechanisms generating diversity in glucocorticoid 
receptor signaling,‖ Annals of the New York Academy of Sciences 1179:167-178. 
Rexed B (1952) The cytoarchitectonic organization of the spinal cord in the cat. J. Comp. 
Neurol. 96:414-495. 
Rexed B (1954) A cytoarchitectonic atlas of the spinal cord in the cat. J. Comp. Neurol. 
100: 297-379. 
Roberts A, Roberts BL (1983) Neural origins of rhythmic movements. Cambridge, UK: 
Cambridge University Press. 
Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F (2007) 
Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential. 
2:746-767. 
Romanelli MN, Gualtieri F (2003) Cholinergic nicotinic receptors: competitive ligands, 
allosteric modulators, and their potential applications. Med. Res. Rev. 23:393-426. 
Rossi MA, Chan CK, Christensen JD, DeGuzman EJ, Durieux ME (1996) Interactions 
between propofol and lipid mediator receptors: inhibition of lysophosphatidate signaling. 
Anesth. Analg. 83:1090-1096. 
Rossignol S, Chau C, Brustein E, Giroux N, Bouyer L, Barbeau H, Reader TA (1998) 
Pharmacological activation and modulation of the central pattern generator for 
locomotion in the cat. Ann. N. Y. Acad. Sci. 860:346-359. 
 
 
Page 174 
 
Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW (1993) Chronic inhibition of glutamate 
uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 90:6591-
6595. 
Rowland JW, Hawryluk GW, Kwon B, Fehlings MG (2008) Current status of acute spinal 
cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg. 
Focus. 25:E2. 
Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: molecular targets 
of thunder god vine. Biochem. Biophys. Res. Commun. 394:439-442.  
Salzman SK, Lee WA, Sabato S, Mendez AA, Agresta CA, Kelly G (1993) Halothane 
anesthesia is neuroprotective in experimental spinal cord injury: early hemodynamic 
mechanisms of action. Res. Commun. Chem. Pathol. Pharmacol. 80:59-81. 
Sámano C, Kaur J, Nistri A (2016) A study of methylprednisolone neuroprotection 
against acute injury to the rat spinal cord in vitro. Neuroscience 315:136-149.  
Samuelson PN, Merin RG, Taves DR, Freeman RB, Calimlim JF, Kumazawa T (1976) 
Toxicity following methoxyflurane anaesthesia: IV. The role of obesity and the effect of 
low dose anaesthesia on fluoride metabolism and renal function. Canadian Anaesthetists’ 
Society Journal 23:465-479. 
Sanchez E (1990) Hsp56: a novel heat shock protein associated with untransformed 
steroid receptor complexes. The Journal of Biological Chemistry 265:22067-22070. 
Sanchez-Conde P, Rodriguez-Lopez JM, Nicolas JL, Lozano FS, Garcia-Criado FJ, 
Cascajo C, Gonzalez-Sarmiento R, Muriel C (2008) The comparative abilities of propofol 
and sevoflurane to modulate inflammation and oxidative stress in the kidney after aortic 
cross-clamping. Anesth. Analg. 106:371-378. 
Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress 
responses? Integrating permissive, suppressive, stimulatory, and preparative actions. 
Endocr. Rev. 21:55-89.  
Sargent PB (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu. 
Rev. Neurosci. 16:403-443. 
 
 
Page 175 
 
Sassa H, Kogure K, Takaishi Y, Terada H (1994) Structural basis of potent 
antiperoxidation activity of the triterpene celastrol in mitochondria: effect of negative 
membrane surface charge on lipid peroxidation. Free Radic. Biol. Med. 17:201-207. 
Sassa H, Takaishi Y, Terada H (1990) The triterpene celastrol as a very potent inhibitor 
of lipid peroxidation in mitochondria. Biochem. Biophys. Res. Commun. 172:890-897. 
Sauerland S, Nagelschmidt M, Mallmann P, Neugebauer EA (2000) Risks and benefits of 
preoperative high dose Methylprednisolone in surgical patients: A systematic review. 
Drug Saf. 23:449-461. 
Scarr E (2012) Muscarinic Receptors: Their Roles in Disorders of the Central Nervous 
System and Potential as Therapeutic Targets. CNS Neurosci. Ther. 18:369-379. 
Schanne FA, Kane AB, Young EE, Farber JL (1979) Calcium dependence of toxic cell 
death: a final common pathway. Science 206:700-702.  
Schoenen J, Faull RLM (2004) Spinal cord: cyto- and chemoarchitecture. In: Paxinos G, 
Mai JK, editors. The human nervous system. 2nd ed. San Diego: Elsevier Academic 
Press. 190-232. 
Sekhon LH & Fehlings MG (2001) Epidemiology, demo-graphics, and Pathophysiology 
of acute spinal cord injury. Spine 26:S2-S12. 
Selverston AI (2005) A neural infrastructure for rhythmic motor patterns. Cell. Mol. 
Neurobiol. 25:223-244. 
Shabbir A, Bianchetti E, Cargonja R, Petrovic A, Mladinic M, Pilipović K, Nistri A 
(2015) Role of HSP70 in motoneuron survival after excitotoxic stress in a rat spinal cord 
injury model in vitro. Eur J Neurosci 42:3054-3065. 
Shabbir A, Bianchetti E, Nistri A (2015) The volatile anesthetic methoxyflurane protects 
motoneurons against excitotoxicity in an in vitro model of rat spinal cord injury. 
Neuroscience 285:269-280. 
Shaqura M, Li X, Al-Khrasani M et al (2016) Membrane-bound glucocorticoid receptors 
on distinct nociceptive neurons as potential targets for pain control through rapid non-
genomic effects. Neuropharmacology 111:1-13. 
 
 
Page 176 
 
Shaqura M, Li X, Al-Madol MA et al (2016) Acute mechanical sensitization of peripheral 
nociceptors by aldosterone through non-genomic activation of membrane bound 
mineralocorticoid receptors in naive rats. Neuropharmacology 107:251-261. 
Shaw PJ (1994) Excitotoxicity and motor neurone disease: a review of the evidence. J. 
Neurol. Sci. 124:6-13. 
Shibata M, Hisahara S, Hara H, Yamawaki T, Fukuuchi Y, Yuan J, Okano H, Miura M 
(2000) Caspases determine the vulnerability of oligodendrocytes in the ischemic brain. J. 
Clin. Invest. 106:643-653. 
Shuman SL, Bresnahan JC, Beattie MS (1997) Apoptosis of microglia and 
oligodendrocytes after spinal cord contusion in rats. J. Neurosci. Res. 50:798-808. 
Sidman RL, Angevine JB Jr, Pierce ET (1971) Atlas of the mouse brain and spinal cord. 
Cambridge: Harvard University Press. 
Sieghart W (1995) Structure and pharmacology of γ-aminobutyric acidA receptor 
subtypes. Pharmacol. Rev. 47:181-234. 
Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS, Bulloch K (2008) Steroid 
hormone receptor expression and function in microglia. Glia 56:659-674. 
Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA (2004) Analysis of the set of 
GABAA receptor genes in the human genome. J. Biol. Chem. 279: 41422-41435. 
Sine SM, Engel AG (2006) Recent advances in Cys-loop receptor structure and 
function. Nature 440:448-455.  
Skinner RD, Kinjo N, Henderson V, Garcia-Rill E (1990) Locomotor projections from 
the pedunculopontine nucleus to the spinal cord. Neurological Reports 1:183-186. 
Smith C, McEwan AI, Jhaveri R, Wilkinson M, Goodman D, Smith LR, Canada AT, 
Glass PS (1994) The interaction of fentanyl on the Cp50 of propofol for loss of 
consciousness and skin incision. Anesthesiology 81:820-828. 
Sonner JM, Antognini JF, Dutton RC, Flood P, Gray AT, Harris RA, Homanics GE, 
Kendig J, Orser B, Raines DE, Rampil IJ, Trudell J, Vissel B, Eger EI 2nd (2003) Inhaled 
 
 
Page 177 
 
anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic 
concentration. Anesth. Analg. 97:718-740. 
Spencer RL, Young EA, Choo PH, McEwen B (1990) Adrenal steroid type I and type II 
receptor binding: estimates of in vivo receptor number, occupancy, and activation with 
varying level of steroid. Brain Research 514:37-48.  
Springer JE, Azbill RD, Knapp PE (1999) Activation of the caspase-3 apoptotic cascade 
intraumatic spinal cord injury. Nat.Med. 5:943-946. 
Stein RB, Capaday C (1988) The modulation of human reflexes during functional motor 
tasks. Trends Neurosci. 11:328-332. 
Streit J (1996) Mechanisms of pattern generation in cocultures of embryonic spinal cord 
and skeletal muscle. Int. J. Dev. Neurosci. 14:137-148. 
Sun YY, Wang CY, Hsu MF, Juan SH, Chang CY, Chou CM, Yang LY, Hung KS, Xu J, 
Lee YH, Hsu CY (2010) Glucocorticoid protection of oligodendrocytes against 
excitotoxin involving hypoxia-inducible factor-1a in a cell-type-specific manner. J. 
Neurosci. 30:9621-9630. 
Taccola G, Margaryan G, Mladinic M, Nistri A (2008) Kainate and metabolic 
perturbation mimicking spinal injury differentially contribute to early damage of 
locomotor networks in the in vitro neonatal rat spinal cord. Neuroscience 155:538-555. 
Taccola G, Mladinic M, Nistri A (2010) Dynamics of early locomotor network 
dysfunction following a focal lesion in an in vitro model of spinal injury. Eur J Neurosci. 
31:60-78. 
Taccola G, Nistri A (2007) Differential modulation by tetraethylammonium of the 
processes underlying network bursting in the neonatal rat spinal cord in vitro. 
Neuroscience 146:1906-1917.  
Takakusaki K, Chiba R, Tsukasa N, Okumura T (2016) Brainstem control of locomotion 
and muscle tone with special reference to the role of the mesopontine tegmentum and 
medullary reticulospinal systems. Journal of Neural Transmission. 123:695-729. 
Takakusaki K, Obara K, Nozu T, Okumura T (2011) Modulatory effects of the 
GABAergic basal ganglia neurons on the PPN and the muscle tone inhibitory system in 
cats. Archives Italiennes de Biologie 149:385-405. 
 
 
Page 178 
 
Takakusaki K, Shiroyama T, Yamamoto T, Kitai ST (1996) Cholinergic and 
noncholinergic tegmental pedunculopontine projection neurons in rats revealed by 
intracellular labeling. J. Comp. Neurol. 371:345-361. 
Talpalar AE, et al (2011) Identification of minimal neuronal networks involved in flexor-
extensor alternation in the mammalian spinal cord. Neuron 71:1071-1084. 
Talpalar AE, Bouvier J, Borgius L, Fortin G, Pierani A, Kiehn O (2013) Dual-mode 
operation of neuronal networks involved in left–right alternation. Nature 500:85-88.  
Tinetti ME (2003) Clinical practice. Preventing falls in elderly persons. N. Engl. J. Med. 
348:42-49. 
Todd AJ, Sullivan AC (1990) Light microscope study of the coexistence of GABA-like 
and glycin-like immunoreactivity in the spinal cord of the rat. J. Comp. Neurol. 296:496-
505.  
Traub RD, Miles R, Jefferys JGR (1993) Synaptic and intrinsic conductances shape 
picrotoxin-induced synchronized after-discharges in the guinea-pig hippocampal slice. J. 
Physiol. (Lond) 461:525-547. 
Tscherter A, Heuschkel MO, Renaud P, Streit J (2001) Spatiotemporal characterization of 
rhythmic activity in rat spinal cord slice cultures. Eur. J. Neurosci. 14:179-190. 
van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J (2010) 
Incidence of spinal cord injury worldwide: asystematic review. Neuroepidemiology 
34:184-192. 
Vasileiou I, Xanthos T, Koudouna E, Perrea D, Klonaris C, Katsargyris A, Papadimitriou 
L (2009) Propofol: A review of its non-anaesthetic effects. European Journal of 
Pharmacology 605:1–8. 
Velasco I, Tapia R, Massieu L (1996) Inhibition of glutamate uptake induces progressive 
accumulation of extracellular glutamate and neuronal damage in rat cortical cultures. J. 
Neurosci. Res. 44:551-561. 
Veselis RA, Pryor KO, Reinsel RA, Mehta M, Pan H, Johnson Jr, R (2008) Low dose 
propofol-induced amnesia is not due to a failure of encoding: left inferior prefrontal 
cortex is still active. Anesthesiology 109:213-224. 
 
 
Page 179 
 
Veselis RA, Reinsel RA, Feshchenko VA, Johnson Jr, R, (2004) Information loss over 
time defines the memory defect of propofol: a comparative response with thiopental and 
dexmedetomidine. Anesthesiology 101:831-841. 
Vielkind U, Walencewicz A, Levine JM, Bohn MC (1990) Type-II glucocorticoid 
receptors are expressed in oligodendrocytes and astrocytes. Journal of Neuroscience 
Research 27:360-373. 
Vincent P & Mulle C (2009) Kainate receptors in epilepsy and excitotoxicity. 
Neuroscience 158:309-323. 
von Euler M, Li-Li M, Whittemore S, Seiger A, Sundström E (1997) No protective effect 
of the NMDA antagonist memantine in experimental spinal cord injuries. J. Neurotrauma. 
14:53-61. 
Wang J, Yang X, Camporesi CV, Yang Z, Bosco G, Chen C, Camporesi EM (2002) 
Propofol reduces infarct size and striatal dopamine accumulation following transient 
middle cerebral artery occlusion: a microdialysis study. Eur. J. Pharmacol. 452:303-308. 
Wang Q, Yu S, Simonyi A, Sun GY, Sun AY (2005) Kainic acid-mediated excitotoxicity 
as a model for neurodegeneration. Molecular Neurobiology 31:3-16. 
Wang QS, Jiang YH, Wang TD, Xiao T, Wang JK (2013) Effects of betamethasone on 
neuropathic pain in a rat spare nerve injury model. Clin. Exp. Pharmacol. Physiol. 40:22-
27. 
Wang Y, Cao L, Xu LM, Cao FF, Peng B, Zhang X, Shen YF, Uzan G, Zhang DH (2015) 
Celastrol ameliorates EAE induction by suppressing pathogenic T cell responses in the 
peripheral and central nervous systems. J. Neuroimmune. Pharmacol. 10:506-516.  
Warembourg M, Otten U, Schwab ME (1981) Labelling of schwann and satellite cells by 
[3H]dexamethasone in a rat sympathetic ganglion and sciatic nerve. Neuroscience 
6:1139-1143. 
Watson C, Paxinos G, Kayalioglu G, Heise C (2009) An atlas of the mouse spinal cord. 
In: Watson C, Paxinos G, Kayalioglu G, editors. The spinal cord. A Christopher and Dana 
Reeve foundation text and atlas. San Diego: Elsevier Academic Press. 308-379. 
 
 
Page 180 
 
Weber I, Veress G, Szucs P, Antal M, Birinyi A (2007) Neurotransmitter systems of 
commissural interneurons in the lumbar spinal cord of neonatal rats. Brain Res. 1178:65-
72. 
Wei ZL, Xiao Y, Yuan H, Baydyuk M, Petukhov PA, Musachio JL, Kellar KJ, 
Kozikowski AP (2005) Novel pyridyl ring C5 substituted analogues of epibatidine and 3-
(1-methyl-2(S)-pyrrolidinylmethoxy) pyridine (A-84543) as highly selective agents for 
neuronal nicotinic acetylcholine receptors containing beta2 subunits. J. Med. Chem. 
48:1721-1724. 
Wess J (1996) Molecular biology of muscarinic acetylcholine receptors. Crit. Rev. 
Neurobiol. 10:69-99. 
Wessler I, Kirkpatrick CJ (2008) Acetylcholine beyond neurons: the non-neuronal 
cholinergic system in humans. Br. J. Pharmacol. 154:1558-1571.  
Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, Gu 
W, Devlin JP, Silverman RB, Morimoto RI (2004) Celastrols as inducers of the heat 
shock response and cytoprotection. J. Biol. Chem. 279:56053-56060. 
Wharton RS, Sievenpiper TS, Mazze RI (1980) Developmental toxicity of 
methoxyflurane in mice. Anesth. Analg. 59:421-425. 
Whiting P, Lindstrom J (1986b) Pharmacological properties of immuno-isolated neuronal 
nicotinic receptors. J. Neurosci. 6:3061-3069. 
Whiting P, Lindstrom J (1987) Purification and characterization of a nicotinic 
acetylcholine receptor from rat brain. Proc. Natl. Acad. Sci. U.S.A 84:595-599. 
Whiting PJ, Lindstrom JM (1986a) Purification and characterization of a nicotinic 
acetylcholine receptor from chick brain. Biochemistry 25:2082–2093. 
Wolman L (1965) The disturbances of circulation in traumatic paraplegia in acute and 
late stages: a pathological study. Paraplegia 2:213-226. 
Wong KF, Yuan Y, Luk JM (2012) Tripterygium wilfordii bioactive compounds as 
anticancer and anti-inflammatory agents. Clin. Exp. Pharmacol. Physiol. 39:311-320. 
 
 
Page 181 
 
Woodbridge PD (1957) Changing concepts concerning depth of anesthesia. 
Anesthesiology 18:536-550.  
Woolf NJ (1991) Cholinergic systems in mammalian brain and spinal cord. Prog. 
Neurobiol. 37:475-524. 
Wrathal JR, Teng YD, Marriott R (1997) Delayed antagonism of AMPA/kainate 
receptors reduces long-term functional deficits resulting from spinal cord trauma. Exp. 
Neurol. 145:565-573. 
Xiong Y, Rabchevsky AG, Hall ED (2007) Role of peroxynitrite in secondary oxidative 
damage after spinal cord injury. J. Neurochem. 100:639-649.   
Xu J, Fan G, Chen S, Wu Y, Xu XM, Hsu CY (1998a) Methylprednisolone inhibition of 
TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res. 
Mol. Brain Res. 59:135-142. 
Yamasaki T, Nakakimura K, Matsumoto M, Xiong L, Ishikawa T, Sakabe T (1999) 
Effects of graded suppression of the EEG with propofol on the neurological outcome 
following incomplete cerebral ischaemia in rats. Eur. J. Anaesthesiol. 16:320-329. 
Young W (1993) Secondary injury mechanisms in acute spinal cord injury. J. Emerg. 
Med. 11:13-22. 
Zacny JP, Coalson DW, Young CJ, Klafta JM, Lichtor JL, Rupani G, Thapar P, 
Apfelbaum JL (1996) Propofol at conscious sedation doses produces mild analgesia to 
cold pressor-induced pain in healthy volunteers. J. clin. anaesth. 8:469-474. 
Zhang CX, Ge ZM, Cheng TM, Li RT (2006) Synthesis and analgesic activity of 
secondary amine analogues of pyridylmethylamine and positional isomeric analogues of 
ABT-594. Bioorg. Med. Chem. Lett. 16:2013-2016.  
Zhang J, et al (2014) V1 and v2b interneurons secure the alternating flexor-extensor 
motor activity mice require for limbed locomotion. Neuron 82:138:150.  
 
 
 
 
 
Page 182 
 
 
9 SUPPLEMENTARY DATA 
9.1 Appendix I: Neurotoxicity of nicotine 
 
1) We studied the structural and functional changes evoked by application 10 µM 
nicotine (for 1 or 4 h) after or during excitotoxicity induced by kainate (50 µM) in 
an in vitro SCI model. These experiments followed the same methods as 
previously explained in the result section. 
 
Fig. 1 Changes in percent pyknosis (stained with DAPI, blue) and neuronal (stained with 
NeuN, red) numbers by nicotine application alone (1 or 4 h) or after kainate (KA) and 
nicotine treatment (1 or 4 h) in all three ROI. (A, B) No damage induced by application of 
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nicotine alone. Kainate application induced significant percent pyknosis in all three ROI 
i.e., dorsal, central and ventral horn which is antagonized by nicotine treatment (***P = 
0.001). (A, C) No change in the number of neurons in dorsal horn after nicotine alone 
application, however, the neuronal number was significantly reduced in central (P = 
0.001) and ventral horn (P = 0.001) when nicotine was applied alone for 4 h. Kainate, 
when applied alone, has drastically reduced the number of neurons in all the ROI in 
comparison to sham or nicotine alone (P = 0.001). When nicotine was applied with or 
after kainate increased the neuronal number only in the dorsal ROI (P = 0.001) whereas 
no change observed in the central and ventral horn of spinal cord. Data are mean ±SEM. 
Scale bar = 100 µm. n = 3 to 6 where n is the number of spinal cords used and 3 to 5 
sections/preparation were taken.   
 
Fig. 2 Changes in motoneuronal number 24 h after excitotoxic injury by kainate alone or 
kainate and nicotine application. (A) Examples of motoneurons immuno-stained with 
SMI32, green. (B) Bar graph represents the significant reduction in motoneuronal number 
after nicotine alone application either for 1 h (**P = 0.002) or 4 h (***P = 0.001). 
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Kainate alone application has reduced the motoneuronal number to less than half in 
comparison to sham which was not significantly recovered by nicotine treatment with or 
after kainate except when nicotine was applied for 1 h after kainate (P = 0.001; KA vs 
KA/N 1h). Data are mean ±SEM. Scale bar = 100 µm. n = 3 to 7 where n is the number of 
spinal cords used and 4 to 7 sections/preparation were taken. 
 
 
Fig. 3 Effect of nicotine and kainate on astroglia immunostained with S100 (green) and 
GFAP (red) 24 h later in vitro. (A) Examples of astroglia in sham, N 4h, KA, KA/N 4 h 
and KA+N/N 4 h treatments. (B, C) Histograms shows no alterations in 
immunofluorescence intensity of astroglia labelled with S100 and GFAP except in case of 
nicotine when applied alone in comparison to sham preparations in all the three ROI 
(dorsal: **P = 0.003; central: *P = 0.03; ventral: P = 0.013). Data are mean ±SEM. Scale 
bar = 100 µm. n = 7 to 10 where n is number of spinal cords used and 8 to 10 
sections/preparation were taken. 
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Fig. 4 Effect of nicotine (10 µM) and kainate (50 µM) on synaptic transmission recorded 
24 h later. (A, B) Example recordings of monosynaptic and polysynaptic reflex responses 
in sham (n = 9), nicotine 4 h (N 4h; n = 5), kainate (KA; n = 8), kainate followed by 
nicotine 4 h (KA/N 4h; n = 7) and kainate co-applied with nicotine followed by nicotine 
for 4 h (KA+N/N 4h; n = 7) treatments. (D, E) Bar graphs show no change in 
polysynaptic reflexes (D, E) after nicotine alone application which were highly depressed 
by kainate when applied alone and a modest improvement observed by treatment with 
nicotine after or together with kainate (amplitude: ***P ≤ 0.001, *P ≤ 0.05; area: P ≤ 
0.001; KA vs KA/N 4h, KA vs KA+N/N 4h, respectively). However, monosynaptic 
reflexes(C) were depressed in all cases in comparison to sham (P ≤ 0.001) as represented 
in the example records (A)    and bar graph (C). Data are mean ±SEM. n denotes the 
number of spinal cords used.  
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Fig. 5 Changes in DR train evoked VR responses after 24 h in vitro. (A) Examples of 
fictive locomotion induced by DR train in sham (n = 9), N 4h (n = 5), KA (n = 8), KA/N 
4h (n = 7) and KA+N/N 4h (n = 7). (B-D) Histograms showing intense depression evoked 
by kainate alone application which was modestly improved after nicotine application 
(number of oscillations: ***P ≤ 0.001, KA vs KA/N 4h, KA vs KA+N/N 4h; cumulative 
depolarization: *P ≤ 0.05, KA vs KA/N 4h).  Data are mean ±SEM. n denotes the number 
of spinal cords used.  
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Fig. 6 Changes in chemically induced fictive locomotion recorded after 24 h in vitro. (A) 
Sample records of fictive locomotor patterns in sham (n = 9), N 4h (n = 5), KA (n = 8), 
KA/N 4h (n = 7) and KA+N/N 4h (n = 7). (B, C) The cycle amplitude has reduced and 
the periodicity has increased after application of nicotine alone. Kainate alone application 
has fully abolished the fictive locomotor patterns which were reversed by nicotine even 
though with smaller amplitude and longer periodicity (***P ≤ 0.001, KA vs KA/N 4h, 
KA vs KA+N/N 4h). Data are mean ±SEM. n denotes the number of spinal cords used. 
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Fig. 7 Changes in intrinsic rhythmicity of spinal cords following kainate and nicotine 
treatment. (A) Example records of disinhibited bursts evoked by inhibiting GABAergic 
and glycinergic transmission with bicuculline and strychnine 24 h after in sham (n = 9), N 
4h (n = 5), KA (n = 8), KA/N 4h (n = 7) and KA+N/N 4h (n = 7) preparations. (B, C) Bar 
graphs showing a significant decrease in number of bursts after nicotine alone application 
with no change in amplitude of the same in comparison to sham treated spinal cords. 
Kainate alone application has strongly depressed the number and amplitude of bursts. A 
significant recovery in number of bursts by nicotine applied after or together with kainate 
application with no further change in amplitude (***P ≤ 0.001). Data are mean ±SEM. n 
denotes the number of spinal cords used. 
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Fig. 8 Changes in DR-DR evoked responses recorded 24 h in vitro. (A) Representative 
traces of DR-DR evoked responses in sham (n = 4), N 4h (n = 3), KA (n = 4), KA/N 4h (n 
= 4) and KA+N/ 4 h (n = 5). (B) Histogram illustrates that kainate application has 
completely disrupted the amplitude of DR-DR responses which has significantly reversed 
by nicotine application (***P ≤ 0.001).  
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9.2 Appendix II: Effects of celastrol 
 
2) Changes in functional outcome were studied by pre-treating the spinal cords with 
celastrol for 6 h (0.75 µM) followed by excitotoxic injury (kainate, 1 h, 50 µM). 
These experiments followed the same methods as described in the enclosed papers 
in the result section.   
  
 
Fig. 1 Changes in reflex responses after celastrol and kainate application recorded from 
lumbar VRs 24 h after in vitro. (A, B) Sample records of mono- and polysynaptic reflex 
responses in sham, celastrol applied for 6 h (Cel 6 h), kainate application for 1 h (KA) 
and celastrol (6 h) for by kainate (CEL 6 h/ KA) treatments. (C) Histogram showing 
strong reduction in monosynaptic reflex responses in all the cases when compared to 
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sham preparations. (D, E) Bar graphs illustrating a good recovery in polysynaptic reflexes 
by pre-treating the preparations with celastrol followed by kainate in comparison to 
kainate alone (***P ≤ 0.001).  
 
 
 
Fig. 2 Effect of celastrol pre-treatment followed by kainate on DR train evoked fictive 
locomotion. Note a strong recovery in electrically evoked fictive locomotion observed 
after celastrol followed by kainate application (P ≤ 0.001) as exemplified in sample 
records (A) and bar graphs (B-D). 
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Fig. 3 Alternations in fictive locomotor patterns evoked by application of NMDA+5HT 
recorded 24 h in vitro. (A) Examples of chemically induced fictive locomotion in sham, 
Cel 6 h, KA and Cel 6 h/KA treatments. (B, C) Histograms represent a significant 
reduction of cycle amplitude and increased periodicity after celastrol alone application (6 
h). Kainate alone application has completely abolished the fictive locomotion which was 
reversed by pre-treating the spinal cord with celastrol followed by kainate, although with 
less amplitude and longer periodicity (***P ≤ 0.001).     
 
